**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10–K**

☒   **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended **December 31, 2024**

**or**

☐   **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from                     to**

**Commission file number: 000-55768**

|  |
| --- |
| **HealthLynked Corp.** |
| (Exact name of registrant as specified in its charter) |

|  |  |  |
| --- | --- | --- |
| **Nevada** |  | **47-1634127** |
| (State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.) |

|  |  |  |
| --- | --- | --- |
| **1265 Creekside Parkway, Suite 302, Naples, Florida** |  | **34108** |
| (Address of principal executive offices) |  | (Zip Code) |

Registrant’s telephone number, including area code: **(800) 928-7144**

Securities registered pursuant to Section 12(b) of the Act:**None.**

Securities registered pursuant to Section 12(g) of the Act:  **Common Stock, par value $0.0001 per share**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|  |  |  |  |
| --- | --- | --- | --- |
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒

On June 30, 2024, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was $14,334,980, based upon the closing price on that date of the Common Stock of the registrant on the OTCQB of $0.076. For purposes of this response, the registrant has assumed that its directors, executive officers and beneficial owners of 10% or more of its Common Stock are deemed affiliates of the registrant.

As of March 31, 2025, there were 281,947,651 shares of the registrant’s common stock, par value $0.0001, issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

None

**TABLE OF CONTENTS**

|  |  |  |
| --- | --- | --- |
|  |  | **PAGE** |
| [**PART I**](#a_001) |  |  |
| Item 1. | [BUSINESS](#a_002) | 1 |
| Item 1A. | [RISK FACTORS](#a_003) | 15 |
| Item 1B. | [UNRESOLVED STAFF COMMENTS](#a_004) | 24 |
| Item 1C. | [CYBERSECURITY](#a_005) | 24 |
| Item 2. | [PROPERTIES](#a_006) | 24 |
| Item 3. | [LEGAL PROCEEDINGS](#a_007) | 24 |
| Item 4. | [MINE SAFETY DISCLOSURE](#a_008) | 24 |
| [**PART II**](#a_009) |  |  |
| Item 5. | [MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES](#a_010) | 25 |
| Item 6. | [[RESERVED]](#a_011) | 26 |
| Item 7. | [MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#a_012) | 26 |
| Item 7A. | [QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](#a_013) | 33 |
| Item 8. | [FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA](#a_014) | F-1 |
| Item 9. | [CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE](#a_015) | 34 |
| Item 9A. | [CONTROLS AND PROCEDURES](#a_016) | 34 |
| Item 9B. | [OTHER INFORMATION](#a_017) | 34 |
| Item 9C. | [DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS](#a_018) | 34 |
| [**PART III**](#a_019) |  |  |
| Item 10. | [DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE](#a_020) | 35 |
| Item 11. | [EXECUTIVE COMPENSATION](#a_021) | 38 |
| Item 12. | [SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS](#a_022) | 40 |
| Item 13. | [CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE](#a_023) | 43 |
| Item 14. | [PRINCIPAL ACCOUNTANT FEES AND SERVICES](#a_024) | 45 |
| [**PART IV**](#a_025) |  |  |
| Item 15. | [EXHIBITS AND FINANCIAL STATEMENT SCHEDULES](#a_026) | 46 |
| Item 16. | [FORM 10-K SUMMARY](#a_027) | 46 |
| [SIGNATURES](#a_028) | | 47 |

i

**Forward-Looking Statements**

All statements contained in this Annual Report on Form 10-K, other than statements of historical facts, that address future activities, events or developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), including, but not limited to, statements containing the word “believe,” “anticipate,” “expect” and words of similar import. These statements are based on certain assumptions and analyses made by the Company in light of its experience and assessment of historical trends, current conditions and expected future developments as well as other factors the Company believes are appropriate under the circumstances. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from those projected. The Company cautions investors that any forward-looking statements made by the Company are not guarantees of future performance and that actual results may differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation: established competitors who have substantially greater financial resources and operating histories, regulatory delays or denials, ability to compete as a start-up company in a highly competitive market, and access to sources of capital.

ii

**PART I.**

**Item 1. Business**

**Overview**

HealthLynked Corp. (the “Company,” “we,” “our,”) is a healthcare technology company incorporated in the State of Nevada on August 6, 2014. We operate across three primary divisions—Digital Healthcare, Medical Distribution, and Health Services—each dedicated to leveraging innovative solutions that enhance patient care, reduce costs, and generate long-term value for shareholders.

Our key objectives are to:

|  |  |  |
| --- | --- | --- |
|  | 1. | Improve patient care management; |

|  |  |  |
| --- | --- | --- |
|  | 2. | Enhance the operational efficiency of medical practices; and |

|  |  |  |
| --- | --- | --- |
|  | 3. | Utilize healthcare data to gain unique insights into diseases, leading to better health outcomes |

*Digital Healthcare Division*

Within our Digital Healthcare division, we develop and manage the HealthLynked Network, a robust, cloud-based platform that centralizes personal medical records and streamlines communication between patients and healthcare providers. Our platform integrates AI-driven capabilities, on-demand telemedicine services, and concierge support, delivering an advanced, technology-enabled patient experience.

*Health Services Division*

Our Health Services division encompasses a diverse range of clinical operations, offering services such as functional medicine, physical therapy, primary care, and cosmetic treatments. By integrating these patient-focused medical services, we continuously test and refine our healthcare technologies in real-world clinical settings. This approach not only enhances the effectiveness of our tools but also diversifies our revenue streams.

*Medical Distribution Division*

Operating under MedOffice Direct LLC (“MOD”), our Medical Distribution division serves as a virtual distributor of discounted medical supplies to medical practices and individual consumers across the United States. Through strategic partnerships and direct-to-consumer shipping, we provide cost-effective solutions while strengthening HealthLynked’s overall consumer value.

By aligning our three divisions, we aim to strengthen our position in the healthcare industry, drive innovation, and create meaningful value for our patients, partners, and shareholders.

**Digital Healthcare Division**

*Our Mission*

We strive to transform the healthcare landscape through the efficient exchange of healthcare data using unique software and AI-driven solutions that enable 24/7 personalized patient care. By uniting patients, providers, and personal health data on a secure and easily accessible platform, we aim to improve care coordination, maintain privacy, and enhance health outcomes. Our long-term vision is to set the industry standard for efficient, patient-centric healthcare, delivering sustained growth and value for our shareholders.

1

*The HealthLynked Network*

At the core of our Digital Healthcare division is the HealthLynked Network—a cloud-based Patient Information Network (“PIN”) that revolutionizes the way medical records are shared and managed. By streamlining the flow of health data between patients and their providers, the Network improves medical practice efficiency, shortens patient wait times, and promotes accurate diagnoses.

The HealthLynked Network comprises our proprietary medical records management platform, enhanced by a suite of applications and services that include ARi (our AI Healthcare Guide), personalized concierge service, nationwide telemedicine, a discount prescription drug program, and Oohvie, our women’s health-focused application.

Through seamless interoperability and user-friendly design, the Network fosters coordinated care across specialties and geographies, empowering users to take control of their health data.

*Medical Records Management*

One of the features of the HealthLynked Network is its ability to provide secure medical records management. By centralizing patient data, we enable efficient sharing among authorized providers and caregivers, allowing immediate, up-to-date access to essential information. Patients can create accounts for dependents, track immunizations, and share medical histories with selected physicians—all while controlling the level and duration of access.

Our system remains EMR-agnostic, accommodating both electronic and fax-based transmissions, and leverages unique patient-specific barcodes to organize and archive records automatically. This cross-platform flexibility significantly lowers barriers to entry, fostering broader adoption and a more expansive, profitable user base.

*Mobile Check-In*

To further improve operational efficiency, we offer a mobile check-in system that streamlines the patient intake process. Patients can use their mobile devices to check in via barcode, update their medical records, create or log in to their HealthLynked account, and pay co-pays directly—reducing administrative overhead for practices and enhancing patient flow and efficiency.

*ARi AI Healthcare Guide*

One of our most innovative offerings is ARi, an AI-driven personal healthcare assistant developed in collaboration with OpenAI. ARi is exclusively available to paid HealthLynked members via our app and draws on each user’s unique health profile to deliver personalized medical guidance. Key features include:

|  |  |  |
| --- | --- | --- |
|  | ● | **Voice-Driven Profile Creation:** ARi allows patients to seamlessly create or update health profiles through natural conversation, eliminating paperwork. |

|  |  |  |
| --- | --- | --- |
|  | ● | **Personalized Guidance:** Context-aware insights tailored to each patient’s medical history and real-time health data. |

|  |  |  |
| --- | --- | --- |
|  | ● | **Diagnostic Support:** AI-powered suggestions for possible next steps, directing patients to the most suitable provider or service. |

|  |  |  |
| --- | --- | --- |
|  | ● | **Effortless Scheduling:** Ability to book both in-person and telemedicine appointments via our online scheduling application. |

|  |  |  |
| --- | --- | --- |
|  | ● | **Proactive Health Tracking:** Automatic updates to medical records keep profiles accurate and help identify potential concerns early. |

|  |  |  |
| --- | --- | --- |
|  | ● | **24/7 Intelligent Assistance:** Around-the-clock healthcare support informed by patient-specific data. |

This dynamic AI platform exemplifies our commitment to integrating cutting-edge technology for improved health outcomes and enhanced shareholder value through service differentiation.

2

*Concierge Service*

Our premium Concierge Service supports HealthLynked Network members for a small monthly fee. Through personalized assistance from a live Concierge team, members can schedule appointments nationwide, request and organize medical records, and receive guidance from nursing professionals. This high-touch approach fosters patient loyalty, enhances customer satisfaction, and cultivates a recurring revenue model aligned with our strategic growth goals.

*Telemedicine Services*

In 2024, we expanded our telemedicine offerings from limited coverage in Florida to 24/7 nationwide access. By allowing patients to consult licensed providers within 20 minutes for urgent care needs, we address the rising demand for flexible, remote healthcare services. Visits start at $50 for HealthLynked Network members, providing an affordable, efficient alternative to in-person appointments—a service that strengthens our competitive edge and broadens our market reach.

*Discount Prescription Drug Program*

Also in 2024, we introduced a discount prescription drug program to further reduce healthcare costs for our growing member base. This service provides HealthLynked Network users with savings vouchers for a wide range of medications, promoting affordability and improved adherence to treatment plans. By integrating this feature into our digital ecosystem, we enhance the overall patient experience and deliver additional value that supports user retention and revenue growth.

*Oohvie: An Integrated Women’s Health Solution*

Originally launched in 2020 as a women’s health application, Oohvie has evolved along with the HealthLynked ecosystem, offering a comprehensive suite of features designed to enhance women’s healthcare management.

The app provides menstrual cycle tracking, appointment scheduling (including telehealth visits), real-time health forums, and discounted direct-to-consumer purchases of feminine hygiene products. By fostering high user engagement—particularly within the women’s health sector—Oohvie strengthens our connection to a vital demographic and reinforces our commitment to inclusive healthcare solutions.

Users can track their cycles for both contraceptive planning and conception goals, set reminders for birth control or hormone treatments, and even consult live nurses for real-time medical guidance. Additionally, Oohvie paid subscribers gain access to HealthLynked, expanding their healthcare resources within our network.

Through this targeted and data-driven approach, Oohvie not only addresses a critical healthcare need but also aims to play vital role in expanding HealthLynked’s reach, driving engagement, and supporting long-term growth.

**Health Services Division**

Our Health Services division represents the patient-facing arm of our operations, playing a crucial role in both revenue generation and the continuous enhancement of the HealthLynked Network. By integrating clinical operations with our technology platform, we gain valuable real-world feedback to refine our software solutions and tools. The division includes:

|  |  |  |
| --- | --- | --- |
|  | 1. | **Naples Center for Functional Medicine (“NCFM”)** – A functional medicine practice rebranded from Hughes Center for Functional Medicine. NCFM employs a specialized team of physicians, nurses, and support staff to address chronic and neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Multiple Sclerosis. Its services include comprehensive membership programs, office visits, cutting-edge treatments (e.g., IV therapy, ozone therapy, hyperbaric oxygen), and supplement sales. |

|  |  |  |
| --- | --- | --- |
|  | 2. | **Bridging the Gap Physical Therapy (“BTG”)** –delivering hands-on, functional manual therapy to accelerate patient recovery and alleviate pain without the reliance on medication or surgery. |

|  |  |  |
| --- | --- | --- |
|  | 3. | **Concierge Care Naples (“CCN”)** – In October 2024, we closed Naples Women’s Center (“NWC”) and launched CCN, expanding our focus from higher-risk obstetrical services to a comprehensive primary care model. CCN provides a full spectrum of medical services, emphasizing preventative care, coordinated treatment, and personalized patient support to improve health outcomes. This transition allows us to streamline operations, enhance patient engagement, and further develop our concierge healthcare offerings, reinforcing our commitment to delivering high-quality, patient-centered care. |

|  |  |  |
| --- | --- | --- |
|  | 4. | **Aesthetic Enhancements Unlimited (AEU)** – Specializing in minimally and non-invasive cosmetic procedures such as fat reduction, body sculpting, wrinkle reduction, and hair removal. We relocated AEU to CCN’s office location in July 2024 to streamline service offerings and improve patient access. |

3

**Medical Distribution Division**

Our Medical Distribution division centers on MedOfficeDirect LLC (“MOD”), acquired in October 2020. MOD operates as a Naples, Florida-based virtual distributor providing deeply discounted medical supplies to both individual consumers and healthcare practices across the country.

Leveraging Group Purchasing Organization (GPO) pricing, MOD offers over 15,000 brand-name medical products within more than 150 categories. Its direct-to-consumer shipping model and convenient online marketplace—accessible at www.medofficedirect.com—enable customers to optimize costs while ensuring timely product delivery. Medical supplies are an essential part of Healthcare and providing a direct-to-consumer service we see as adding value to our current users.

**Sale of ACO Health Partners**

Prior to January 2023, we operated an Accountable Care Organization (ACO) and Managed Service Organization (MSO) under Cura Health Management LLC (“CHM”) and its subsidiary ACO Health Partners LLC (“AHP”). AHP assisted physician practices in delivering coordinated, efficient care to Medicare patients via the Medicare Shared Savings Program (“MSSP”).

On January 17, 2023, we entered into an Agreement and Plan of Merger (the “AHP Merger Agreement”), leading to the sale of AHP to PBACO Holding, LLC (“Buyer”), an established ACO operator. Concurrently, AHP and the Buyer signed a Management Services Agreement (“MSA”), transferring operational management and expenses to the Buyer after January 16, 2023. As a result, the Buyer assumed full control of AHP’s operations.

This divestiture allowed us to focus on our core competencies in Digital Healthcare, Medical Distribution, and Health Services, directing capital and resources to areas with the highest potential for market growth and shareholder returns.

**Our Mission: Transforming Healthcare Through Data, AI, and Connectivity**

At HealthLynked, our mission is to revolutionize healthcare by improving the management and exchange of healthcare data while leveraging AI-driven technology to deliver personalized, 24/7 patient care. By seamlessly connecting patients with healthcare providers and their medical data, we aim to enhance communication, ensure data privacy, and drive better health outcomes.

At the core of our approach is the efficient exchange of health information, enabling real-time access to critical patient data across providers, facilities, and healthcare systems. By creating a centralized, cloud-based repository for comprehensive patient health records, we empower individuals with greater control over their medical history while equipping healthcare professionals with the information they need to make faster, more accurate clinical decisions.

Beyond improving patient care, our unified health data ecosystem serves as a foundation for medical innovation. With patient consent, HealthLynked aims to partner with pharmaceutical companies and medical researchers to leverage aggregated health data for groundbreaking discoveries in early disease detection, personalized treatment plans, and AI-powered health recommendations. These collaborations are intended to drive advancements in preventative care, accelerate research, and improve patient outcomes.

By making healthcare more accessible, efficient, and data-driven, HealthLynked is setting a new standard for patient-centered care. Our vision is to create a fully connected, intelligent, and responsive healthcare ecosystem that improves patient outcomes on both an individual and global scale.

**The HealthLynked Network – How it Works**

Through our Digital Healthcare Division, we operate a cloud-based PIN and record archiving system with related applications, referred to as the “HealthLynked Network”, which aims to improve healthcare by the efficient transfer of medical information between patients and their healthcare providers, improving medical practice efficiency, increasing access to quality healthcare, and facilitating accurate medical diagnosis. The HealthLynked Network is comprised of our medical records management system combined with an ecosystem of applications and services designed to ensure coordinated and comprehensive care across all aspects of the healthcare journey, including: ARi our AI Healthcare Guide, personalized Concierge Service, on-demand Telemedicine Services, Discount Prescription Drug Program, and Oohvie our female focused menstrual tracking application.

4

*Medical Records Management*

The HealthLynked Network centralizes medical records, streamlining the management of personal and family health information. Patients can securely share their records with providers and caregivers, ensuring coordinated and comprehensive care across all aspects of their healthcare journey.

Our system walks patients through a series of easy-to-use pages with point and click selections and drop-down menus that allow them to enter their past medical history, past surgical history, allergies, medications, and family medical history. In addition, members can create accounts for their children under the age of 18 and keep track of required visits and vaccines. Members select healthcare providers, and other parties to whom they wish to grant access to their medical records. This access can be either ongoing, or restricted by time and date, in accordance with the patient’s control settings.

To participate in the HealthLynked Network, practices and providers must be in-network, and patients must grant them access to their HealthLynked profile and medical records. Once access is granted, healthcare providers can instantly download a patient’s medical history, eliminating the need for lengthy and repetitive paperwork.

Following an office visit, providers are required to upload the patient’s updated medical record within 24 hours. This can be done via eFax, API integrations with select EMRs, or directly through the HealthLynked portal. Each patient account is assigned a unique barcode, which, when faxed into our system, is automatically recognized, archived, and organized by date and provider within the patient’s chart.

Unlike traditional EMR systems, the HealthLynked Network operates independently, requiring only a computer or fax machine for participation. This minimal technology requirement reduces barriers to adoption, allowing for seamless integration, broader market penetration, and improved continuity of care across healthcare providers.

In addition to serving as a complete medical record archive, we believe that the HealthLynked Network allows for shorter wait times at doctors’ offices by giving doctors immediate access to patients’ complete medical information, insurance information and required treatment consent forms. Patients only need to verify their treating physician’s access to their files upon or prior to their doctor’s visit. Patients are also able to coordinate multiple physician visits and keep an updated and complete personal medical record archive. These files may also be shared among a patient’s different specialty physicians, a function that we believe is especially helpful for patients who travel and may need to access their records or obtain physician referrals in multiple localities. We also believe that the HealthLynked Network is especially valuable in medical emergencies, where patients may be unable to provide their medical history. Our system allows patients to pre-authorize healthcare providers and first responders to access critical medical information during emergencies, ensuring timely and informed treatment. By granting advance emergency access, patients enable paramedics, emergency room staff, and other first responders to quickly retrieve vital details, such as allergies, medications, pre-existing conditions, and prior treatments. This capability enhances patient safety, reduces delays in care, and improves medical outcomes in urgent situations.

*Mobile Check-In: Enhancing Efficiency and Patient Experience*

HealthLynked offers a seamless and efficient mobile check-in system, enabling patients to check in for appointments using their mobile device and a secure barcode system. This streamlined process allows patients to update their medical records, create an account, and pay copays—all from their smartphone—reducing wait times and administrative burdens for both patients and staff.

Beyond convenience, the mobile check-in system provides valuable analytics to healthcare practices, offering insights into patient flow, wait times, and overall operational efficiency. For practices seeking more advanced data and security, the Patient Access Hub (PAH) extends these capabilities by integrating a secure Wi-Fi network in the waiting room, delivering detailed practice analytics to further enhance patient experience and optimize office performance.

*ARi AI Healthcare Guide*

We recently released ARi, a revolutionary AI-driven personal healthcare assistant designed to redefine patient engagement and empower personalized care. ARi was launched in partnership with OpenAi and provides the most advanced AI tool to provide personalized healthcare guidance. ARi is able to use the information in the patients HealthLynked profile to provide specific medical guidance to the patient and answer medical questions using this information to provide more comprehensive and accurate information leading to better diagnosis and care management. ARi, available only through the HealthLynked app to paid users, aims to ensure seamless integration with the HealthLynked ecosystem through Voice-Driven Profile Creation, Personalized Guidance, AI-Powered Diagnostic Support, Effortless Scheduling, Proactive Health Tracking, and 24/7 Intelligent Assistance.

5

*Concierge Service*

The HealthLynked Network premium Concierge Service offers members access to healthcare management for a small monthly fee. This premium service offers personalized assistance from our live Concierge team to book appointments with any doctor in the U.S. on behalf of a patient and collect and organize patient medical records to establish a HealthLynked Network profile. Concierge Service also includes access to Concierge nurse staff to help manage the patient’s healthcare needs. The concierge service allows for patients to speak with a HealthLynked representative to help with their medical onboarding, schedule an appointment with any doctor in the U.S. even if they are out of network, and obtain their medical records from third parties like laboratory and other healthcare providers to create a comprehensive healthcare profile.

*Telemedicine Services*

HealthLynked expanded its Telehealth services in 2024 from limited coverage in Florida to 24/7 nationwide access. This expansion ensures patients can connect with licensed healthcare providers at any time, addressing the growing demand for flexible, remote medical consultations across the U.S. Patients can connect with licensed doctors within 20 minutes for urgent care needs. The platform ensures secure, private access to patient medical records and offers affordable telehealth visits starting at $50 for HealthLynked Network members.

*Discount Prescription Drug Program*

To further reduce healthcare costs for its members, during 2024 we introduced a discount prescription drug program, a health platform that offers a next-generation pharmacy discount. This initiative offers HealthLynked Network members savings vouchers on medications, enhancing affordability and improving access to essential treatments. This service is available to all users and provided significant savings to HealthLynked users.

*Oohvie*

In 2020, we launched Oohvie, an application focused on women’s healthcare. the application has continued to evolve and is integrated with HealthLynked. User can now book appointments and schedule telemedicine visits from the Oohvie app. Menstrual tracking apps have the highest engagement among healthcare app and offer valuable services to women which comprise half the worlds population. Tracking women’s menstrual cycles leads to insights into over female health and is important for either avoiding pregnancy or achieving pregnancy if a woman is looking to have a baby.

|  |  |  |
| --- | --- | --- |
|  | ● | A health forum designed specifically for women |

|  |  |  |
| --- | --- | --- |
|  | ● | Ability to schedule virtual telehealth consultations with healthcare providers without leaving the app |

|  |  |  |
| --- | --- | --- |
|  | ● | A real time chat feature where users can discuss their experiences with birth control pills, menstrual symptoms, and other issues in private |

|  |  |  |
| --- | --- | --- |
|  | ● | Users can purchase name brand feminine hygiene products that are shipped directly to their home at significantly discounted prices |

|  |  |  |
| --- | --- | --- |
|  | ● | Users can use the app to schedule reminders for taking birth control pills or hormones |

|  |  |  |
| --- | --- | --- |
|  | ● | Users can chat with a live nurse to answer their medical questions and order feminine products at low cost. |

**Business Model**

Our business model employs both consumer (B2C) and enterprise (B2B) revenue streams, driven by patient subscriptions, telemedicine services, appointment booking fees for in-network providers, and strategic partnerships with insurers, employers, and research organizations.

*Patients*

Patients can download the HealthLynked mobile app and create an account at no cost, placing them in the Freemium tier with basic features. Free users have limited data storage, self-managed profiles, limited appointment bookings, the ability to schedule only with in-network physicians, standard-rate telemedicine visits, and basic chat support. This Freemium approach expands user adoption by lowering entry barriers and encouraging patients to explore our fundamental services.

For more extensive functionality, patients may upgrade to a Concierge membership, which costs $12 per month or $120 per year if prepaid. Concierge users enjoy access to unlimited medical record storage, full profile management with dedicated concierge support, the ability to book appointments with any physician nationwide, and enhanced healthcare guidance through our ARi system. They also benefit from more robust family connectivity features, a dynamic rewards program, priority support, and a $20 discount on each telemedicine visit. This subscription-based model provides a predictable recurring revenue stream while significantly enhancing the patient experience.

6

*Medical Practices/ Providers*

We maintain base profiles for approximately 880,000 physicians across the United States, which helps patients easily discover and connect with medical professionals through our platform. Providers fall into two categories: out-of-network and in-network. Out-of-network providers have a basic listing in our directory and may claim and update their profiles with essential details, images, and videos. Once a provider elects to join the HealthLynked Network, pays the one-time activation fee, and agrees to allow patients to request appointments online, the provider is designated as in-network.

In-network providers unlock key benefits such as direct online booking, enhanced exposure to potential patients, and the ability to integrate our mobile check-in service to streamline patient intake and record management. We charge a booking fee for each patient who schedules an appointment through the HealthLynked online booking system, ensuring there is no ongoing cost unless the practice successfully receives patient appointments. This structure incentivizes providers to remain active and engaged on our platform, as it links cost to realized patient volume.

By digitizing and centralizing intake procedures, we help practices reduce administrative overhead while achieving compliance with the 21st Century Cures Act, which mandates timely patient access to medical records. Patients can quickly update their profiles before a visit, enabling physicians to review more complete medical histories and provide more effective care. We believe this integration of scheduling and record management promotes a positive patient experience and fosters loyalty to both the practice and the platform as a whole.

*Strategic Partnerships*

Beyond individual patients and providers, HealthLynked’s business model can extend to strategic partnerships with insurance companies, large employers, pharmaceutical companies, and medical research organizations. By integrating our care management technology and ARi guidance platform, insurers and employers can improve patient outcomes, reduce healthcare costs, and offer robust solutions for their member or employee populations. Pharmaceutical and research entities may leverage our aggregated, de-identified data to better understand treatment patterns, accelerate research, and conduct targeted outreach programs.

These partnerships may take the form of licensing agreements, per-member-per-month (PMPM) contracts, or co-branded integrations. Along with patient membership and provider booking fees, these B2B agreements create an additional revenue pillar that strengthens the HealthLynked Network and drives platform adoption across multiple healthcare touchpoints.

**Sales Strategy**

Growing our patient membership is central to our market penetration strategy. The Freemium model attracts a broad user base by offering basic features without charge, while our tiered approach naturally encourages an upgrade to Concierge services for those seeking more personalized healthcare management, expanded data storage, reduced telemedicine fees, and dedicated support. We promote these benefits through targeted internet-based advertising, search engine optimization, and direct-to-consumer email campaigns that emphasize the convenience and cost-savings of Concierge membership.

On the provider side, our marketing focuses on how HealthLynked can enhance practice revenues, streamline front-office workflow, and meet regulatory mandates more efficiently. Once a physician joins the Network, they pay a one-time activation fee, claim their online profile, and invite their existing patients to create HealthLynked accounts before upcoming visits. By providing a simplified patient onboarding process—thanks to a mobile check-in feature that imports patient data directly into the practice’s system—our platform reduces administrative bottlenecks and helps physicians devote more time to patient care.

To further accelerate adoption among insurers and large employers, we highlight our ARi platform’s capacity to deliver proactive care management and enable better health outcomes at lower costs. We believe that forging alliances with these strategic partners will unlock opportunities to deploy our solutions at scale, benefiting both our bottom line and the wider healthcare community. We also engage in affiliate marketing campaigns with pharmaceutical companies, medical distributors, medical societies, and large healthcare systems. We believe these collaborations help expand awareness of our services, attract new patients and providers, and strengthen our reputation as a leader in connected healthcare.

By combining a robust, tiered patient subscription system, value-driven provider engagement, and forward-thinking strategic partnerships, HealthLynked continues to build a multifaceted sales pipeline that underpins our long-term objective of improving the coordination and quality of healthcare for all stakeholders involved.

7

**Information Security**

Patient data is stored in conformity with the *Health Insurance Portability and Accountability Act* of 1996, *the Health Information Technology for Economic and Clinical Health Act, and the regulations promulgated under each by the U.S. Department of Health and Human Services, Office of Civil Rights*(collectively, “HIPAA”). The network utilizes Amazon AWS infrastructure which uses Amazon HIPPA compliant servers along with Amazon RDS with LAMP, HTML5 and several JavaScript frameworks, including Angular and React. Recommendations for end users are a 512 kbps+ internet connection speed and a web browser such as Google Chrome, Microsoft Edge, Mozilla Firefox, Safari or handheld devices such as iOS devices, android phones or tablets. Our developers utilize third party controls for functionality and user interface where the use of those controls adds value to the system beyond custom creation of new tools. We intend to adjust forward compatibility for major browser version updates, new browsers, operating system updates or new operating system as needed. The HealthLynked Network is EMR agnostic, and is compatible with all electronic medical records systems, allowing for minimal barriers to participation and broader penetration of the market.

**Intellectual Property**

On March 7, 2023, we were issued patent No. 11600395 by the United States Patent and Trademark Office (the “USPTO”). The patent, entitled “Secure patient access via healthcare service provider specific wireless access point,” encompasses systems and methods for providing a healthcare service provider-specific wireless access point, or “HUB”, that facilitates secure communication amongst patients, providers, and third-party services. When in range of the HUB (e.g., in a doctor’s office waiting room), patient devices can connect to the healthcare service provider’s wireless access point. The access point can be configured to detect the presence of a patient device, obtain identifying information, and send the information to a server. The server uses the obtained information to create or update a profile for the patient associated with their device. This profile can be updated with additional information derived from the patient’s interaction with the network, provider input, or the patient updating their profile or inputting additional information. This innovative approach allows for streamlined communication and enhanced data security within the healthcare setting.

In October 2024, we filed a non-provisional patent application for our artificial intelligence (AI) program, ARI (Augmented Real-time Interface). ARI is a healthcare companion designed to make healthcare more interactive, personalized, and user-friendly. By leveraging the capabilities of artificial intelligence, ARI aims to blend technology and human touch, with the goal to provide timely and relevant healthcare advice. One of ARi’s key features is its ability to answer specific medical questions while incorporating patient data to ensure recommendations are relevant and personalized.

We have registered “HealthLynked” and our corporate logo as a service mark with the USPTO.

**Research and Development**

Our research and development efforts consist of building, developing, and enhancing the HealthLynked Network, including comprehensive marketing to active and inactive patients, the real time scheduling of appointments through our new mobile application, regular appointment scheduling, telemedicine appointment scheduling, sharing of secured documents between physicians and patients, and independent access via mobile, tablet and web browser. Further, we are developing our systems to provide for secured data storage, drug interaction alerts, and the barcoding of documents for retrieval and storage.

**Professional and General Liability Coverage**

We maintain directors’ and officers’, professional and general liability insurance policies with third-party insurers generally on a claims-made basis, subject to deductibles, policy aggregates, exclusions, and other restrictions, in accordance with standard industry practice. We believe that our insurance coverage is appropriate based upon our claims experience and the nature and risks of our business. However, no assurance can be given that any pending or future claim against us will not be successful or if successful, will not exceed the limits of available insurance coverage. Our business entails an inherent risk of claims of medical malpractice against our affiliated physicians and us. We contract and pay premiums for professional liability insurance that indemnifies us and our affiliated healthcare professionals generally on a claims-made basis for losses incurred related to medical malpractice litigation. Professional liability coverage is required in order for our physicians to maintain hospital privileges.

8

**Employees**

As of March 31, 2025, we had 20 employees. None of our employees are covered by a collective bargaining agreement. We consider our relationship with our employees to be good.

**Competition**

The markets for our Digital Healthcare products and services are highly competitive and are characterized by rapidly evolving technology and product standards, as well as frequent introduction of new products and services. Most of our competitors are more established, benefit from greater name recognition, and have substantially greater financial, technical, and marketing resources than we do. Our principal existing competitors include, but are not limited to, ZocDoc, Inc., AthenaHealth Inc., All-scripts Healthcare Solutions, Inc., Cerner Corporation, Epic Systems Corporation, Teledoc Health Inc., Veritone Inc., Oscar Health, Good RX and Doximity. In addition, we expect that major software information systems companies, large information technology consulting service providers, start-up companies, managed care companies and others specializing in the health care industry may offer competitive products and services. Amazon, Google, and Apple have also entered into the digital healthcare space, including in the area of patient health records.

We believe that we differ from our competitors in that we are not a practice management software or an EMR provider. Companies like AthenaHealth Inc., Allscripts Healthcare Solutions, Inc., Cerner and Epic Systems Corporation offer software solutions to operate and manage a medical practice. Functions of these systems include patient billing, monitoring patient account balances and payments, tracking of appointments and creating encounter visits and a medical record for each patient seen. HealthLynked works in conjunction with these practice management software systems and does not seek to replace them. Patients’ medical records created by these systems are uploaded to the patient’s profile in the HealthLynked Network. The HealthLynked Network can incorporate any physical or digital documents into a patient’s medical record history and thus allow it to be utilized across all healthcare platforms. HealthLynked provides an online appointment scheduling application that is similar to ZocDoc, Inc.’s offering, but in addition offers telemedicine appointments through our own patient interface, and we do not charge practices for cancelled appointments.

The advantage of having a healthcare network independent of any one practice management or EMR software allows the HealthLynked system to be fully utilized across the entire medical community. Integration and participation by both patients and healthcare providers in a unified platform offers significant advantages in the quality and nature of healthcare delivery in the future. To our knowledge a unified healthcare network like HealthLynked currently does not exist in the market.

Competitors in our Patient Services division include women’s health, functional medicine, physical therapy practices and day spas throughout southwest Florida.

Competitors in our Medical Distribution division indirectly include large unit-of-measure distributors such as McKesson Corp. and Medline as well as small unit-of-measure distributor Henry Schein offering direct to physician, dental and veterinary practices. We attempt to differentiate MOD’s model from these large distributors by focusing on small unit-of-measure distribution direct to patients and physician practices at competitive pricing.

**Government Regulation**

The healthcare industry is governed by a framework of federal and state laws, rules and regulations that are extensive and complex and for which, in many cases, the industry has the benefit of only limited judicial and regulatory interpretation. If we are found to have violated these laws, rules, or regulations, our business, financial condition, and results of operations could be materially adversely affected. Moreover, healthcare reform continues to attract significant legislative interest, regulatory activity, new approaches, legal challenges, and public attention that create uncertainty and the potential for additional changes. Healthcare reform implementation, additional legislation or regulations, and other changes in government policy or regulation may affect our reimbursement, restrict our existing operations, limit the expansion of our business, or impose additional compliance requirements and costs, any of which could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our common stock.

9

*Healthcare Reform*

Health care laws and regulations are rapidly evolving and may change significantly in the future, which could adversely affect our financial condition and results of operations. In March 2010, the Patient Protection and Affordable Care Act and the accompanying Health Care and Education Affordability Reconciliation Act, collectively referred to as the ACA, were enacted. The ACA includes a variety of health care reform provisions and requirements, which became effective at varying times since its enactment and substantially changed the way health care is financed by both governmental and private insurers.

In January 2017, President Donald Trump issued an executive order titled “Minimizing the Economic Burden of the Patient Protection and Affordable Care Act Pending Repeal.” The order directed agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, health care providers, health insurers, or manufacturers of pharmaceuticals or medical devices. In October 2017, President Trump issued a second executive order relating to the ACA titled “Promoting Healthcare Choice and Competition Across the United States,” which further directs federal agencies to modify how the ACA is implemented, and soon after announced the termination of the cost-sharing subsidies that reimburse insurers under the ACA. To date, Congressional efforts to completely repeal and replace the ACA have been unsuccessful. However, the individual mandate for health insurance coverage under the ACA was repealed by Congress as part of the Tax Cuts and Jobs Act that was signed into law on December 22, 2017.

Other proposed changes and reforms to the ACA have included, or may include the following: prohibiting the federal government from operating health insurance marketplaces; eliminating the advanced premium tax credits, and cost sharing reductions for low income individuals who purchase their health insurance through the marketplaces; expanding and encouraging the use of private health savings accounts; providing for insurance plans that offer fewer and less extensive health insurance benefits than under the ACA’s essential health benefits package, including broader use of catastrophic coverage plans, or short-term health insurance; establishing and funding high risk pools or reinsurance programs for individuals with chronic or high cost conditions; and allowing insurers to sell insurance across state lines.

Because of the continued uncertainty about the implementation of the ACA, including the timing of and potential for legal challenges, repeal or amendment of that legislation and the future of the health insurance exchanges, we cannot quantify or predict with any certainty the likely impact of the ACA on our business, financial condition, operating results and prospects.

*Licensing and Certification*

Our clinical personnel are subject to numerous federal, state, and local licensing laws and regulations, relating to, among other things, professional credentialing and professional ethics. Penalties for non-compliance with these laws and standards include loss of professional license, civil or criminal fines and penalties, and exclusion from participation in various governmental and other third-party healthcare programs. Our clinical professionals are also subject to state and federal regulation regarding prescribing medication and controlled substances. Every physician who administers, prescribes, or dispenses any controlled substance must be registered with the Drug Enforcement Administration (“DEA”). Additionally, our clinical personnel are required to meet applicable Medicaid and Medicare provider requirements, as set forth under state and federal laws, rules, and regulations. Further, our facilities are also subject to federal, state, and local licensing regulations: we may have to obtain regulatory approval, including certificates of need, before establishing certain types of healthcare facilities, offering certain services, or expending amounts in excess of statutory thresholds for healthcare equipment, facilities or programs. Our ability to operate profitably will depend, in part, upon our ability and the ability of our clinicians and facilities to obtain and maintain all necessary licenses, certifications, accreditations, and other approvals.

*Fraud and Abuse Provisions*

Existing federal laws, as well as similar state laws, relating to government-sponsored or funded healthcare programs, or “GHC Programs,” impose a variety of fraud and abuse prohibitions on healthcare companies like us. These laws are interpreted broadly and enforced aggressively by multiple government agencies, including the Office of Inspector General of the Department of Health and Human Services, the Department of Justice (the “DOJ”) and various state agencies. In addition, in the Deficit Reduction Act of 2005, Congress established a Medicaid Integrity Program to enhance federal and state efforts to detect Medicaid fraud, waste, and abuse and provide financial incentives for states to enact their own false claims legislation as an additional enforcement tool against Medicaid fraud and abuse. Since then, a growing number of states have enacted or expanded healthcare fraud and abuse laws.

10

The fraud and abuse provisions include extensive federal and state laws, rules and regulations applicable to us, particularly on the services offered at NWC through October 2024. In particular, the federal anti-kickback statute has criminal provisions relating to the offer, payment, solicitation or receipt of any remuneration in return for either referring Medicaid, Medicare or other GHC Program business, or purchasing, leasing, ordering, or arranging for or recommending any service or item for which payment may be made by GHC Programs. In addition, the federal physician self-referral law, commonly known as the “Stark Law,” applies to physician ordering of certain designated health services reimbursable by Medicare from an entity with which the physician has a prohibited financial relationship. These laws are broadly worded and have been broadly interpreted by federal courts, and potentially subject many healthcare business arrangements to government investigation and prosecution, which can be costly and time consuming. Violations of these laws are punishable by substantial penalties, including monetary fines, civil penalties, administrative remedies, criminal sanctions (in the case of the anti-kickback statute), exclusion from participation in GHC Programs and forfeiture of amounts collected in violation of such laws, any of which could have an adverse effect on our business and results of operations.

There are a variety of other types of federal and state fraud and abuse laws, including laws authorizing the imposition of criminal, civil and administrative penalties for filing false or fraudulent claims for reimbursement with government healthcare programs. These laws include the civil False Claims Act (“FCA”), which prohibits the submission of, or causing to be submitted, false claims to GHC Programs, including Medicaid, Medicare, TRICARE (the program for military dependents and retirees), the Federal Employees Health Benefits Program, and insurance plans purchased through ACA exchanges. Substantial civil fines and multiple damages, along with other remedies, can be imposed for violating the FCA. Furthermore, proving a violation of the FCA requires only that the government show that the individual or company that submitted or caused to be submitted an allegedly false claim acted in “reckless disregard” or in “deliberate ignorance” of the truth or falsity of the claim or with “willful disregard,” notwithstanding that there may have been no specific intent to defraud the government program and no actual knowledge that the claim was false (which typically are required to be shown to sustain a criminal conviction). The FCA also applies to the improper retention of known overpayments and includes “whistleblower” provisions that permit private citizens to sue a claimant on behalf of the government and thereby share in the amounts recovered under the law and to receive additional remedies. In recent years, many cases have been brought against healthcare companies by such “whistleblowers,” which have resulted in judgments or, more often, settlements involving substantial payments to the government by the companies involved. It is anticipated that the number of such actions against healthcare companies will continue to increase with the enactment or enhancement of a growing number of state false claims acts, certain amendments to the FCA and enhanced government enforcement.

Further, HIPAA established a national Health Care Fraud and Abuse Control Program under the joint direction of the Attorney General and the Secretary of the U.S. Department of Health and Human Services (HHS), acting through the Inspector General, designed to coordinate federal, state, and local law enforcement activities with respect to health care fraud and abuse. Under HIPAA, a healthcare benefit program includes any private plan or contract affecting interstate commerce under which any medical benefit, item, or service is provided. A person or entity that knowingly and willfully obtains the money or property of any healthcare benefit program by means of false or fraudulent representations in connection with the delivery of healthcare services is subject to a fine or imprisonment, or both. In addition, HIPAA authorizes the imposition of civil money penalties against entities that employ or enter into contracts with excluded Medicare or Medicaid program participants if such entities provide services to federal health program beneficiaries.

In addition, federal and state agencies that administer healthcare programs have at their disposal statutes, commonly known as “civil money penalty laws,” that authorize substantial administrative fines and exclusion from government programs in cases where an individual or company that filed a false claim, or caused a false claim to be filed, knew or should have known that the claim was false or fraudulent. As under the FCA, it often is not necessary for the agency to show that the claimant had actual knowledge that the claim was false or fraudulent in order to impose these penalties.

The civil and administrative false claims statutes are being applied in an increasingly broad range of circumstances. For example, government authorities have asserted that claiming reimbursement for services that fail to meet applicable quality standards may, under certain circumstances, violate these statutes. Government authorities also often take the position, now with support in the FCA, that claims for services that were induced by kickbacks, Stark Law violations or other illicit marketing schemes are fraudulent and, therefore, violate the false claims statutes. Many of the laws and regulations referenced above can be used in conjunction with each other.

11

If we were excluded from participation in any government-sponsored healthcare programs, not only would we be prohibited from submitting claims for reimbursement under such programs, but we also would be unable to contract with other healthcare providers, such as hospitals, to provide services to them. It could also adversely affect our ability to contract with, or to obtain payment from, non-governmental payors.

Although we intend to conduct our business in compliance with all applicable federal and state fraud and abuse laws, many of the laws, rules and regulations applicable to us, including those relating to billing and those relating to financial relationships with physicians and hospitals, are broadly worded and may be interpreted or applied by prosecutorial, regulatory or judicial authorities in ways that we cannot predict. Accordingly, we cannot assure you that our arrangements or business practices will not be subject to government scrutiny or be alleged or found to violate applicable fraud and abuse laws. Moreover, the standards of business conduct expected of healthcare companies under these laws and regulations have become more stringent in recent years, even in instances where there has been no change in statutory or regulatory language. If there is a determination by government authorities that we have not complied with any of these laws, rules and regulations, our business, financial condition and results of operations could be materially, adversely affected.

*False or Fraudulent Claim Laws; Medical Billing and Coding*

Medical billing, coding and collection activities are governed by numerous federal and state civil and criminal laws, regulations, and sub-regulatory guidance. We provide billing and coding services, claims processing and other solutions to providers that relate to, or directly involve, the reimbursement of health services covered by Medicare, Medicaid, other federal and state healthcare programs and private payers. These services may subject us to, or we may be contractually required to comply with, numerous federal and state laws that prohibit false or fraudulent claims including but not limited to the FCA, the federal Civil Monetary Penalties Law (“CMP Law”), and state equivalents. We rely on our customers to provide us with accurate and complete information and to appropriately use the solutions we provide to them, but they may not always do so.

The FCA prohibits the knowing submission of false claims or statements to the federal government, including to the Medicare and Medicaid programs. The FCA defines the term “knowingly” broadly to include not only actual knowledge of a claim’s falsity, but also reckless disregard of the truth of the information, or deliberate ignorance of the truth or falsity of a claim. Specific intent to defraud is not required. The FCA may be enforced by the federal government directly or by a qui tam plaintiff, or whistleblower, on the government’s behalf. The government may use the FCA to prosecute Medicare and other government program fraud in areas such as coding errors and billing for services not rendered. Further, submission of a claim for an item or service generated in violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. When an entity is determined to have violated the FCA, it may be required to pay three times the actual damages sustained by the government, plus substantial civil penalties for each false claim, and may be excluded from participation in federal healthcare programs. We rely on our customers to provide us with accurate and complete information and to appropriately use the solutions we provide to them, but they may not always do so.

*Government Reimbursement Requirements*

In order to participate in the various state Medicaid programs and in the Medicare program, we must comply with stringent and often complex enrollment and reimbursement requirements. Moreover, different states impose differing standards for their Medicaid programs. While we believe that we adhere to the laws, rules and regulations applicable to the government programs in which we participate, any failure to comply with these laws, rules and regulations could negatively affect our business, financial condition and results of operations.

12

In addition, GHC Programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review and new governmental funding restrictions, all of which may materially increase or decrease program payments, as well as affect the cost of providing services and the timing of payments to providers. Moreover, because these programs generally provide for reimbursement on a fee-schedule basis rather than on a charge-related basis, we generally cannot increase our revenue by increasing the amount we charge for our services. To the extent our costs increase, we may not be able to recover our increased costs from these programs, and cost containment measures and market changes in non-governmental insurance plans have generally restricted our ability to recover, or shift to non-governmental payors, these increased costs. In attempts to limit federal and state spending, there have been, and we expect that there will continue to be, a number of proposals to limit or reduce Medicaid and Medicare reimbursement for various services. Our business may be significantly and adversely affected by any such changes in reimbursement policies and other legislative initiatives aimed at reducing healthcare costs associated with Medicaid, Medicare and other government healthcare programs.

Our business also could be adversely affected by reductions in, or limitations of, reimbursement amounts or rates under these government programs, reductions in funding of these programs or elimination of coverage for certain individuals or treatments under these programs.

*HIPAA and Other Privacy Laws*

Numerous federal and state laws, rules, and regulations govern the collection, dissemination, use, and confidentiality of protected health information, including HIPAA, and its implementing regulations, violations of which are punishable by monetary fines, civil penalties and, in some cases, criminal sanctions. As part of the HealthLynked Network and our medical record keeping, third-party billing and other services, we collect and maintain protected health information on the patients that we serve.

Pursuant to HIPAA, the HHS has adopted standards to protect the privacy and security of individually identifiable health information, known as the Privacy Standards and Security Standards. HHS’ Privacy Standards apply to medical records and other individually identifiable health information in any form, whether electronic, paper or oral, that is used or disclosed by healthcare providers, hospitals, health plans and healthcare clearinghouses, which are known as “covered entities.” HHS’ Security Standards require healthcare providers to implement administrative, physical and technical safeguards to protect the integrity, confidentiality and availability of individually identifiable health information that is electronically received, maintained or transmitted (including between us and our affiliated practices). To the extent permitted by applicable privacy regulations and contracts and associated Business Associate Agreements with our customers, we are permitted to use and disclose protected health information to perform our services and for other limited purposes, but other uses and disclosures, such as marketing communications, require written authorization from the patient or must meet an exception specified under the privacy regulations In addition, with respect to our managed physician practices, the HIPAA administrative simplification provisions require the use of uniform electronic data transmission standards of healthcare claims and payment transactions submitted or received electronically. Further, the Health Information Technology for Economic and Clinical Health Act of 2009 (“HITECH”) strengthened and expanded HIPAA, increased penalties for violations, gave patients new rights to restrict uses and disclosures of their health information, and imposed a number of privacy and security requirements directly on business associates that perform functions or services on behalf of covered entities. Specifically, HITECH requires that covered entities report any unauthorized use or disclosure of protected health information that meets the definition of a “breach” to the affected individuals. In addition, HITECH requires that business associates report breaches to their covered entity customers. HITECH also authorizes state Attorneys General to bring civil actions in response to violations of HIPAA that threaten the privacy of state residents. Final regulations implementing the HITECH requirements were issued in January 2013.

To the extent we are permitted under our customer contracts, we may de-identify protected health information and use de-identified information for our purposes without obtaining patient authorization or further complying with HIPAA. Determining whether protected health information has been sufficiently de-identified to comply with the HIPAA privacy standards and our contractual obligations may require complex factual and statistical analyses. Any failure by us to meet HIPAA requirements with respect to de-identification could subject us to penalties.

In addition to the federal HIPAA and HITECH requirements, numerous other state and certain other federal laws protect the confidentiality of patient information, including state medical privacy laws, state social security number protection laws, state genetic privacy laws, human subjects research laws and federal and state consumer protection laws. These state laws govern the collection, dissemination, use, access to and confidentiality of patient information. In many cases, state laws are more restrictive than, and not preempted by, HIPAA, and may allow personal rights of action with respect to privacy or security breaches, as well as fines. State laws are contributing to increased enforcement activity and are also subject to interpretation by various courts and other governmental authorities.

13

*Data Protection and Breaches*

Most states require holders of personal information to maintain safeguards, and all states have laws that require certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals or the state’s attorney general. In some states, these laws are limited to electronic data, but states increasingly are enacting or considering stricter and broader requirements. The laws are inconsistent across states, which can increase the costs of compliance. Additionally, HIPAA imposes certain notification requirements on Business Associates. In certain circumstances involving large breaches, media notice is required. A non-permitted use or disclosure of protected health information is presumed to be a breach under HIPAA unless the Business Associate or covered entity establishes that there is a low probability the information has been compromised consistent with the risk assessment requirements enumerated in HIPAA. In addition, the Federal Trade Commission uses its consumer protection authority to initiate enforcement actions in response to data breaches.

*Compliance Programs*

Organizations that receive reimbursement from a federal or state government payor are expected by the federal government to have a compliance program. Specifically, compliance programs are integral to identifying and rectifying fraud and abuse risk areas, billing and coding violations, and educating employees about the law and other legal requirements or restrictions within the scope of their practice. We maintain a program to monitor compliance with federal and state laws and regulations applicable to healthcare entities. We believe that our compliance program meets the relevant standards provided by the Office of Inspector General of the Department of Health and Human Services.

*Environmental Regulations*

Our healthcare operations generate medical waste that must be disposed of in compliance with federal, state and local environmental laws, rules and regulations. Our office-based operations are subject to compliance with various other environmental laws, rules and regulations. Such compliance does not, and we anticipate that such compliance will not, materially affect our capital expenditures, financial position or results of operations.

*Fair Debt Collection Practices Act*

Some of our operations may be subject to compliance with certain provisions of the Fair Debt Collection Practices Act and comparable state laws. Under the Fair Debt Collection Practices Act, a third-party collection company is restricted in the methods it uses to contact consumer debtors and elicit payments with respect to placed accounts. Requirements under state collection agency statutes vary, with most requiring compliance similar to that required under the Fair Debt Collection Practices Act. Florida’s Consumer Collection Practices Act is broader than the federal legislation, applying the regulations to “creditors” as well as “collectors,” whereas the Fair Debt Collection Practices Act is applicable only to collectors. This prohibits creditors who are attempting to collect their own debts from engaging in behavior prohibited by the Fair Debt Collection Practices Act and Consumer Collection Practices Act. The Consumer Collection Practices Act has very specific guidelines regarding which actions debt collectors and creditors may engage in to collect unpaid debt.

*Government Investigations*

We expect that audits, inquiries and investigations from government authorities, agencies, contractors and payors will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our common stock.

14

**Available Information**

The Company’s Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports are available free of charge through the “Investors” section of the Company’s website, www.healthlynked.com, as soon as reasonably practical after they are filed with the Securities and Exchange Commission (“SEC”). The SEC maintains a website, www.sec.gov, which contains reports, proxy and information statements, and other information filed electronically with the SEC by the Company.

**Item 1A. Risk Factors**

**FINANCIAL AND GENERAL BUSINESS RISKS**

***We believe our current cash and cash equivalents will not be sufficient to fund our business for the next twelve months from the date these financial statements are issued, raising substantial doubt about our ability to continue as a going concern.***

As of December 31, 2024, we had cash balances of $76,241, a working capital deficit of $3,048,832 and an accumulated deficit of $48,164,615. Based on our current business plan, management believes that our available cash and cash equivalents will not be sufficient to fund its operations for the next twelve months from the issuance of the financial statements that are included elsewhere in this Annual Report on Form 10-K without generating positive cash flows and by raising additional capital from outside sources. These conditions raise substantial doubt about our ability to continue as a going concern. In addition, our current operating plan is based on current assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We may be forced to delay or reduce the scope of its commercialization or development programs and/or limit or cease our operations if we are unable to obtain additional funding to support its current business plan.

***A failure to obtain financing could prevent us from executing our business plan or operate as a going concern***

We anticipate that current cash resources and opportunities will be insufficient for us to execute our business plan for twelve months after the date these financial statements are issued. It is possible that if future financing is not obtained, we will not be able to operate as a going concern. We believe that securing substantial additional sources of financing is possible, but there is no assurance of our ability to secure such financing. A failure to obtain additional financing could prevent us from making necessary expenditures for advancement and growth to partner with businesses and hire additional personnel. If we raise additional financing by selling equity, or convertible debt securities, the relative equity ownership of our existing investors could be diluted, or the new investors could obtain terms more favorable than previous investors. If we raise additional funds through debt financing, we could incur significant borrowing costs and be subject to adverse consequences in the event of a default.

Without raising additional capital, whether via sale of equity or debt instruments, from additional advances made pursuant to the July 5, 2022 Standby Equity Purchase Agreement (the “SEPA”), from the collection and monetization of remaining contingent consideration related to the sale of AHP, or from other sources, there is substantial doubt about our ability to continue as a going concern. Any equity capital raised may result in substantial dilution in the number of outstanding shares of our Common Stock.

***Our future success depends on our ability to execute our business plan by fully developing the HealthLynked Network and recruiting physicians and patients to adopt and use the system. However, there is no guarantee that we will be able to successfully implement our business plan.***

Our operations to date have been limited to providing patient services at our NCFM, BTG, AEU, CCN and NWC facilities and generating product revenue from our Medical Distribution segment. We continually develop additional functionality of the Network. However, we cannot predict the scale of how many physicians and patients will adopt our technology, or if and when they do, the timing of such large-scale adoption. We have not yet demonstrated our ability to successfully market and generate material revenue from the HealthLynked Network. We have not entered into any agreements with third party doctors or patients to use our system for their medical records and there is no assurance that we will be able to enter into such agreements in the future. Further, it is possible that other competitors with greater resources could enter the market and make it more difficult for us to attract or keep customers.

15

***Failure to remediate a material weakness in internal accounting controls could result in material misstatements in our financial statements.***

Our management has identified material weaknesses in our internal control over financial reporting and has concluded that, due to such material weakness, our disclosure controls and procedures were not effective as of December 31, 2024. If not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.

***We may not be able to effectively control and manage our growth.***

Our strategy envisions a period of potentially rapid growth in our physician network over the next five years based on aggressively increasing our marketing efforts. We currently maintain a small in-house programming, IT, administrative, marketing and sales function. The capacity to service the online medical records platform and our expected growth, including growth via acquisition, may impose a significant burden on our future planned administrative and operational resources. The growth of our business may require significant investments of capital and increased demands on our management, workforce and facilities. We will be required to substantially expand our administrative and operational resources and attract, train, manage and retain qualified employees, management and other personnel. Failure to do so, or to satisfy such increased demands would interrupt or have a material adverse effect on our business and results of operations.

***The departure or loss of Dr. Michael Dent could disrupt our business.***

During 2023 and 2024, we depended heavily on the continued efforts of Dr. Michael Dent, our Chief Executive Officer and Chairman of the Board. Dr. Dent is essential to our strategic vision and day-to-day operations and would be difficult to replace. While we have entered into a written employment contract with Dr. Dent, we cannot be certain that Dr. Dent will continue with us for any particular period of time. The departure or loss of Dr. Dent, or the inability to hire and retain a qualified replacement, could negatively impact our ability to manage our business.

***Our sales strategy may not be successful.***

We have used a sales model that focuses on telesales and internet-based SEM/SEO sales and marketing efforts in lieu of a direct sales force, in large part to reduce our costs. There is no assurance that our sales model will be effective, and this could have a negative effect on our ability to commercialize and monetize the HealthLynked Network and MOD businesses, or limit their growth.

***Key components of our product sales made through MOD are provided by a sole supplier, and supply shortages or loss of this supplier could result in interruptions in supply or increased costs.***

We rely on a sole supplier for the fulfillment of nearly all product sales made through MOD. If this sole supplier is unable to supply to us in the quantities we require, or at all, or otherwise defaults on its supply obligations to us, we may not be able to obtain alternative supplies form other suppliers on acceptable terms, in a timely manner, or at all. In the event the sole supplier breaches its contract with us, our legal remedies associated with such a breach may be insufficient to compensate us for any damages we may suffer.

16

***The healthcare industry is highly regulated, and government authorities may determine that we have failed to comply with applicable laws, rules, or regulations.***

The healthcare industry, healthcare information technology, the online medical records platform services that we provide, and the physicians’ medical practices we engage in through our Health Services segment are subject to extensive and complex federal, state, and local laws, rules and regulations, compliance with which imposes substantial costs on us. Of particular importance are the provisions summarized as follows:

|  |  |  |
| --- | --- | --- |
|  | ● | federal laws (including the Federal False Claims Act) that prohibit entities and individuals from knowingly or recklessly making claims to Medicaid, Medicare and other government-funded programs that contain false or fraudulent information or from improperly retaining known overpayments; |
|  |  |  |
|  | ● | a provision of the Social Security Act, commonly referred to as the “anti-kickback” statute, that prohibits the knowing and willful offer, payment, solicitation or receipt of any bribe, kickback, rebate or other remuneration, in cash or in kind, in return for the referral or recommendation of patients for items and services covered, in whole or in part, by federal healthcare programs, such as Medicaid and Medicare; |
|  |  |  |
|  | ● | a provision of the Social Security Act, commonly referred to as the Stark Law, that, subject to limited exceptions, applies when physicians refer Medicare patients to an entity for the provision of certain “designated health services” if the physician or a member of such physician’s immediate family has a direct or indirect financial relationship (including a compensation arrangement) with the entity; |
|  |  |  |
|  | ● | similar state law provisions pertaining to anti-kickback, fee splitting, self-referral and false claims issues, which typically are not limited to relationships involving government-funded programs; |
|  |  |  |
|  | ● | provisions of the Federal Health Insurance Portability and Accountability Act of 1996, as amended (“HIPAA”) that prohibit knowingly and willfully executing a scheme or artifice to defraud a healthcare benefit program or falsifying, concealing or covering up a material fact or making any material false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; |
|  |  |  |
|  | ● | state laws that prohibit general business corporations from practicing medicine, controlling physicians’ medical decisions or engaging in certain practices, such as splitting fees with physicians; |

|  |  |  |
| --- | --- | --- |
|  | ● | federal and state healthcare programs may deny our application to become a participating provider that could in turn cause us to not be able to treat those patients or prohibit us from billing for the treatment services provided to such patients; |
|  |  |  |
|  | ● | federal and state laws that prohibit providers from billing and receiving payment from Medicaid or Medicare for services unless the services are medically necessary, adequately and accurately documented and billed using codes that accurately reflect the type and level of services rendered; |
|  |  |  |
|  | ● | federal and state laws pertaining to the provision of services by non-physician practitioners, such as advanced nurse practitioners, physician assistants and other clinical professionals, physician supervision of such services and reimbursement requirements that may be dependent on the manner in which the services are provided and documented; and |
|  |  |  |
|  | ● | federal laws that impose civil administrative sanctions for, among other violations, inappropriate billing of services to federally funded healthcare programs, inappropriately reducing hospital care lengths of stay for such patients, or employing individuals who are excluded from participation in federally funded healthcare programs. |

In addition, we believe that our business, including the business conducted through our Health Services segment, will continue to be subject to increasing regulation, the scope and effect of which we cannot predict.

We may in the future become the subject of regulatory or other investigations or proceedings, and our interpretations of applicable laws, rules and regulations may be challenged. For example, regulatory authorities or other parties may assert that our arrangements with physicians using the HealthLynked Network constitute fee splitting and seek to invalidate these arrangements, which could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our common stock. Regulatory authorities or other parties also could assert that our relationships violate the anti-kickback, fee splitting or self-referral laws and regulations. Such investigations, proceedings and challenges could result in substantial defense costs to us and a diversion of management’s time and attention. In addition, violations of these laws are punishable by monetary fines, civil and criminal penalties, exclusion from participation in government-sponsored healthcare programs, and forfeiture of amounts collected in violation of such laws and regulations, any of which could have a material adverse effect on our overall business, financial condition, results of operations, cash flows and the trading price of our common stock.

Furthermore, changes in these laws and regulations, or administrative and judicial interpretations thereof, may require us to change our business practices which could have a material adverse effect on our business, financial condition and results of operations. Because of the complex and far-reaching nature of these laws, there can be no assurance that we would not be required to alter one or more of our practices to be in compliance with these laws.

17

***We rely on Amazon Web Services, or AWS, for the vast majority of our computing, storage, bandwidth, and other services. Any disruption of or interference with our use of the platform would negatively affect our operations and seriously harm our business.***

Amazon provides distributed computing infrastructure platforms for business operations, or what is commonly referred to as a “cloud” computing service. We currently run the vast majority of our computing on AWS, have built our software and computer systems to use computing, storage capabilities, bandwidth, and other services AWS, and our systems are not fully redundant on the platform. Any transition of the cloud services currently provided by AWS to another cloud provider would be difficult to implement and would cause us to incur significant time and expense. Given this, any significant disruption of or interference with our use of AWS would negatively impact our operations and our business would be seriously harmed. If our users or partners are not able to access the HealthLynked Network or specific HealthLynked features, or encounter difficulties in doing so, due to issues or disruptions with AWS, we may lose users, partners, or revenue. The level of service provided by AWS or similar providers may also impact our users’ and partners’ usage of and satisfaction with our web-based product offerings and could seriously harm our business and reputation. If AWS or similar providers experience interruptions in service regularly or for a prolonged basis, or other similar issues, our business would be seriously harmed. Hosting costs also have and will continue to increase as our user base and user engagement grows and may seriously harm our business if we are unable to grow our revenues faster than the cost of utilizing the services of AWS or similar providers.

***Federal and state laws that protect the privacy and security of protected health information may increase our costs and limit our ability to collect and use that information and subject us to penalties if we are unable to fully comply with such laws.***

Numerous federal and state laws and regulations govern the collection, dissemination, use, security and confidentiality of individually identifiable health information. These laws include:

|  |  |  |
| --- | --- | --- |
|  | ● | Provisions of HIPAA that limit how healthcare providers may use and disclose individually identifiable health information, provide certain rights to individuals with respect to that information and impose certain security requirements; |
|  |  |  |
|  | ● | The Health Information Technology for Economic and Clinical Health Act (“HITECH”), which strengthens and expands the HIPAA Privacy Standards and Security Standards and imposes data breach notification obligations; |
|  |  |  |
|  | ● | Other federal and state laws restricting the use and protecting the privacy and security of protected health information, many of which are not preempted by HIPAA; |
|  |  |  |
|  | ● | Federal and state consumer protection laws; and |
|  |  |  |
|  | ● | Federal and state laws regulating the conduct of research with human subjects. |

Through the HealthLynked Network, we collect and maintain protected health information in paper and electronic format. New protected health information standards, whether implemented pursuant to HIPAA, HITECH, congressional action or otherwise, could have a significant effect on the manner in which we handle healthcare-related data and communicate with third parties, and compliance with these standards could impose significant costs on us, or limit our ability to offer certain services, thereby negatively impacting the business opportunities available to us.

In addition, if we do not comply with existing or new laws and regulations related to protected health information, we could be subject to remedies that include monetary fines, civil or administrative penalties, civil damage awards or criminal sanctions.

**RISKS RELATED TO THE HEALTHLYNKED NETWORK**

***The market for Internet-based personal medical information and record archiving systems may not develop substantially further or develop more slowly than we expect, harming the growth of our business.***

It is uncertain whether personal medical information and record archiving systems will achieve and sustain the high levels of demand and market acceptance we anticipate. Further, even though we expect patients and physicians within our own Health Services segment to use the HealthLynked Network, our success will depend, to a substantial extent, on the willingness of unaffiliated patients, physicians and hospitals to use our services. Some patients, physicians and hospitals may be reluctant or unwilling to use our services, because they may have concerns regarding the risks associated with the security and reliability, among other things, of the technology model associated with these services. If our target users do not believe our systems are secure and reliable, then the market for these services may not expand as much or develop as quickly as we expect, either of which would significantly adversely affect our business, financial condition, or operating results.

18

***If we do not continue to innovate and provide services that are useful to our target users, we may not remain competitive, and our revenues and operating results could suffer.***

Our success depends on our ability to keep pace with technological developments, satisfy increasingly sophisticated client requirements, and obtain market acceptance. Our competitors are constantly developing products and services that may become more efficient or appealing to our clients and users. As a result, we will be required to invest significant resources in research and development in order to enhance our existing services and introduce new high-quality services that clients and users will want, while offering these services at competitive prices.

If we are unable to predict user preferences or industry changes, or if we are unable to modify our services on a timely or cost-effective basis, we may lose clients and target users. Our operating results would also suffer if our innovations are not responsive to the needs of our clients and users, are not appropriately timed with market opportunity, or are not effectively brought to market. As technology continues to develop, our competitors may be able to offer results that are, or that are perceived to be, substantially similar to or better than those generated by our services. This may force us to compete on additional service attributes and to expend significant resources in order to remain competitive.

***We may be unable to adequately protect, and we may incur significant costs in enforcing, our intellectual property and other proprietary rights.***

Our success depends in part on our ability to enforce our intellectual property and other proprietary rights. We expect to rely upon a combination of copyright, trademark, trade secret, and unfair competition laws, as well as license and access agreements and other contractual provisions, to protect these rights.

Our attempts to protect our intellectual property through copyright, patent, and trademark registration may be challenged by others or invalidated through administrative process or litigation. While we have been granted a patent for our PAH, have submitted a patent related to our ARi AI tool, and intend to submit other patent applications covering our integrated technology, the scope of issued patents, if any, may be insufficient to prevent competitors from providing products and services similar to ours, our patents may be successfully challenged, and we may not be able to obtain additional meaningful patent protection in the future. There can be no assurance that our patent registration efforts will be successful.

Our expected agreements with clients, users, vendors and strategic partners will limit their use of, and allow us to retain our rights in, our intellectual property and proprietary information. Further, we anticipate that these agreements will grant us ownership of intellectual property created in the performance of those agreements to the extent that it relates to the provision of our services. In addition, we require certain of our employees and consultants to enter into confidentiality, non-competition, and assignment of inventions agreements. We also require certain of our vendors and strategic partners to agree to contract provisions regarding confidentiality and non-competition. However, no assurance can be given that these agreements will not be breached, and we may not have adequate remedies for any such breach. Further, no assurance can be given that these agreements will be effective in preventing the unauthorized access to, or use of, our proprietary information or the reverse engineering of our technology. Agreement terms that address non-competition are difficult to enforce in many jurisdictions and may not be enforceable in any particular case. In any event, these agreements do not prevent our competitors from independently developing technology or authoring clinical information that is substantially equivalent or superior to our technology or the information we distribute.

To the extent that our intellectual property and other proprietary rights are not adequately protected, third parties might gain access to our proprietary information, develop and market products or services similar to ours, or use trademarks similar to ours, each of which could materially harm our business. Existing U.S. federal and state intellectual property laws offer only limited protection. In addition, if we resort to legal proceedings to enforce our intellectual property rights or to determine the validity and scope of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results, or financial condition.

19

In addition, our platforms incorporate “open source” software components that are licensed to us under various public domain licenses. While we believe that we have complied with our obligations under the various applicable licenses for open source software that we use, open source license terms are often ambiguous, and there is little or no legal precedent governing the interpretation of many of the terms of certain of these licenses. Therefore, the potential impact of such terms on our business is somewhat unknown. For example, some open source licenses require that those using the associated code disclose modifications made to that code and such modifications be licensed to third parties at no cost. We monitor our use of open source software in an effort to avoid uses in a manner that would require us to disclose or grant licenses under our proprietary source code. However, there can be no assurance that such efforts will be successful, and such use could inadvertently occur.

***We may be sued by third parties for alleged infringement of their proprietary rights.***

The software and internet industries are characterized by the existence of a large number of patents, trademarks, and copyrights and by frequent litigation based on allegations of infringement or other violations of intellectual property rights. We may receive in the future communications from third parties claiming that we, our technology, or components thereof, infringe on the intellectual property rights of others. We may not be able to withstand such third-party claims against our technology, and we could lose the right to use third-party technologies that are the subject of such claims. Any intellectual property claims, whether with or without merit, could be time-consuming and expensive to resolve, divert management attention from executing our business plan, and require us to pay monetary damages or enter into royalty or licensing agreements. Although we intend that many of our third-party service providers will be obligated to indemnify us if their products infringe the rights of others, such indemnification may not be effective or adequate to protect us or the indemnifying party may be unable to uphold its contractual obligations.

Moreover, any settlement or adverse judgment resulting from such a claim could require us to pay substantial amounts of money or obtain a license to continue to use the technology or information that is the subject of the claim, or otherwise restrict or prohibit our use of the technology or information. There can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all, from third parties asserting an infringement claim; that we would be able to develop alternative technology on a timely basis, if at all; that we would be able to obtain a license to use a suitable alternative technology or information to permit us to continue offering, and our clients to continue using, our affected services; or that we would not need to change our product and design plans, which could require us to redesign affected products or services or delay new offerings. Accordingly, an adverse determination could prevent us from implementing our strategy or offering our services and products, as currently contemplated.

***We may not be able to properly safeguard the information on the HealthLynked Network.***

Information security risks have generally increased in recent years because of new technologies and the increased activities of perpetrators of cyber-attacks resulting in the theft of protected health, business or financial information. A failure in, or a breach of our information systems as a result of cyber-attacks could disrupt our business, result in the release or misuse of confidential or proprietary information, damage our reputation, and increase our administrative expenses. Further, any such breaches could result in exposure to liability under U.S. federal and state laws and could adversely impact our business. Although we have robust information security procedures and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures or to investigate and remediate any information security vulnerabilities. Any of these disruptions or breaches of security could have a material adverse effect on our business, financial condition, and results of operations.

***Our employees may not take all appropriate measures to secure and protect confidential information in their possession.***

Each of our employees is advised that they are responsible for the security of the information in our systems and to ensure that private information is kept confidential. Should an employee not follow appropriate security measures, including those that have been put in place to prevent cyber threats or attacks, the improper release of protected health information could result. The release of such information could have a material adverse effect on our reputation and our business, financial condition, results of operations, and cash flows.

20

**RISKS RELATED TO THE PROVISION OF MEDICAL SERVICES**

***We may not be able to successfully recruit and retain qualified physicians, who are key to our Health Services segment’s revenues and billing.***

We have experienced substantial turnover of physicians at our Health Service Division facilities. Our ability to operate profitably will depend, in part, upon our ability to recruit and retain qualified physicians, who are key to our Health Services segment’s revenues and billing. We compete with many types of healthcare providers, including teaching, research and government institutions, hospitals and health systems and other practice groups, for the services of qualified doctors, nurses, physical therapists and other skilled healthcare providers essential to our Health Services segment. We may not be able to continue to recruit new, qualified providers or renew contracts with existing providers on acceptable terms. If we do not do so, our ability to service execute our business plan may be adversely affected.

***A significant number of physicians could leave our practices and we may be unable to enforce the non-competition covenants of departed employees.***

We have entered into employment agreements with certain of our physicians that can be terminated without cause by any party upon prior written notice. In addition, substantially all of our physicians have agreed not to compete with us within a specified geographic area for a certain period after termination of employment. The law governing non-compete agreements and other forms of restrictive covenants varies from state to state. Although we believe that the non-competition and other restrictive covenants applicable to our affiliated physicians are reasonable in scope and duration and therefore enforceable under applicable state law, courts and arbitrators in some states are reluctant to strictly enforce non-compete agreements and restrictive covenants against physicians. Our physicians may leave our practices for a variety of reasons, including providing services for other types of healthcare providers, such as teaching, research and government institutions, hospitals and health systems and other practice groups. If a substantial number of our physicians leave our practices or we are unable to enforce the non-competition covenants in the employment agreements, our business, financial condition, results of operations and cash flows could be materially, and adversely affected. We cannot predict whether a court or arbitration panel would enforce these covenants in any particular case.

***We may be subject to medical malpractice and other lawsuits not covered by insurance.***

Our business entails an inherent risk of claims of medical malpractice against our affiliated physicians and us. We may also be subject to other lawsuits which may involve large claims and significant defense costs. Although we currently maintain liability insurance coverage intended to cover professional liability and other claims, there can be no assurance that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us. Liabilities in excess of our insurance coverage, including coverage for professional liability and other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our common stock. See “Professional and General Liability Coverage.”

***Certain federal and state laws may limit our effectiveness at collecting monies owed to us from patients.***

We utilize third parties to collect from patients any co-payments and other payments for services that are provided by our physicians. The Federal Fair Debt Collection Practices Act restricts the methods that third-party collection companies may use to contact and seek payment from consumer debtors regarding past due accounts. State laws vary with respect to debt collection practices, although most state requirements are similar to those under the Fair Debt Collection Practices Act. The Florida Consumer Collection Practices Act, is broader than the federal legislation, applying the regulations to “creditors” as well as “collectors,” whereas the Fair Debt Collection Practices Act is applicable only to collectors. This prohibits creditors who are attempting to collect their own debts from engaging in behavior prohibited by the Fair Debt Collection Practices Act and Florida Consumer Collection Practices Act. The Florida Consumer Collection Practices Act has very specific guidelines regarding which actions debt collectors and creditors may engage in to collect unpaid debt. If our collection practices or those of our collection agencies are inconsistent with these standards, we may be subject to actual damages and penalties. These factors and events could have a material adverse effect on our business, financial condition and results of operations.

***We may not be able to maintain effective and efficient information systems.***

The profitability of our business is dependent on uninterrupted performance of our information systems. Failure to maintain reliable information systems, disruptions in our existing information systems or the implementation of new systems could cause disruptions in our business operations, including errors and delays in billings and collections, disputes with patients and payors, violations of patient privacy and confidentiality requirements and other regulatory requirements, increased administrative expenses and other adverse consequences.

21

**RISKS RELATING TO OUR ORGANIZATION**

***Our articles of incorporation authorize our Board to create a new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our common stock.***

Our Board has the authority to fix and determine the relative rights and preferences of preferred stock. Our Board also has the authority to issue preferred stock without further stockholder approval. As a result, our Board could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our common stock. In addition, our Board could authorize the issuance of a series of preferred stock that has greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative voting power of our common stock or result in dilution to our existing stockholders.

***Stockholders’ ability to influence corporate decisions may be limited because Michael Dent, our Chief Executive Officer and Chairman of the Board, currently owns a controlling percentage of the voting power of our common stock.***

Currently, our officer and directors as a group beneficially control approximately 72.1% of our voting power, of which approximately 70.7% is controlled by our Chairman and CEO, Dr. Michael Dent. As a result of this voting control, our officer and directors can control all matters submitted to our stockholders for approval, including the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our Company on terms that other stockholders may desire. In addition, as the interests of our officer and directors and our minority stockholders may not always be the same, this large concentration of voting power may lead to stockholder votes that are inconsistent with the best interests of our minority stockholders or the best interest of the Company as a whole.

***If we fail to establish and maintain an effective system of internal control, we may not be able to report our financial results accurately or to prevent fraud. Any inability to report and file our financial results accurately and timely could harm our reputation and adversely impact the trading price of our common stock.***

Effective internal control is necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed, and our business and reputation with investors may be harmed. As a result, our small size and any current internal control deficiencies may adversely affect our financial condition, results of operation and access to capital. We have not performed an in-depth analysis to determine if historical undiscovered failures of internal controls exist and may in the future discover areas of our internal control that need improvement.

We are required to comply with the SEC’s rules implementing Section 302 of the Sarbanes-Oxley Act of 2002, which require our management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of our internal control over financial reporting. However, our independent registered public accounting firm is not yet required to formally attest to the effectiveness of our internal controls over financial reporting and will not be required to do so for as long as we are a “non-accelerated filer” as defined in Rule 12b-2 of the Exchange Act.

***The public market for our common stock is limited.  Failure to develop or maintain a trading market could negatively affect its value and make it difficult or impossible for you to sell your shares.***

Our common stock has traded on the OTCQB under the symbol “HLYK” since May 10, 2017.  There is a limited public market for our common stock and a more active public market for our common stock may not develop.  Failure to develop or maintain an active trading market could make it difficult to sell shares or recover any part of an investment in our common shares.  Even if a market for our common stock does develop, the market price of our common stock may be highly volatile.  In addition to the uncertainties relating to future operating performance and the profitability of operations, factors such as variations in interim financial results or various, as yet unpredictable, factors, many of which are beyond our control, may have a negative effect on the market price of our common stock.

22

***Our common stock is subject to the “penny stock” rules of the SEC and the trading market in the securities is limited, which makes transactions in our common stock cumbersome and may reduce the value of an investment in our common stock.***

Rule 15g-9 under the Exchange Act establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions.  For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person’s account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

In order to approve a person’s account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information, investment experience, and investment objectives of the person and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and that the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) confirms that the broker or dealer received a signed, written agreement from the investor prior to the transaction.  Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules.  This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our common stock.

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker or dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions.  Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

***We are a “smaller reporting company”, and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.***

We are a “smaller reporting company” as defined in Rule 12b-2 of the Exchange Act. As a smaller reporting company, we are able to take advantage of certain exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and providing only two years of audited financial statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

***Our stockholders are subject to significant dilution upon the occurrence of certain events which could result in a decrease in our stock price.***

As of March 31, 2025, we had approximately 180,290,305 shares of our common stock reserved or designated for future issuance upon the exercise of outstanding options, warrants, unvested employee grants, common stock issuable, convertible debt and Series B Convertible Preferred Stock. Future sales of substantial amounts of our common stock into the public and the issuance of the shares reserved for future issuance, in payment of our debt, and/or upon exercise of outstanding options and warrants, will be dilutive to our existing stockholders and could result in a decrease in our stock price.

23

**Item 1B. Unresolved Staff Comments**

None.

**Item 1C. Cybersecurity.**

We rely on information systems and the data stored on them to conduct its operations. We have adopted and maintain a cybersecurity risk management program in accordance with our risk profile and business that is informed by and incorporates elements of industry standards.

Our cybersecurity risk management program incorporates multiple components, including, but not limited to, ongoing monitoring of critical risks from cybersecurity threats using automated tools. Additionally, we have implemented an employee education and training program, which we provide on an annual basis, that is designed to raise awareness of cybersecurity threats. To support our cybersecurity risk management program, we leverage managed service providers and other third-party information technology and cybersecurity providers and consultants, including to perform regular system scans and threat intelligence analysis. Additionally, we require certain third-party providers and consultants to adhere to contractual requirements relating to privacy and cybersecurity standards. We do not have a board of directors committee or subcommittee responsible for the oversight of risks from cybersecurity threats.

We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. However, like other companies in our industry, we and our third-party vendors have from time-to-time experienced threats and security incidents that could affect our information or systems. For more information, please see the section entitled “Risk Factors.”

**Item 2. Properties**

The Company leases its operating facilities pursuant to the following lease agreements: (i) amendment to our existing lease agreement for our CCN and AEU practices for approximately 3,650 square feet that commenced in August 2023 and expires in July 2026, located in Naples, FL; (ii) amendment to our existing lease agreement for our BTG practice for approximately 2,150 square feet that commenced in April 2023 and expires in March 2025, located in Bonita Springs, FL; (iii) amendment to our existing lease agreement for our NCFM practice for approximately 3,700 square feet that commenced in June 2022 and expires in May 2025, located in Naples, FL; and (iv) amendment to our existing lease agreement for our corporate office for approximately 3,517 square feet that commenced in August 2024 and expires December 2026, located in Naples, FL.

**Item 3. Legal Proceedings**

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not aware of any such legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

**Item 4. Mine Safety Disclosure**

Not applicable.

24

**PART II.**

**Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities**

**Market Information**

Since May 10, 2017, our common stock has been eligible for quotation and trades on the OTCQB under the symbol “HLYK.”  Quotations on the OTCQB reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

**Holders**

As of March 31, 2025, there were approximately 306 registered holders of record of the Company’s common stock. A substantially greater number of holders of Company common stock are “street name” or beneficial holders, whose shares of record are held by banks, brokers, and other financial institutions.

**Dividend Policy**

We have never declared or paid cash dividends on our common stock, and we do not intend to pay any cash dividends on our common stock in the foreseeable future. Rather, we expect to retain future earnings (if any) to fund the operation and expansion of our business and for general corporate purposes.

**Unregistered Sales of Equity Securities**

Except as previously disclosed in a Current Report on Form 8-K or in a Form 10-Q, or as set forth below, the Company has not sold securities that were not registered under the Securities Act of 1933, as amended (the “Securities Act”), during the year ended December 31, 2024 and through the date of this report:

On April 22, 2024, we issued a promissory note payable to an investor with a stated principal amount of $161,000 and prepaid interest of $19,320 for total repayments of $180,320. We received net proceeds of $118,787 after original issue discount of $21,000, fees of $5,000, and withholding of the final payment due on a prior note payable to the same investor in the amount of $16,213. The note does not bear interest in excess of the original issue discount and prepaid interest and matures on February 28, 2025. The Company is required to make 10 monthly payments of $18,032 starting May 30, 2024 and ending on February 28, 2025. The note gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock only in the event of default.

On July 30, 2024, our wholly owned subsidiary, HLYK Florida LLC, which owns NCFM, issued a promissory note payable to an investor with total principal repayments of $223,649. We received net proceeds of $200,000 after original issue discount of $19,649 and fees of $4,000. The note does not bear interest in excess of the original issue discount. We are required to make 24 monthly payments of $9,319 starting August 20, 2024 and ending on July 20, 2026. The note is secured by all of NCFM’s assets and is personally guaranteed by the Company’s CEO, Dr. Michael Dent.

On December 4, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible promissory note in the aggregate principal amount of $25,000, with an interest rate of 12% per annum and a maturity date May 4, 2025. The convertible note payable is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.033 per share, or 757,576 shares.

On December 17, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible promissory note in the aggregate principal amount of $70,000, with an interest rate of 12% per annum and a maturity date June 17, 2025. The convertible note payable is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.026 per share, or 2,692,308 shares.

25

On December 31, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible promissory note in the aggregate principal amount of $120,000, with an interest rate of 12% per annum and a maturity date July 1, 2025. The convertible note payable is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.023 per share, or 5,217,391 shares.

On December 31, 2024, we issued 617,750 ten-year warrants with an exercise price of $0.0226 per share in connection with the extension of two existing notes payable to a trust controlled by Dr. Michael Dent.

The sales of the above securities were exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act, as transactions by an issuer not involving any public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions.

**Recent Repurchases of Securities.**

None.

**Item 6. [Reserved]**

**Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations**

**Forward-Looking Statements**

*You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Item 1A. Risk Factors” included elsewhere in this Annual Report on Form 10-K. All amounts in this report are in U.S. dollars, unless otherwise noted.*

**Overview**

HealthLynked was incorporated in the State of Nevada on August 4, 2014. We currently operate in three distinct divisions: the Health Services Division, the Digital Healthcare Division, and the Medical Distribution Division. Our Health Services division is comprised of the operations of (i) NCFM, a functional medical practice engaged in improving the health of its patients through individualized and integrative health care, (ii) BTG, a physical therapy practice in Bonita Springs, Florida that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery, (iii) CCN, a primary care providing a comprehensive range of medical services, and (iv) AEU, a minimally and non-invasive cosmetic services. During 2024, we replaced our NWC Obstetrics and Gynecology (OB/GYN) practice with CCN and relocated its AEU practice to the CCN office location.

Our Digital Healthcare division develops and operates an online personal medical information and record archive system, the “HealthLynked Network,” which facilitates efficient management of medical records and care, allowing seamless patient appointment scheduling, comprehensive telemedicine services, and a cloud-based system for medical information and records management. Our Medical Distribution Division is comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States.

**Critical accounting policies and significant judgments and estimates**

For a discussion of our critical accounting policies, see Note 2, “*Significant Accounting Policies,”* in the Notes to consolidated Financial Statements.

26

**Results of Operations: Years Ended December 31, 2024 and 2023**

The following table summarizes the changes in our results of operations for the year ended December 31, 2024 compared with the year ended December 31, 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |  | **Change** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |  | **$** | |  |  | **%** | |  |
|  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Patient service revenue, net |  | $ | 2,872,177 |  |  | $ | 5,484,278 |  |  | $ | (2,612,101 | ) |  |  | -48 | % |
| Subscription revenue |  |  | 32,425 |  |  |  | 58,901 |  |  |  | (26,476 | ) |  |  | -45 | % |
| Product revenue |  |  | 103,759 |  |  |  | 179,200 |  |  |  | (75,441 | ) |  |  | -42 | % |
| Total revenue |  |  | 3,008,361 |  |  |  | 5,722,379 |  |  |  | (2,714,018 | ) |  |  | -47 | % |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Operating Expenses and Costs** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Practice salaries and benefits |  |  | 1,995,127 |  |  |  | 3,231,117 |  |  |  | (1,235,990 | ) |  |  | -38 | % |
| Other practice operating expenses |  |  | 1,556,759 |  |  |  | 2,205,085 |  |  |  | (648,326 | ) |  |  | -29 | % |
| Cost of product revenue |  |  | 96,237 |  |  |  | 142,501 |  |  |  | (46,264 | ) |  |  | -32 | % |
| Selling, general and administrative expenses |  |  | 3,038,936 |  |  |  | 3,623,402 |  |  |  | (584,466 | ) |  |  | -16 | % |
| Depreciation and amortization |  |  | 282,950 |  |  |  | 352,027 |  |  |  | (69,077 | ) |  |  | -20 | % |
| Impairment loss |  |  | 716,000 |  |  |  | 319,958 |  |  |  | 396,042 |  |  |  | 124 | % |
| Loss from operations |  |  | (4,677,648 | ) |  |  | (4,151,711 | ) |  |  | (525,937 | ) |  |  | 13 | % |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Other Income (Expenses)** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss on extinguishment of debt |  |  | (178,986 | ) |  |  | (145,212 | ) |  |  | (33,774 | ) |  |  | 23 | % |
| Change in fair value of debt |  |  | 84,109 |  |  |  | --- |  |  |  | 84,109 |  |  |  | \* |  |
| Gain from expiration of liability classified equity instruments |  |  | --- |  |  |  | 92,641 |  |  |  | (92,641 | ) |  |  | -100 | % |
| Amortization of original issue discounts on notes payable |  |  | (1,316,165 | ) |  |  | (427,808 | ) |  |  | (888,357 | ) |  |  | 208 | % |
| Gain from realization of contingent sale consideration receivable |  |  | 125,355 |  |  |  | 1,090,857 |  |  |  | (965,502 | ) |  |  | -89 | % |
| Interest expense and other |  |  | (168,144 | ) |  |  | (72,718 | ) |  |  | (95,426 | ) |  |  | 131 | % |
| Total other income (expenses) |  |  | (1,453,831 | ) |  |  | 537,760 |  |  |  | (1,991,591 | ) |  |  | -370 | % |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss from continuing operations |  |  | (6,131,479 | ) |  |  | (3,613,951 | ) |  |  | (2,517,528 | ) |  |  | 70 | % |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Discontinued operations** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss from operations of discontinued operations |  |  | --- |  |  |  | (72,321 | ) |  |  | 72,321 |  |  |  | -100 | % |
| Gain from disposal of discontinued operations |  |  | --- |  |  |  | 2,674,069 |  |  |  | (2,674,069 | ) |  |  | -100 | % |
| Gain on discontinued operations |  |  | --- |  |  |  | 2,601,748 |  |  |  | (2,601,748 | ) |  |  | -100 | % |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Net loss** |  | $ | (6,131,479 | ) |  | $ | (1,012,203 | ) |  | $ | (5,119,276 | ) |  |  | 506 | % |

|  |  |  |
| --- | --- | --- |
|  | \* | - Denotes line item on statement of operations for which there was no corresponding activity in the same period of prior year. |

*Revenue*

Patient service revenue decreased by $2,612,101, or 48% year-over-year, from $5,484,278 in the year ended December 31, 2023, to $2,872,177 in the year ended December 31, 2024, primarily as a result of (i) a 49% year-over-year decrease at our NCFM practice of $2,054,954 due to changes in clinical staffing that saw the departure of three physicians in 2023, two of which have been replaced, (ii) a 54% decrease at our NWC practice facility of $382,288, and (iii) an 89% year-over-year decrease at our AEU practice of $246,757 due to the departure of our primary physician and attrition from the practice, offset by (iv) 21% increase of $63,266 at our BTG practice and (v) 2024 revenue of $8,632 from our newly-launched CCN practice. The reduction in revenue was offset in part by a corresponding designed reduction in practice operating costs as described below in the fluctuation of “Practice salaries and benefits” and “Other practice operating costs,” which declined by a combined $1,884,316 from the year ended December 31, 2023 to the year ended December 31, 2024. While we plan for patient service revenue to increase in future periods from levels realized in the year ended December 31, 2024 as we plan to add additional physicians and continue patient marketing and retention efforts, there is no guarantee that such increases will occur.

27

Subscription revenue in the year ended December 31, 2024 decreased by $26,476, or 45% year-over-year, to $32,425 in the year ended December 31, 2024, from $58,901 in the year ended December 31, 2023, due primarily to a decrease in HealthLynked Network paid subscriptions that were paired with NCFM membership contracts.

Product revenue was $103,759 in the year ended December 31, 2024, compared to $179,200 in the year ended December 31, 2023, a decrease of $75,441, or 42%. Product revenue was earned by the Medical Distribution Division, comprised of the operations of MOD, which decreased due to decreased marketing efforts and demand for our products at our offered price points.

*Operating Expenses and Costs*

Practice salaries and benefits decreased by $1,235,990, or 38%, to $1,995,127 in the year ended December 31, 2024, compared to $3,231,117 in the year ended December 31, 2023, primarily as a result of focused cost reduction efforts at all of our practices starting in mid-2023 and continuing through 2024.

Other practice operating costs decreased by $648,326 or 29%, to $1,556,759 in the year ended December 31, 2024 from $2,205,085 in the year ended December 31, 2023, primarily as a result of focused cost reduction efforts at all of our practices starting in mid-2023 and continuing through mid-2024.

Cost of product revenue was $96,237 in the year ended December 31, 2024, a decrease of $46,264, or 32%, compared to $142,501 in the same period of 2023, corresponding to the decline in product sales for the period compared to the same period in the prior year.

Selling, general and administrative costs decreased by $584,466, or 16%, to $3,038,936 in the year ended December 31, 2024 compared to $3,623,402 in the year ended December 31, 2023, primarily due to lower consulting and other office and overhead costs in our corporate function resulting from focused cost cutting efforts, as well as lower stock-based compensation expense resulting from fewer employee and consultant grants in 2024.

Depreciation and amortization in the year ended December 31, 2024 decreased by $69,077, or 20%, to $282,950 compared to $352,027 in the year ended December 31, 2023, primarily as a result of certain fixed asset reaching the end of their depreciable lives during 2023 without corresponding additions.

During the third quarter of 2024, the Company determined that triggering events had occurred that required an impairment assessment of the NCFM Medical Database. The triggering events included (i) a material decline in revenue during third quarter 2024, including a 65% decline compared to the third quarter of 2023 and a 35% decline compared to the preceding sconed quarter of 2024, (ii) substantial operating losses and negative cash flows generated from the practice during the third quarter of 2024 for the first time since its acquisition, and (iii) substantial downsizing of the practice personnel and overhead. We determined that the carrying amount of the reporting unit, which consists of the NCFM practice, exceeded its estimated fair value. Accordingly, we recorded an impairment charge in the amount of $716,000 to adjust carrying value of the NCFM Medical Database to its estimated fair value of $-0- in the year ended December 31, 2024. During the year ended December 31, 2023, we determined that triggering events had occurred that required impairment assessments of goodwill related to our AEU business. The triggering events included (i) a material decline in revenue during third quarter 2023, and (ii) an inability of the business to achieve profitability since its acquisition. We determined that the carrying amount of the reporting unit, which consists of the AEU practice, exceeded its estimated fair value. Accordingly, we recorded an impairment charge in the amount of $319,958 to adjust carrying value of AEU goodwill to its estimated fair value of $-0- in the year ended December 31, 2023.

Loss from operations increased by $525,967, or 13%, to $4,677,648 in the year ended December 31, 2024 compared to $4,151,711 in the year ended December 31, 2023, primarily as a result of decreased revenue and increased impairment charges in 2024, offset in part by reduced practice operating costs and corporate overhead costs.

*Other Income (Expenses)*

Loss on extinguishment of debt in the year ended December 31, 2024 was $178,986, compared to a loss of $145,212 in the year ended December 31, 2023. Loss on extinguishment of debt in 2023 resulted from early repayment of eight notes payable and extension of two related party notes payable. Loss on extinguishment of debt in 2024 resulted from two maturing notes payable to Dr. Dent refinanced with new convertible notes payable in the same amount and the extension of the maturity date of four additional notes payable to Dr. Dent.

Gains from the change in fair value of debt was $84,109 in the year ended December 31, 2024 related to three notes payable to Dr. Michael Dent that were recorded at fair value following extension of the maturity dates of the notes. These notes are revalued at their fair value at the end of each period, with the changes recorded as gains or losses from the change in fair value of debt. There were no such gains or losses in the year ended December 31, 2023.

28

Gain from expiration of liability classified equity instruments was $92,641 in the year ended December 31, 2023 and resulted from the expiration of liability-classified warrants issued in 2020. There were no such gains or losses in the year ended December 31, 2024.

Amortization of original issue and debt discounts on notes payable and convertible notes in the year ended December 31, 2024 was $1,316,165, an increase of $888,357, or 208%, compared to $427,808 in the year ended December 31, 2023. Amortization of discounts arose from original issue discounts on notes payable, warrants attached to notes payable, and beneficial conversion features in convertible notes payable. The increase was due to higher notes payable balances and larger equity-based and original issue discounts offered for new notes payable, and therefore larger corresponding amortizable discount balances, in 2024 compared to 2023.

Gain from realization of contingent sale consideration receivable was $125,355 in the year ended December 31, 2024, a decrease of $965,502, or 89% compared to a gain of $1,090,857 in the year ended December 31, 2023. The gains resulted from actual proceeds received during the period from contingent sale consideration related to the sale of AHP in excess of the amount estimated to be received at the time of the sale in January 2023. Receipts during the year ended December 31, 2024 included $500,000 gross ($325,000 net) from the receipt of Physician Advance Consideration in November 2024. Receipts during the year ended December 31, 2023 included $1,750,000 gross ($1,540,000 net) in Incremental Cash Consideration and $1,873,993 gross ($1,186,231 net) from the 2022 MSSP Consideration.

Interest expense and other increased by $95,426, or 131%, to $168,144 for the year ended December 31, 2024, compared to $72,718 in the year ended December 31, 2023, due to an increase in interest-bearing notes payable to related parties and third parties during 2024, primarily in the form of new notes and convertible notes payable to Dr. Dent.

Total other income (expenses) increased by $1,991,591, or 370%, to net expense of $1,453,831 in the year ended December 31, 2024 compared to net income of $537,760 in the year ended December 31, 2023. The change was primarily a result of a $1,090,857 gain from realization of contingent sale consideration receivable related to the collection of consideration in the AHP sale in 2023 and higher debt-related discount amortization and interest charges in 2024 corresponding to higher debt balances with larger initial fees and discounts.

Loss from continuing operations increased by $2,517,528, or 70%, to $6,131,479 in the year ended December 31, 2024, compared to $3,613,951 in the year ended December 31, 2023. The increased loss in 2024 was due primarily to a decrease in revenue, a $1,090,857 gain from realization of contingent sale consideration receivable related to the collection of consideration in the AHP sale in 2023, higher impairment charges and increased debt-related discount amortization and interest charges, offset in part by reduced practice operating costs and corporate overhead costs.

*Gain (loss) from operations of discontinued operations*

As a result of the AHP Sale on January 17, 2023, our ACO/MSO Division was classified as discontinued operations in the accompanying consolidated statement of operations for the year ended December 31, 2024 and 2023. Loss from operations of discontinued operations decreased by $72,321, or 100%, from $72,321 in the year ended December 31, 2023 to $-0- in the year ended December 31, 2024. The loss in 2023 reflects winding down costs of the discontinued operation after the sale on January 17, 2023. No revenue or costs were incurred related to the business in the year ended December 31, 2024.

Effective January 17, 2023, we completed the AHP Sale, at which time we discontinued the operations of CHM and ceased to have a controlling financial interest in AHP. In connection with the AHP Sale, as of January 17, 2023, we recognized the fair value of consideration received and receivable from the AHP Sale, recognized an indemnification liability related to potential claims resulting from the AHP Sale, derecognized the carrying value of assets and liabilities transferred to the Buyer or otherwise derecognized in connection with in the AHP Sale, and recorded a gain on sale for the excess of consideration received over carrying value of assets derecognized and liabilities recognized. Accordingly, we recorded a gain from disposal of AHP in the amount of $2,674,069 in the year ended December 31, 2023.

*Net loss*

Net loss increased by $5,119,276, or 506%, to $6,131,479 in the year ended December 31, 2024, compared to net loss of $1,012,203 in the year ended December 31, 2023, primarily as a result of (i) the gain from disposal of AHP in the amount of $2,674,069 in the year ended December 31, 2023 with no corresponding gain in the year ended December 31, 2024, (ii) a decrease in revenue and increased impairment charges and debt-related discount amortization and interest charges, and (iii) a $1,090,857 gain from realization of contingent sale consideration receivable related to the collection of consideration in the AHP sale in 2023, offset in part by (iv) reduced practice operating costs and corporate overhead costs from cost cutting measures implemented in 2024.

29

**Seasonal Nature of Operations**

We do not experience any material seasonality related to any of our operations.

**Impairment**

Impairment Reviews

Long-lived assets (including amortizable identifiable intangible assets) or asset groups held for use are tested for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. When such events occur, we compare the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset or asset group to the carrying amount of a long-lived asset or asset group. The cash flows are based on our best estimate of future cash flows derived from the most recent business projections. If this comparison indicates that the asset is not recoverable, we estimate the fair value of the asset group using a discounted cash flow model. An impairment charge is then recorded for any excess carrying value above the estimated fair value of the asset group.

Goodwill is tested for impairment on an annual basis and more often if circumstances indicate that an impairment may be necessary. Goodwill impairment is recognized for any excess carrying value above the estimated fair value of the asset group. Fair value is estimated using the same approach as described above for long-lived asset testing.

The significant assumptions we use in the discounted cash flow models are revenue growth rate, gross profit margins on product sales, operating income margin, and the discount rate used to determine the present value of the cash flow projections. Among other inputs, revenue growth rate and operating income margin are determined by management using historical performance trends, projected performance from existing partnerships, industry data, relevant changes in the reporting unit’s underlying business, and other market trends that may affect the reporting unit. The discount rate is based on the estimated weighted average cost of capital as of the test date of market participants in the industry in which the reporting unit operates. The assumptions used in the discounted cash flow model are subject to significant judgment and uncertainty. Changes in projected revenue growth rates, gross profit margins, projected operating income margins, or estimated discount rates due to uncertain market conditions, losses of key physicians in our Health Services reporting unit, changes in technology, or other factors, could result in one or more of our reporting units with a significant amount of identifiable intangible assets recognizing material impairment charges, which could be material to our results of operations and financial position. Our historical or projected revenues or cash flows may not be indicative of actual future results.

Impairment of NCFM Medical Database – 2024

During the third quarter of 2024, we determined that triggering events had occurred that required an impairment assessment of the NCFM Medical Database. The triggering events included (i) a material decline in revenue during third quarter 2024, including a 65% decline compared to third quarter of 2023 and a 35% decline compared to the second quarter of 2024, (ii) substantial operating losses and negative cash flows generated from the practice for the first time since its acquisition, and (iii) substantial downsizing of the practice personnel and overhead. We do not believe that the levels of revenue and profitability achieved since acquisition of NCFM are reasonably likely to return to the extent that projected cash flows from the practice can substantiate the carrying value of the NCFM Medical Database.

An impairment loss is recognized if the carrying amount of a reporting unit exceeds its fair value. The amount of impairment loss is measured as the excess of the reporting unit’s carrying value over its fair value. We determined that the carrying amount of the reporting unit, which consists of the NCFM practice, exceeded its estimated fair value. Accordingly, we recorded an impairment charge in the amount of $716,000 to adjust carrying value of the NCFM Medical Database to its estimated fair value of $-0- in the year ended December 31, 2024.

The fair value of the NCFM reporting unit was determined using a discounted cash flow approach, which applies a market discount rate to a projected stream of cash flows, as estimated by management. As such, the fair values of the NCFM reporting unit and goodwill rely on significant unobservable inputs and assumptions and there is uncertainty in the expected future cash flows used in the impairment review.

30

Impairment of AEU Goodwill – 2023

During the third quarter of 2023, we determined that triggering events had occurred that required an impairment assessment of the AEU goodwill. The triggering events included (i) a material decline in revenue during third quarter 2023, and (ii) an inability of the business to achieve profitability since its acquisition. An impairment loss is recognized if the carrying amount of a reporting unit exceeds its fair value. The amount of impairment loss is measured as the excess of the reporting unit’s carrying value over its fair value. We determined that the carrying amount of the reporting unit, which consists of the AEU practice, exceeded its estimated fair value. Accordingly, we recorded an impairment charge in the amount of $319,958 to adjust carrying value of AEU goodwill to its estimated fair value of $-0- in the year ended December 31, 2023.

The fair value of the AEU reporting unit was determined using an expected present value approach, which applies a market discount rate to a probability-weighted stream of cash flows based on multiple scenarios, as estimated by management. As such, the fair values of the AEU reporting unit and goodwill rely on significant unobservable inputs and assumptions and there is uncertainty in the expected future cash flows used in the impairment review.

**Liquidity and Capital Resources**

Liquidity Condition

During the 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This update provided U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. Under this standard, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period, including interim periods. In evaluating our ability to continue as a going concern, management considered the conditions and events that could raise substantial doubt about our ability to continue as a going concern within 12 months after our financial statements were issued (March 31, 2026).

Management considered our current financial condition and liquidity sources, including current funds available, forecasted future cash flows and our obligations due before March 31, 2026 and concluded that, without additional funding, we will not have sufficient funds to meet our obligations within one year from the date the consolidated financial statements were issued. Without raising additional capital, either via additional advances made pursuant to the SEPA or from other sources, there is substantial doubt about our ability to continue as a going concern through March 31, 2026. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. This basis of presentation contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business.

We are subject to a number of risks, including uncertainty related to product development and generation of revenues and positive cash flow from our Digital Healthcare Division and a dependence on outside sources of capital. The attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill our growth and operating activities and generating a level of revenues adequate to support our cost structure.

As of December 31, 2024, we had cash balances of $76,241, a working capital deficit of $3,048,832 and an accumulated deficit of $48,164,615. For the year ended December 31, 2024, we had a net loss of $6,131,479 and we used cash from operating activities of $3,494,122. We expect to continue to incur net losses and have significant cash outflows for at least the next 12 months.

31

Significant Liquidity Transactions

Through December 31, 2024, we have funded our operations principally through a combination of sales of our common stock, convertible and non-convertible promissory notes, government issued debt, and related party debt, as described below.

On July 5, 2022, we entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”). Pursuant to the SEPA, we have the right to sell to Yorkville up to 30,000,000 shares of our common stock, par value $0.0001 per share, at our request any time during the three-year commitment period set forth in the SEPA. Because the purchase price per share to be paid by Yorkville for the shares of common stock sold by us to Yorkville pursuant to the SEPA, if any, will fluctuate based on the market prices of our common stock during the applicable pricing period, we cannot reliably predict the actual purchase price per share to be paid by Yorkville for those shares, or the actual gross proceeds we will receive from those sales, if any. During January 2023, we sold 225,000 shares of common stock under the SEPA, receiving $18,765 in proceeds, all of which was applied to the balance of a then-outstanding promissory note payable to Yorkville. We have not sold any additional shares under the SEPA since January 2023.

During the year ended December 31, 2024, we issued 19 new convertible notes payable to, and received three undocumented advances from, our CEO, Dr. Michael Dent, for aggregate net cash proceeds of $3,270,000 and refinanced or extended five existing notes with an aggregate principal of $866,500. We also issued notes payable to third parties for net cash proceeds of $335,000. We made repayments on related party and third-party notes of $167,601 and $941,660 in the years ended December 31, 2024 and 2023, respectively.

During the year ended December 31, 2024, we sold 5,977,193 shares of common stock to four investors in separate private placement transactions. We received $405,000 in proceeds from the sales. In connection with the stock sales, we also issued 2,500,000 five-year warrants to purchase shares of common stock at an exercise price of $0.17 per share and 438,596 five-year warrants to purchase shares of common stock at an exercise price of $0.16 per share.

On January 17, 2023, we entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and we agreed to sell, AHP. Since the sale date, we have received the following proceeds: (i) $750,000 upon signing of the AHP Merger Agreement, (ii) $31,381 in March 2023 for the Stub Period Reimbursement, (iii) $1,750,000 ($1,540,000 net after commissions) in Incremental Cash Consideration during June, July and August for meeting participating physician transfer milestones, (iv) $1,873,993 gross ($1,186,231 net after commissions) in October 2023 from the 2022 MSSP Consideration, and (v) $500,000 ($325,000 net after payments to participating physicians and commissions) in November 2024 from the Physician Advance Consideration. We may receive future proceeds comprised of proceeds from sale of shares of the Buyer if the Buyer completes an initial public offering by May 1, 2025.

Without raising additional capital, whether via the sale of equity or debt instruments, from receipt of remaining contingent consideration related to the sale of the ACO/MSO Division, from additional advances made pursuant to the SEPA, or from other sources, there is substantial doubt about the Company’s ability to continue as a going concern through March 31, 2026. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of presentation contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

Plan of operation and future funding requirements

Our plan of operations is to profitably operate our Health Services business and continue to invest in our Digital Healthcare business, including our cloud-based online personal medical information and record archiving system, the “HealthLynked Network.”

We are marketing the HealthLynked Network by targeting large health systems, hospitals and universities. In addition, we are marketing via direct-to-patient marketing, affiliated marketing campaigns, co-marketing with our Medical Distribution businesses subsidiary MOD, and expanded southeast regional sales efforts. Our initial sales strategy is utilizing Internet-based marketing to increase penetration to targeted geographical areas. These campaigns are focused on both physician practices and patient members. We also are leveraging MOD’s discounted medical supplies as an offering to our patient and physician members in the HealthLynked Network. We also intend to utilize physician telesales through the use of telesales representatives whom we will hire as access to capital allows. If we fail to complete the development of, or successfully market, the HealthLynked Network, our ability to realize future increases in revenue and operating profits could be impacted, and our results of operations and financial position would be materially adversely affected.

We plan to raise additional capital to fund our ongoing plan of operation.

32

Historical Cash Flows

Cash flows during the years ended December 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| Net cash (used in) provided by: |  |  | |  |  |  | |  |
| Net cash used in continuing operating activities |  | $ | (3,494,122 | ) |  | $ | (4,020,022 | ) |
| Net cash used in discontinued operating activities |  |  | --- |  |  |  | (124,846 | ) |
| Net cash used in operating activities |  |  | (3,494,122 | ) |  |  | (4,144,868 | ) |
|  |  |  |  |  |  |  |  |  |
| Net cash provided by continuing investing activities |  |  | 422,402 |  |  |  | 3,506,112 |  |
| Net cash provided by discontinued investing activities |  |  | --- |  |  |  | --- |  |
| Net cash provided by investing activities |  |  | 422,402 |  |  |  | 3,506,112 |  |
|  |  |  |  |  |  |  |  |  |
| Net cash provided by continuing financing activities |  |  | 2,900,739 |  |  |  | 824,087 |  |
| Net cash provided by discontinued financing activities |  |  | --- |  |  |  | --- |  |
| Net cash provided by financing activities |  |  | 2,900,739 |  |  |  | 824,087 |  |
|  |  |  |  |  |  |  |  |  |
| Net increase (decrease) in cash from continuing operating |  |  | (170,981 | ) |  |  | 310,177 |  |
| Net (decrease) in cash from discontinued operating |  |  | --- |  |  |  | (124,846 | ) |
| Net increase (decrease) in cash |  | $ | (170,981 | ) |  | $ | 185,331 |  |

*Operating Activities* – During the year ended December 31, 2024, we used cash from operating activities of $3,494,122, as compared with $4,144,868 in the year ended December 31, 2023. The decrease in cash usage results primarily from cost reduction efforts at our Health Services practices and corporate offices and a decrease of $124,846 in cash used in operations of our discontinued ACO/MSO Division resulting from the unit being sold on January 17, 2023.

*Investing Activities* – During the years ended December 31, 2024 and 2023, we realized $422,402 and $3,506,112, respectively, from investing activities, comprised primarily of cash proceeds received from the AHP Sale, offset by the acquisition of computers and office equipment.

*Financing Activities* – During the years ended December 31, 2024 and 2023, we received cash of $2,900,739 and $824,087, respectively, from financing activities. Cash provided by financing activities in 2024 was comprised of $405,000 from the sale of common stock, $3,270,000 from the issuance of notes payable to related parties, and $335,000 from the issuance of notes payable to third parties, offset by $1,109,261 repayments made against notes payable balances to related and third parties. Cash provided by financing activities in 2023 was comprised of $850,000 proceeds from the sale of common stock (net of $18,765 received from sales of common stock under the SEPA that were applied to the balance of the Note Payable) and $2,481,749 from the issuance of notes payable, offset by $2,507,662 repayments made against notes payable balances (net of $18,765 received from sales of common stock under the SEPA that were applied to the balance of the Note Payable).

**Exercise of Warrants and Options**

No warrants or options were exercised during the years ended December 31, 2024 or 2023.

**Other Outstanding Obligations at December 31, 2024**

As of December 31, 2024, 101,488,821 shares of our common stock are issuable pursuant to the exercise of warrants with exercise prices ranging from $0.023 to $1.05.

As of December 31, 2024, 6,157,422 shares of our common stock are issuable pursuant to the exercise of options with exercise prices ranging from $0.0569 to $0.263.

As of December 31, 2024, 3,063,188 shares of our common stock are earned but unissued pursuant to consulting and director agreements.

As of December 31, 2024, 62,537,933 shares of our common stock are issuable upon the conversion of outstanding convertible notes payable at the option of the beneficial holder of those instruments, Dr. Michael Dent.

**Off Balance Sheet Arrangements**

We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable Securities and Exchange Commission rules.

**Item 7A. Quantitative and Qualitative Disclosures about Market Risk**

Pursuant to Item 305(e) of Regulation S-K (§229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

33

**Item 8. Financial Statements and Supplementary Data**

**INDEX TO FINANCIAL STATEMENTS**

|  |  |
| --- | --- |
|  | **Page** |
| [Report of Independent Registered Public Accounting Firm](#fin_001) | F-2 |
| [Consolidated balance sheets at December 31, 2024 and 2023](#fin_002) | F-3 |
| [Consolidated statements of operations for the years ended December 31, 2024 and 2023](#fin_003) | F-4 |
| [Consolidated statements of changes in shareholders’ equity (deficit) for the years ended December 31, 2024 and 2023](#fin_004) | F-5 |
| [Consolidated statements of cash flows for the years ended December 31, 2024 and 2023](#fin_005) | F-6 |
| [Notes to consolidated financial statements](#fin_006) | F-8 |

F-1

**Report of Independent Registered Public Accounting Firm**

|  |  |  |
| --- | --- | --- |
|  |  | 7915 FM 1960 W  Suite 220 Houston, TX 77070    ***www.rbsmllp.com*** |

To the Board of Directors and Shareholders of

HealthLynked Corp. and Subsidiaries

**Opinion on the Consolidated Financial Statements**

We have audited the accompanying consolidated balance sheets of HealthLynked Corp. and subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, changes in shareholders’ equity (deficit) and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

**The Company’s Ability to Continue as a Going Concern**

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, the Company has recurring losses from operations, limited cash flow, and an accumulated deficit. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Our opinion is not modified with respect to that matter.

**Basis for Opinion**

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matters**

Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

|  |  |
| --- | --- |
| ***/s/ RBSM LLP*** |  |
|  |  |
| We have served as the Company’s auditor since 2014. |  |
|  |  |
| Houston, TX |  |
| March 31, 2025  PCAOB ID Number 587 |  |

F-2

**HEALTHLYNKED CORP.**

**CONSOLIDATED BALANCE SHEETS**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| **ASSETS** |  |  | |  |  |  | |  |
| **Current Assets** |  |  | |  |  |  | |  |
| Cash |  | $ | 76,241 |  |  | $ | 247,222 |  |
| Accounts receivable, net of allowance for doubtful accounts of $-0- and $-0- as of December 31, 2024 and 2023, respectively |  |  | --- |  |  |  | 20,861 |  |
| Inventory, net |  |  | 44,686 |  |  |  | 133,222 |  |
| Prepaid expenses and other current assets |  |  | 56,719 |  |  |  | 55,210 |  |
| Contingent sale consideration receivable, current portion |  |  | 1,463,518 |  |  |  | 199,645 |  |
| Total Current Assets |  |  | 1,641,164 |  |  |  | 656,160 |  |
|  |  |  |  |  |  |  |  |  |
| Property and equipment, net of accumulated depreciation of $634,839 and $521,062 as of December 31, 2024 and 2023, respectively |  |  | 176,576 |  |  |  | 290,755 |  |
| Intangible assets, net of accumulated amortization of $-0- and $258,690 as of December 31, 2024 and 2023, respectively |  |  | --- |  |  |  | 883,848 |  |
| Right of use lease assets |  |  | 361,109 |  |  |  | 935,812 |  |
| Deposits, long term portion |  |  | 44,140 |  |  |  | 50,047 |  |
| Contingent sale consideration receivable, long term portion |  |  | --- |  |  |  | 1,463,518 |  |
|  |  |  |  |  |  |  |  |  |
| Total Assets |  | $ | 2,222,989 |  |  | $ | 4,280,140 |  |
|  |  |  |  |  |  |  |  |  |
| **LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)** |  |  |  |  |  |  |  |  |
| **Current Liabilities** |  |  |  |  |  |  |  |  |
| Accounts payable, accrued expenses and other current liabilities |  | $ | 765,312 |  |  | $ | 614,178 |  |
| Contract liabilities |  |  | 232,545 |  |  |  | 271,774 |  |
| Lease liability, current portion |  |  | 208,549 |  |  |  | 326,033 |  |
| Notes payable and other amounts due to related party, net of unamortized original issue discount of $494,104 and $34,834 as of December 31, 2024 and 2023, respectively |  |  | 3,212,521 |  |  |  | 471,742 |  |
| Notes payable, current portion, net of unamortized original issue discount of $27,414 and $166,487 as of December 31, 2024 and 2023, respectively |  |  | 127,095 |  |  |  | 584,323 |  |
| Indemnification liability |  |  | 143,974 |  |  |  | 143,974 |  |
| Total Current Liabilities |  |  | 4,689,996 |  |  |  | 2,412,024 |  |
|  |  |  |  |  |  |  |  |  |
| **Long-Term Liabilities** |  |  |  |  |  |  |  |  |
| Lease liability, long term portion |  |  | 153,592 |  |  |  | 613,386 |  |
| Government notes payable, long term portion |  |  | 508,610 |  |  |  | 450,000 |  |
|  |  |  |  |  |  |  |  |  |
| Total Liabilities |  |  | 5,352,198 |  |  |  | 3,475,410 |  |
|  |  |  |  |  |  |  |  |  |
| Commitments and contingencies (Note 14) |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| **Shareholders’ Equity (Deficit)** |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 281,947,151 and 275,964,958 shares issued and outstanding as of December 31, 2024 and 2023, respectively |  |  | 28,195 |  |  |  | 27,597 |  |
| Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and 2,750,000 shares issued and outstanding as of December 31, 2024 and 2023, respectively |  |  | 2,750 |  |  |  | 2,750 |  |
| Common stock issuable, $0.0001 par value; 3,063,188 and 2,764,352 as of December 31, 2024 and 2023, respectively |  |  | 161,632 |  |  |  | 281,682 |  |
| Additional paid-in capital |  |  | 44,842,829 |  |  |  | 42,525,837 |  |
| Accumulated deficit |  |  | (48,164,615 | ) |  |  | (42,033,136 | ) |
| Total Shareholders’ Equity (Deficit) |  |  | (3,129,209 | ) |  |  | 804,730 |  |
|  |  |  |  |  |  |  |  |  |
| Total Liabilities and Shareholders’ Equity (Deficit) |  | $ | 2,222,989 |  |  | $ | 4,280,140 |  |

See the accompanying notes to these Consolidated Financial Statements

F-3

**HEALTHLYNKED CORP.**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| **Revenue** |  |  | |  |  |  | |  |
| Patient service revenue, net |  | $ | 2,872,177 |  |  | $ | 5,484,278 |  |
| Subscription revenue |  |  | 32,425 |  |  |  | 58,901 |  |
| Product revenue |  |  | 103,759 |  |  |  | 179,200 |  |
| Total revenue |  |  | 3,008,361 |  |  |  | 5,722,379 |  |
|  |  |  |  |  |  |  |  |  |
| **Operating Expenses and Costs** |  |  |  |  |  |  |  |  |
| Practice salaries and benefits |  |  | 1,995,127 |  |  |  | 3,231,117 |  |
| Other practice operating expenses |  |  | 1,556,759 |  |  |  | 2,205,085 |  |
| Cost of product revenue |  |  | 96,237 |  |  |  | 142,501 |  |
| Selling, general and administrative expenses |  |  | 3,038,936 |  |  |  | 3,623,402 |  |
| Depreciation and amortization |  |  | 282,950 |  |  |  | 352,027 |  |
| Impairment loss |  |  | 716,000 |  |  |  | 319,958 |  |
| Total Operating Expenses and Costs |  |  | 7,686,009 |  |  |  | 9,874,090 |  |
|  |  |  |  |  |  |  |  |  |
| Loss from operations |  |  | (4,677,648 | ) |  |  | (4,151,711 | ) |
|  |  |  |  |  |  |  |  |  |
| **Other Income (Expenses)** |  |  |  |  |  |  |  |  |
| Loss on extinguishment of debt |  |  | (178,986 | ) |  |  | (145,212 | ) |
| Change in fair value of debt |  |  | 84,109 |  |  |  | --- |  |
| Gain from expiration of liability classified equity instruments |  |  | --- |  |  |  | 92,641 |  |
| Amortization of original issue discounts on notes payable |  |  | (1,316,165 | ) |  |  | (427,808 | ) |
| Gain from realization of contingent sale consideration receivable |  |  | 125,355 |  |  |  | 1,090,857 |  |
| Interest expense and other |  |  | (168,144 | ) |  |  | (72,718 | ) |
| Total other income (expenses) |  |  | (1,453,831 | ) |  |  | 537,760 |  |
|  |  |  |  |  |  |  |  |  |
| Loss from continuing operations before provision for income taxes |  |  | (6,131,479 | ) |  |  | (3,613,951 | ) |
|  |  |  |  |  |  |  |  |  |
| Provision for income taxes |  |  | --- |  |  |  | --- |  |
|  |  |  |  |  |  |  |  |  |
| Loss from continuing operations |  |  | (6,131,479 | ) |  |  | (3,613,951 | ) |
|  |  |  |  |  |  |  |  |  |
| **Discontinued operations (Note 4)** |  |  |  |  |  |  |  |  |
| Loss from operations of discontinued operations |  |  | --- |  |  |  | (72,321 | ) |
| Gain from disposal of discontinued operations |  |  | --- |  |  |  | 2,674,069 |  |
| Gain on discontinued operations |  |  | --- |  |  |  | 2,601,748 |  |
|  |  |  |  |  |  |  |  |  |
| Net loss |  | $ | (6,131,479 | ) |  | $ | (1,012,203 | ) |
|  |  |  |  |  |  |  |  |  |
| Loss per share from continuing operations, basic and diluted: |  |  |  |  |  |  |  |  |
| Basic |  | $ | (0.02 | ) |  | $ | (0.01 | ) |
| Fully diluted |  |  | (0.02 | ) |  |  | (0.01 | ) |
|  |  |  |  |  |  |  |  |  |
| Gain on discontinued operations, basic and diluted: |  |  |  |  |  |  |  |  |
| Basic |  | $ | 0.00 |  |  | $ | 0.01 |  |
| Fully diluted |  |  | 0.00 |  |  |  | 0.01 |  |
|  |  |  |  |  |  |  |  |  |
| Net loss per share, basic and diluted: |  |  |  |  |  |  |  |  |
| Basic |  | $ | (0.02 | ) |  | $ | (0.00 | ) |
| Fully diluted |  |  | (0.02 | ) |  |  | (0.00 | ) |
|  |  |  |  |  |  |  |  |  |
| Weighted average number of common shares: |  |  |  |  |  |  |  |  |
| Basic |  |  | 281,544,002 |  |  |  | 262,891,873 |  |
| Fully diluted |  |  | 281,544,002 |  |  |  | 262,891,873 |  |

See the accompanying notes to these Consolidated Financial Statements

F-4

**HEALTHLYNKED CORP.**

**CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)**

**YEAR ENDED DECEMBER 31, 2024 AND 2023**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Number of Shares** | | | | | |  |  |  | |  |  |  | |  |  | **Common** | |  |  | **Additional** | |  |  |  | |  |  | **Total** | |  |
|  |  | **Common** | |  |  | **Preferred** | |  |  | **Common** | |  |  | **Preferred** | |  |  | **Stock** | |  |  | **Paid-in** | |  |  | **Accumulated** | |  |  | **Shareholders’** | |  |
|  |  | **Stock** | |  |  | **Stock** | |  |  | **Stock** | |  |  | **Stock** | |  |  | **Issuable** | |  |  | **Capital** | |  |  | **Deficit** | |  |  | **Equity** | |  |
|  |  | ***(#)*** | |  |  | ***(#)*** | |  |  | ***($)*** | |  |  | ***($)*** | |  |  | ***($)*** | |  |  | ***($)*** | |  |  | ***($)*** | |  |  | ***($)*** | |  |
| **Balance at December 31, 2022** |  |  | **255,940,389** |  |  |  | **2,750,000** |  |  |  | **25,594** |  |  |  | **2,750** |  |  |  | **225,584** |  |  |  | **41,081,455** |  |  |  | **(41,020,933** | **)** |  |  | **314,450** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sales of common stock pursuant to Standby Equity Purchase Agreement |  |  | 225,000 |  |  |  | --- |  |  |  | 22 |  |  |  | --- |  |  |  | --- |  |  |  | 18,743 |  |  |  | --- |  |  |  | 18,765 |  |
| Other sales of common stock |  |  | 15,952,992 |  |  |  | --- |  |  |  | 1,596 |  |  |  | --- |  |  |  | --- |  |  |  | 544,587 |  |  |  | --- |  |  |  | 546,183 |  |
| Fair value of warrants allocated to proceeds of common stock |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 303,817 |  |  |  | --- |  |  |  | 303,817 |  |
| Fair value of warrants allocated to proceeds of related party debt |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 221,899 |  |  |  | --- |  |  |  | 221,899 |  |
| Fair value of warrants allocated to proceeds of third party debt |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 15,140 |  |  |  | --- |  |  |  | 15,140 |  |
| Fair value of beneficial conversion feature on third party note payable |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 33,000 |  |  |  | --- |  |  |  | 33,000 |  |
| Fair value of warrants issued to pay liability |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 10,820 |  |  |  | --- |  |  |  | 10,820 |  |
| Consultant and director fees payable with common shares and warrants |  |  | 1,969,523 |  |  |  | --- |  |  |  | 197 |  |  |  | --- |  |  |  | 90,298 |  |  |  | 90,203 |  |  |  | --- |  |  |  | 180,698 |  |
| Shares and options issued to employees |  |  | 1,147,500 |  |  |  | --- |  |  |  | 115 |  |  |  | --- |  |  |  | (34,200 | ) |  |  | 153,008 |  |  |  | --- |  |  |  | 118,923 |  |
| Incremental fair value of repriced warrants |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 4,358 |  |  |  | --- |  |  |  | 4,358 |  |
| Shares issued to vendors |  |  | 729,554 |  |  |  | --- |  |  |  | 73 |  |  |  | --- |  |  |  | --- |  |  |  | 48,807 |  |  |  | --- |  |  |  | 48,880 |  |
| Net loss |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | (1,012,203 | ) |  |  | (1,012,203 | ) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Balance at December 31, 2023** |  |  | **275,964,958** |  |  |  | **2,750,000** |  |  |  | **27,597** |  |  |  | **2,750** |  |  |  | **281,682** |  |  |  | **42,525,837** |  |  |  | **(42,033,136** | **)** |  |  | **804,730** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sales of common stock |  |  | 5,977,193 |  |  |  | --- |  |  |  | 597 |  |  |  | --- |  |  |  | --- |  |  |  | 294,147 |  |  |  | --- |  |  |  | 294,744 |  |
| Fair value of warrants allocated to proceeds of common stock |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 110,255 |  |  |  | --- |  |  |  | 110,255 |  |
| Fair value of warrants allocated to proceeds of related party debt |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 797,167 |  |  |  | --- |  |  |  | 797,167 |  |
| Fair value of beneficial conversion feature allocated to proceeds of related party debt |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 785,039 |  |  |  | --- |  |  |  | 785,039 |  |
| Shares and options issued to employees |  |  | 5,000 |  |  |  | --- |  |  |  | 1 |  |  |  | --- |  |  |  | (283,869 | ) |  |  | 365,518 |  |  |  | --- |  |  |  | 81,650 |  |
| Consultant and director fees payable with common shares and warrants |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 157,819 |  |  |  | --- |  |  |  | --- |  |  |  | 157,819 |  |
| Stock fees related to sales of common stock |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 6,000 |  |  |  | (35,134 | ) |  |  | --- |  |  |  | (29,134 | ) |
| Net loss |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | (6,131,479 | ) |  |  | (6,131,479 | ) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Balance at December 31, 2024** |  |  | **281,947,151** |  |  |  | **2,750,000** |  |  |  | **28,195** |  |  |  | **2,750** |  |  |  | **161,632** |  |  |  | **44,842,829** |  |  |  | **(48,164,615** | **)** |  |  | **(3,129,209** | **)** |

See the accompanying notes to these Consolidated Financial Statements

F-5

**HEALTHLYNKED CORP.**

**CONSOLIDATED STATEMENT OF CASH FLOWS**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| **Cash Flows from Operating Activities** |  |  | |  |  |  | |  |
| Net loss |  | $ | (6,131,479 | ) |  | $ | (1,012,203 | ) |
| Loss from discontinued operations |  |  | --- |  |  |  | 72,321 |  |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |  |
| Gain from disposal of discontinued operations |  |  | --- |  |  |  | (2,674,069 | ) |
| Depreciation and amortization |  |  | 282,950 |  |  |  | 352,027 |  |
| Impairment loss |  |  | 716,000 |  |  |  | 319,958 |  |
| Stock based compensation, including amortization of deferred equity compensation |  |  | 210,333 |  |  |  | 303,979 |  |
| Gain from expiration of liability classified equity instruments |  |  | --- |  |  |  | (92,641 | ) |
| Amortization of debt discount |  |  | 1,316,165 |  |  |  | 427,808 |  |
| Loss on extinguishment of debt |  |  | 178,986 |  |  |  | 145,212 |  |
| Change in fair value of debt |  |  | (84,109 | ) |  |  | --- |  |
| Gain from realization of contingent sale consideration receivable |  |  | (125,355 | ) |  |  | (1,090,857 | ) |
| Other non-cash adjustments |  |  | (1,662 | ) |  |  | (11,094 | ) |
| Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |
| Accounts receivable |  |  | 20,861 |  |  |  | 28,916 |  |
| Inventory |  |  | 88,536 |  |  |  | 59,611 |  |
| Contract assets |  |  | (14,948 | ) |  |  | 264,626 |  |
| Prepaid expenses and other current assets |  |  | 19,346 |  |  |  | (31,299 | ) |
| Right of use lease assets |  |  | 309,199 |  |  |  | 403,287 |  |
| Accounts payable and accrued expenses |  |  | 70,911 |  |  |  | (780,239 | ) |
| Lease liability |  |  | (310,627 | ) |  |  | (402,292 | ) |
| Contract liabilities |  |  | (39,229 | ) |  |  | (303,073 | ) |
| Net cash used in continuing operating activities |  |  | (3,494,122 | ) |  |  | (4,020,022 | ) |
| Net cash used in discontinued operating activities |  |  | --- |  |  |  | (124,846 | ) |
| Net cash used in operating activities |  |  | (3,494,122 | ) |  |  | (4,144,868 | ) |
|  |  |  |  |  |  |  |  |  |
| **Cash Flows from Investing Activities** |  |  |  |  |  |  |  |  |
| Proceeds from sale of discontinued operations |  |  | 425,000 |  |  |  | 3,507,612 |  |
| Acquisition of property and equipment |  |  | (2,598 | ) |  |  | (1,500 | ) |
| Net cash provided by continuing investing activities |  |  | 422,402 |  |  |  | 3,506,112 |  |
| Net cash used in discontinued investing activities |  |  | --- |  |  |  | --- |  |
| Net cash provided by investing activities |  |  | 422,402 |  |  |  | 3,506,112 |  |
|  |  |  |  |  |  |  |  |  |
| **Cash Flows from Financing Activities** |  |  |  |  |  |  |  |  |
| Proceeds from sale of common stock |  |  | 405,000 |  |  |  | 850,000 |  |
| Proceeds from related party notes payable |  |  | 3,270,000 |  |  |  | 1,198,500 |  |
| Proceeds from third party notes payable |  |  | 335,000 |  |  |  | 1,283,249 |  |
| Repayment of related party notes payable |  |  | (167,601 | ) |  |  | (1,411,004 | ) |
| Repayment of third party notes payable |  |  | (941,660 | ) |  |  | (1,096,658 | ) |
| Net cash provided by continuing financing activities |  |  | 2,900,739 |  |  |  | 824,087 |  |
| Net cash provided by discontinued financing activities |  |  | --- |  |  |  | --- |  |
| Net cash provided by financing activities |  |  | 2,900,739 |  |  |  | 824,087 |  |
|  |  |  |  |  |  |  |  |  |
| **Net increase (decrease) in cash** |  |  | **(170,981** | **)** |  |  | **185,331** |  |
| Cash, beginning of period |  |  | 247,222 |  |  |  | 61,891 |  |
|  |  |  |  |  |  |  |  |  |
| **Cash, end of period** |  | **$** | **76,241** |  |  | **$** | **247,222** |  |

*(continued)*

F-6

**HEALTHLYNKED CORP.**

**CONSOLIDATED STATEMENT OF CASH FLOWS**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| Supplemental disclosure of cash flow information: |  |  | |  |  |  | |  |
| Cash paid during the period for interest |  | $ | 26,316 |  |  | $ | 21,041 |  |
| Cash paid during the period for income tax |  | $ | --- |  |  | $ | --- |  |
| Schedule of non-cash investing and financing activities: |  |  |  |  |  |  |  |  |
| Recognition of operating lease: right of use asset and lease liability |  | $ | 177,782 |  |  | $ | 798,918 |  |
| Extinguishment and modification of operating lease: right of use asset and lease liability |  | $ | (444,434 | ) |  | $ |  |  |
| Common stock issuable issued during period |  | $ | --- |  |  | $ | 108,928 |  |
| Fair value of options issued in satisfaction of common stock issuable |  | $ | 283,869 |  |  | $ |  |  |
| Fair value of warrants allocated to proceeds of related party notes payable |  | $ | 758,523 |  |  | $ | 171,874 |  |
| Fair value of warrants allocated to proceeds of third party notes payable |  | $ | --- |  |  | $ | 15,139 |  |
| Fair value of beneficial conversion feature allocated to proceeds of related party notes payable |  | $ | 785,040 |  |  | $ | --- |  |
| Fair value of beneficial conversion feature allocated to proceeds of third party notes payable |  | $ |  |  |  | $ | 33,000 |  |
| Original issue discounts allocated to proceeds of notes payable |  |  | 163,969 |  |  | $ | 367,919 |  |
| Fair value of warrants issued to extend related party debt |  | $ | 38,645 |  |  | $ | 50,025 |  |
| Principal amount of convertible notes payable to related party refinanced |  | $ | 866,500 |  |  | $ | --- |  |
| Note payable to related party balance classified as accrued interest |  | $ | 17,588 |  |  | $ | --- |  |
| Warrant liability incurred in connection with collection of contingent sale consideration receivable |  | $ | --- |  |  | $ | 10,820 |  |
| Net carrying value of equity liabilities (assets) written off |  | $ | --- |  |  | $ | 64,647 |  |
| Proceeds from sale of common stock under Standby Equity Purchase Agreement applied to note payable balance |  | $ | --- |  |  | $ | 18,765 |  |
| Fair value of shares issued to pay vendor accounts payable balance |  | $ | --- |  |  | $ | 48,881 |  |
| Fair value of shares issued for equity issuance costs |  | $ | 35,134 |  |  | $ | -- |  |

See the accompanying notes to these Consolidated Financial Statements

F-7

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 1 - BUSINESS AND BUSINESS PRESENTATION**

HealthLynked Corp. (the “Company”) was incorporated in the State of Nevada on August 4, 2014. On September 2, 2014, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of Nevada setting the total number of authorized shares at 500,000,000 shares, which included up to 480,000,000 shares of common stock and 20,000,000 shares of “blank check” preferred stock. On February 5, 2018, the Company filed an Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of Nevada to increase the number of authorized shares of common stock to 500,000,000 shares.

The Company currently operates in three distinct divisions:

|  |  |  |
| --- | --- | --- |
|  | ● | **Health Services Division**: This division is comprised of the operations of (i) Naples Center for Functional Medicine (“NCFM”), a functional medical practice engaged in improving the health of its patients through individualized and integrative health care, (ii) Bridging the Gap Physical Therapy (“BTG”), a physical therapy practice in Bonita Springs, Florida that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery, (iii) Concierge Care Naples (“CCN”), a primary care providing a comprehensive range of medical services, and (iv) Aesthetic Enhancements Unlimited (“AEU”), a minimally and non-invasive cosmetic services. During 2024, the Company replaced our Naples Women’s Center (“NWC”) Obstetrics and Gynecology (OB/GYN) practice with CCN and relocated its AEU practice to the CCN office location. |

|  |  |  |
| --- | --- | --- |
|  | ● | **Digital Healthcare Division**: At the forefront of healthcare innovation, this division develops and manages an advanced online concierge medical service. The HealthLynked Network facilitates efficient management of medical records and care, allowing seamless patient appointment scheduling, comprehensive telemedicine services, and a cloud-based system for medical information and records management. It also supports physicians in expanding their practices and acquiring new patients through our robust online scheduling system. |

|  |  |  |
| --- | --- | --- |
|  | ● | **Medical Distribution Division**: MedOffice Direct LLC (“MOD”), a part of this division, operates as a virtual distributor of discounted medical supplies to consumers and medical practices nationwide, ensuring timely and cost-effective delivery. |

In a strategic restructuring, during October 2022, our Board of Directors (the “Board”) approved the divestiture of the former ACO/MSO Division, including Cura Health Management LLC (“CHM”) and its subsidiary ACO Health Partners LLC (“AHP”). CHM and AHP were involved in enhancing coordinated care through the Medicare Shared Savings Program (“MSSP”). The divestiture was completed on January 17, 2023, aligning with the Company’s focus on core growth areas. See Note 4, “Discontinued Operations,” for additional information.

These consolidated financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“GAAP”).

On a consolidated basis, the Company’s operations are comprised of the parent company, HealthLynked Corp., and its operating subsidiaries: NCFM, BTG, CCN (after October 1, 2024), AEU, NWC (through October 1, 2024), and MOD. Results through January 17, 2023 also include operations of AHP, which was sold, and CHM, which was discontinued, both effective as of January 17, 2023. All significant intercompany transactions and balances have been eliminated upon consolidation. In addition, certain amounts in the prior periods’ consolidated financial statements have been reclassified to conform to the current period presentation.

Uncertainty Due to Geopolitical Events

Due to the Hamas-Israel, Iran-Israel and Russia-Ukraine conflicts, there has been uncertainty and disruption in the global economy. Although these events did not have a direct material adverse impact on the Company’s financial results for the year ended December 31, 2024, at this time the Company is unable to fully assess the aggregate impact the Hamas-Israel and Russia-Ukraine conflicts will have on its business due to various uncertainties, which include, but are not limited to, the duration of the conflicts, the conflicts’ effect on the economy, the impact on the Company’s businesses and actions that may be taken by governmental authorities related to the conflicts.

F-8

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES**

A summary of the significant accounting policies applied in the presentation of the accompanying consolidated financial statements follows:

Basis of Presentation

The accompanying consolidated financial statements have been prepared in conformity with GAAP. All amounts referred to in the notes to the consolidated financial statements are in United States Dollars ($) unless stated otherwise.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets; cash flow and fair value assumptions associated with measurements of contingent sale consideration receivable, contingent acquisition consideration payable, and impairment of intangible assets; valuation of inventory; collection of accounts receivable; the valuation and recognition of stock-based compensation expense; valuation allowance for deferred tax assets; and borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets.

Revenue Recognition

*Patient service revenue*

Patient service revenue is earned for functional medicine services provided to patients by the NCFM practice, physical therapy services provided to patients by the BTG practice, aesthetics services provided by the AEU practice, and medical services provided to patients by the CCN practice (after its establishment in October 2024) and NWC practice (until its discontinuation in October 2024). Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. All amounts are due from patients at the time of service, with the exception of NWC billings incurred prior to October 2024 that were due from third-party payors (including health insurers and government programs) that included variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients at the time of service and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time includes revenue from NCFM annual access contracts (the Medical Membership and Concierge Program prior to October 1, 2023 and the more comprehensive Optimal Health 365 Access Plan thereafter), BTG physical therapy bundles, CCN annual and semi-annual concierge services, and NWC annual administration fees (prior to October 2024). Revenue from NCFM Medical Memberships and Concierge contracts, CCN concierge services, and NWC annual administration fees, which include bundled products and services that have substantially the same pattern of transfer to the customer, is recognized over the period of delivery, which is the same as the period of the contract (typically, six months or one year). Revenue from prepaid BTG physical therapy bundles, for which performance obligations are satisfied over time as visits are incurred, is recognized based on actual visits incurred in relation to total expected visits. At inception of such contracts, the Company recognizes contract liabilities for the value of services to be provided and, where applicable, contract assets for recoverable amounts incurred to obtain a customer contract that would not have incurred if the contract had not been obtained. The Company believes that these methods provide a faithful depiction of the transfer of services over the term of the performance obligations based on the inputs needed to satisfy the obligation.

Revenue for performance obligations satisfied at a point in time, which includes all patient service revenue other than NCFM annual access contracts, BTG physical therapy bundles, CCN concierge services, and NWC annual administration fees, is recognized when goods or services are provided at the time of the patient visit, and at which time the Company is not required to provide additional goods or services to the patient.

F-9

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

Patient service revenues are presented on the statement of operations net of contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Estimates of contractual adjustments and discounts require significant judgment and are based on the Company’s current contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. There were no material changes during the year ended December 31, 2024 or 2023 to the judgments applied in determining the amount and timing of patient service revenue.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

|  |  |  |
| --- | --- | --- |
|  | ● | Medicare: Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates; |

|  |  |  |
| --- | --- | --- |
|  | ● | Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member. |

|  |  |  |
| --- | --- | --- |
|  | ● | Other: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates. |

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. With the discontinuation of the NWC practice in October 2024, the Company no longer expects to bill third-party payors on behalf of its patients.

The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and for those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Patient services provided by NCFM, AEU, BTG, AEU, and CCN are provided on a cash basis and not submitted through third party insurance providers.

F-10

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

*Product and Other Revenue*

Product revenue is derived from the distribution of medical products that are sourced from a third party. The Company recognizes revenue at a point in time when title transfers to customers and the Company has no further obligation to provide services related to such products, which occurs when the product ships. The Company is the principal in its revenue transactions and as a result revenue is recorded on a gross basis. The Company has determined that it controls the ability to direct the use of the product provided prior to transfer to a customer, is primarily responsible for fulfilling the promise to provide the product to its customer, has discretion in establishing prices, and ultimately controls the transfer of the product to the customer. Shipping and handling costs billed to customers are recorded in revenue. Contract liabilities related to product revenue are recognized when payment is received but for which the Company has not met its product fulfillment performance obligation.

Sales are made inclusive of sales tax, where such sales tax is applicable. Sales tax is applicable on sales made in the state of Florida, where the Company has physical nexus. The Company has determined that it does not have economic nexus in any other states. The Company does not sell products outside of the United States.

The Company maintains a return policy that allows customers to return a product within a specified period of time prior to and subsequent to the expiration date of the product. The Company analyzes the need for a product return allowance at the end of each period based on eligible products.

Cash and Cash Equivalents

For financial statement purposes, the Company considers all highly liquid investments with original maturities of six months or less to be cash and cash equivalents. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $-0- and $-0- in cash balances in excess of the FDIC insured limit as of December 31, 2024 and 2023, respectively.

Accounts Receivable

Trade receivables related to NWC services billed to third party payors are carried at the estimated collectible amount, which is the standard charge based on the Company’ list price, net of contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 58% of gross billings. Trade accounts receivable are recorded at this net amount. As of December 31, 2024 and 2023, the Company’s gross patient services accounts receivable were $-0- and $34,481, respectively, and net patient services accounts receivable were $-0- and $20,861, respectively, based upon net reporting of accounts receivable. As of December 31, 2024 and 2023, the Company’s allowance for doubtful accounts was $-0- and $-0-, respectively. With the discontinuation of the NWC practice in October 2024, the Company no longer expects to bill third-party payors on behalf of its patients and therefore does not expect to have any accounts receivable related to such patient service revenue.

Other Comprehensive Income

The Company does not have any activity that results in Other Comprehensive Income.

Leases

Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as ROU assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company’s consolidated balance sheets.

F-11

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Upon termination of a lease, the ROU asset and lease liability are written off. Upon modification of a lease, the ROU asset and lease liability are remeasured based on the modified last terms. See Note 8 for more complete details on balances as of the reporting periods presented herein.

Inventory

Inventory consisting of supplements, is stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Outdated inventory is directly charged to cost of goods sold.

Intangible Assets

The Company recognizes an acquired intangible whenever the intangible arises from contractual or other legal rights, or whenever it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their estimated useful lives unless the estimated useful life is determined to be indefinite. Amortizable intangible assets are being amortized primarily over useful lives of five years. The straight-line method of amortization is used as it has been determined to approximate the use pattern of the assets. Impairment losses are recognized if the carrying amount of an intangible that is subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value. See Note 7, “Intangible Assets and Goodwill,” for further discussion of impairment charges in the years ended December 31, 2024 and 2023.

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD.

Property and Equipment

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized.

The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.

F-12

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

Fair Value of Assets and Liabilities

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs:

|  |  |  |
| --- | --- | --- |
|  | ● | Level 1 – Fair value based on quoted prices in active markets for identical assets or liabilities; |

|  |  |  |
| --- | --- | --- |
|  | ● | Level 2 – Fair value based on significant directly observable data (other than Level 1 quoted prices) or significant indirectly observable data through corroboration with observable market data. Inputs would normally be (i) quoted prices in active markets for similar assets or liabilities, (ii) quoted prices in inactive markets for identical or similar assets or liabilities or (iii) information derived from or corroborated by observable market data; |

|  |  |  |
| --- | --- | --- |
|  | ● | Level 3 – Fair value based on prices or valuation techniques that require significant unobservable data inputs. Inputs would normally be a reporting entity’s own data and judgments about assumptions that market participants would use in pricing the asset or liability. |

The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs.

The Company utilizes a binomial lattice option pricing model to estimate the fair value of options, warrants, beneficial conversion features and other Level 3 financial assets and liabilities. The Company believes that the binomial lattice model results in the best estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fairly value these instruments and, unlike less sophisticated models like the Black-Scholes model, it also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments.

Stock-Based Compensation

The Company accounts for stock-based compensation to employees and nonemployees under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718 “Compensation – Stock Compensation” using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses a binomial lattice pricing model to estimate the fair value of options and warrants granted.

Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No income tax has been provided for the years ended December 31, 2024 and 2023, since the Company has sustained a loss for both periods. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable.

F-13

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

Recurring Fair Value Measurements

The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of accounts receivable, accounts payable, and accrued liabilities approximated their fair value.

Net Income (Loss) per Share

Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the years ended December 31, 2024 and 2023, the Company reported a net loss and excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of December 31, 2024 and 2023, potentially dilutive securities were comprised of (i) 101,488,821 and 77,414,648 warrants outstanding, respectively, (ii) 6,157,422 and 5,093,738 stock options outstanding, respectively, (iii) -0- and 1,484,488 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan, (iv) up to 3,063,188 and 2,764,352 common shares issuable that are earned but not paid under consulting and director compensation arrangements, (v) up to 62,537,933 and 3,780,000 shares potentially issuable upon conversion of outstanding fixed price convertible notes payable, and (vi) up to 13,750,000 and 13,750,000 shares of common stock issuable upon conversion of Series B Preferred stock.

Common Stock Awards

The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. From time to time, the Company also issues stock awards settleable in a variable number of common shares. Such awards are classified as liabilities until such time as the number of shares underlying the grant is determinable.

Warrants

In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes pricing model as of the measurement date. The Company uses a binomial lattice pricing model to estimate the fair value of compensation options and warrants. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period, or at the date of issuance, if there is not a service period. Certain of the Company’s warrants include a so-called down round provision. The Company accounts for such provisions pursuant to ASU No. 2017-11, *Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging*, which calls for the recognition of a deemed dividend in the amount of the incremental fair value of the warrant due to the down round when triggered.

Segment Reporting

The Company uses the “management approach” under ASC 280, “Segment Reporting,” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has three operating segments: Health Services (the NCFM functional medicine practice, the BTG physical therapy practice, the AEU cosmetic services practice, CCN primary care practice, and the NWC GYN practice that was discontinued in October 2024), Digital Healthcare (develops and markets the “HealthLynked Network,” an online personal medical information and record archive system), and Medical Distribution (comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices).

The Company’s ACO/MSO segment was sold on January 17, 2023. As described in further detail in Note 4, “Discontinued Operations,” this unit’s results of operations are classified as “Income (loss) from operations of discontinued operations” in the years ended December 31, 2024 and 2023.

F-14

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

Recently Issued Pronouncements

In March 2024, the FASB issued ASU No. 2024-01, “Compensation—Stock Compensation (Topic 718): Scope Applications of Profits Interests and Similar Awards” (“ASU 2024-01”). ASU 2024-01 adds an example to Topic 718 which illustrates how to apply the scope guidance to determine whether profits interests and similar awards should be accounted for as share-based payment arrangements under Topic 718 or under other U.S. GAAP. ASU 2024-01 is effective for annual periods beginning after December 15, 2025, although early adoption is permitted. Upon adoption, ASU 2024-01 is not expected to have an impact on the Company’s consolidated financial statements.

In March 2024, the FASB issued ASU No 2024-02, “Codification Improvements - Amendments to Remove References to the Concepts Statements” (“ASU 2024-02”). ASU 2024-02 removes references to various Concepts Statements. In most instances, the references are extraneous and not required to understand or apply the guidance. ASU 2024-02 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. ASU 2024-02 can be applied prospectively or retrospectively. Upon adoption, ASU 2024-01 is not expected to have an impact on the Company’s consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40).” This standard requires disclosure of specific information about costs and expenses and becomes effective January 1, 2027. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-04, “Debt - Debt with Conversions and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments” (“ASU 2024-04”). ASU 2024-04 clarifies the requirements for determining whether certain settlements of convertible debt instruments, including convertible debt instruments with cash conversion features or convertible debt instruments that are not currently convertible, should be accounted for as an induced conversion. The requirements of ASU 2024-04 are effective for the Company for fiscal years beginning after December 15, 2025, and interim periods within those periods. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.

Recently Adopted Pronouncements

In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the year ended December 31, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements.

In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the year ended December 31, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements.

No other new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our consolidated Financial Statements.

F-15

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 3 – LIQUIDITY AND GOING CONCERN ANALYSIS**

Under ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. Pursuant to ASU 2014-15, in evaluating the Company’s ability to continue as a going concern, management considered the conditions and events that could raise substantial doubt about the Company’s ability to continue as a going concern within 12 months after the Company’s financial statements were issued (March 31, 2026). Management considered the Company’s current financial condition and liquidity sources, including current funds available, forecasted future cash flows and the Company’s obligations due before March 31, 2026.

The Company is subject to a number of risks, including uncertainty related to product development and generation of revenues and positive cash flow from its Digital Healthcare Division and a dependence on outside sources of capital. The attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill the Company’s growth and operating activities and generating a level of revenues adequate to support the Company’s cost structure.

As of December 31, 2024, the Company had cash balances of $76,241, a working capital deficit of $3,048,832 and an accumulated deficit of $48,164,615. For the year ended December 31, 2024, the Company had a net loss of $6,131,479 and used cash from operating activities of $3,494,122. The Company expects to continue to incur net losses and have significant cash outflows for at least the next 12 months.

Management has evaluated the significance of the conditions described above in relation to the Company’s ability to meet its obligations and concluded that, without additional funding, the Company will not have sufficient funds to meet its obligations within one year from the date the consolidated financial statements were issued.

As described further in Note 4, “Discontinued Operations,” on January 17, 2023, the Company entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and the Company agreed to sell, AHP. Since the sale date, the Company has received the following proceeds: (i) $750,000 upon signing of the AHP Merger Agreement, (ii) $31,381 in March 2023 for the Stub Period Reimbursement, (iii) $1,750,000 ($1,540,000 net after commissions) in Incremental Cash Consideration during June, July and August for meeting participating physician transfer milestones, (iv) $1,873,993 gross ($1,186,231 net after commissions) in October 2023 from the 2022 MSSP Consideration, and (v) $500,000 ($325,000 net after payments to participating physicians and commissions) in November 2024 from the Physician Advance Consideration. The Company may receive future proceeds comprised of proceeds from sale of shares of the Buyer if the Buyer completes an initial public offering by May 1, 2025.

During the year ended December 31, 2024, the Company also (i) received net proceeds from the issuance of notes payable to related parties and third parties totaling $3,605,000 and made repayments on existing and new notes payable to related parties and third parties totaling $1,109,261, and (ii) received $405,000 proceeds from the sale of its common stock.

On July 5, 2022, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”) (See Note 13, “Shareholders’ Equity,” below for additional information on the SEPA). Pursuant to the SEPA, the Company shall have the right to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the three-year commitment period set forth in the SEPA. Because the purchase price per share to be paid by Yorkville for the shares of common stock sold by the Company to Yorkville pursuant to the SEPA, if any, will fluctuate based on the market prices of the Company’s common stock during the applicable pricing period, the Company cannot reliably predict the actual purchase price per share to be paid by Yorkville for those shares, or the actual gross proceeds to be raised by the Company from those sales, if any. During the year ended December 31, 2023, the Company sold 225,000 shares of common stock under the SEPA, receiving $18,765 in proceeds, all of which was applied to the balance of a then-outstanding promissory note payable to Yorkville. The Company has not made any draws pursuant to the SEPA since January 2023.

Without raising additional capital, either via additional advances made pursuant to the SEPA or from other sources, there is substantial doubt about the Company’s ability to continue as a going concern through March 31, 2026. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of presentation contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

F-16

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 4 – DISCONTINUED OPERATIONS**

Description of Transaction

During the fourth quarter of 2022, the Board approved a plan to sell the Company’s ACO/MSO Division, which assists physician practices in providing coordinated and more efficient care to patients via the MSSP as administered by the Center for Medicare and Medicaid Services (the “CMS”), which rewards providers for efficiency in patient care. On January 17, 2023, the Company entered into the AHP Merger Agreement, pursuant to which PBACO Holding, LLC (the “Buyer”) agreed to buy, and the Company agreed to sell, AHP (the “AHP Sale”). Pursuant to the terms of the AHP Merger Agreement, the Company received or was entitled to receive the following consideration: (1) $750,000 in cash paid upon signing of the definitive agreement (received January 18, 2023) (the “Upfront Cash Consideration”); (2) the Buyer shall reimburse the Company for expenses incurred by the Company in operating AHP from January 1, 2023 to January 16, 2023 (the “Stub Period Reimbursement”)($31,381 paid in March 2023); (3) up to $1,750,000 net incremental cash based on the agreement to participate in Buyer’s ACO by AHP’s existing physician practices or newly added practices, scaled based on the number of covered patients transferred to the Buyer by July 31, 2023 (the “Incremental Cash Consideration”), of which $1,225,000 ($1,180,000 net after commissions) was received in June 2023 and $150,000 ($120,000 net after commissions) was received in July 2023; (4) net proceeds, including allocation for expenses, from any MSSP Shared Savings related to AHP’s plan year 2022 (the “2022 MSSP Consideration”), of which the Company realized gross receipts of $1,873,993 and net proceeds of $1,186,231 after payments to participating physicians and commissions in October 2023; (5) $500,000 of the Incremental Cash Consideration allocated to AHP’s participating physicians at closing to be reimbursed to the Company by the Buyer in 2024 from the Buyer’s plan year 2023 (and if necessary, 2024) MSSP Shared Savings (the “Physician Advance Consideration”); and (6) in the event that Buyer completes a planned initial public offering (“IPO”) by a prescribed date (initially February 1, 2025, since extend to May 1, 2025) shares in the public entity at the time of the IPO with a value equal to AHP’s 2021 earnings before interest, taxes depreciation and amortization (“EBITDA”) times the multiple of EBITDA used to value the public entity’s IPO shares, net of any cash consideration previously paid by the Buyer and subject to vesting requirements detailed in the AHP Merger Agreement (the “IPO Share Consideration”). The Company is also required to indemnify the Buyer against liabilities arising from Buyer’s operation of AHP prior to the Buyer’s IPO date, less a deductible equal to 1% of the aggregate merger consideration (the “Indemnification Clause”).

In the event Buyer goes public through means other than an IPO, the parties agreed to modify the terms of the IPO Share Consideration to implement such alternate structure. In the event Buyer does not go public by IPO or other means by May 1, 2025, the Company receives no IPO Share Consideration, and the Transaction consideration is capped at the cash consideration of up to $3,000,000 plus the MSSP Consideration.

Pursuant to the terms of the Merger Agreement, formal transfer of the equity ownership of AHP from the Company to the Buyer will occur at the earlier of (i) Buyer’s IPO, (ii) Buyer going public by other means, or (iii) if Buyer does not go public, on May 1, 2025. Until that time, the Company has the right, but not the obligation, to reacquire AHP for a price equal to any consideration already paid by the Buyer for AHP, plus all expenses incurred by Buyer in operating AHP after January 16, 2023.

Concurrent with the AHP Merger Agreement, AHP and the Buyer also entered into a Management Services Agreement (the “MSA”), pursuant to which the Buyer assumed full control of managing AHP’s business operations and paying AHP’s operating expenses after January 16, 2023. The term of the MSA is from January 17, 2023 to May 1, 2025 (extended from the initial date of August 1, 2024), which is the extended date by which equity ownership of AHP can transfer from the Company to the Buyer. The Buyer agreed in the Merger Agreement to reimburse the Company for reasonable expenses incurred by the Company in operating AHP from January 1, 2023 to January 16, 2023, which we refer to as the Stub Period Reimbursement, during which time the Company had operational and financial control of AHP and CHM. Concurrent with the AHP Merger Agreement and the MSA, and as a result of the Buyer assuming control and responsibility of AHP’s operations, the Company discontinued its operations of CHM.

Discontinued Operations

The Company has classified the results of the ACO/MSO Division as discontinued operations in the accompanying consolidated statement of operations for all periods presented. No assets or liabilities were available to be classified as held for sale as of December 31, 2024 or 2023.

F-17

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 4 – DISCONTINUED OPERATIONS (CONTINUED)**

The financial results of the ACO/MSO Division are presented as income (loss) from discontinued operations, net of income taxes on the Company’s consolidated statement of operations. The following table presents financial results of the ACO/MSO Division for the years ended December 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| **Revenue:** |  |  | |  |  |  | |  |
| Consulting revenue |  | $ | --- |  |  | $ | 23,646 |  |
| Total revenue |  |  | --- |  |  |  | 23,646 |  |
|  |  |  |  |  |  |  |  |  |
| **Operating Expenses and Costs:** |  |  |  |  |  |  |  |  |
| Medicare shared savings expenses |  |  | --- |  |  |  | 95,967 |  |
|  |  |  |  |  |  |  |  |  |
| Loss from operations of discontinued operations before income taxes |  |  | --- |  |  |  | (72,321 | ) |
| Provision for income taxes |  |  | --- |  |  |  | --- |  |
|  |  |  |  |  |  |  |  |  |
| Loss from discontinued operations, net of income taxes |  | $ | --- |  |  | $ | (72,321 | ) |

Net cash used in operations of the ACO/MSO Division was $-0- and $124,846 in the years ended December 31, 2024 and 2023, respectively. There were no cash flows from investing or financing activities of the ACO/MSO Division in the years ended December 31, 2024 and 2023.

Derecognition and Gain from Disposal of Discontinued Operations

As a result of the AHP Sale and pursuant to the terms and conditions of the AHP Merger Agreement and the MSA, the Company ceased to have a controlling financial interest in AHP as of January 17, 2023. Accordingly, in connection with the transaction, the Company deconsolidated AHP as of January 17, 2023.

In connection with the deconsolidation, the Company recognized the fair value of consideration received and receivable from the AHP Sale, recognized an indemnification liability related to potential claims resulting from the AHP Sale, derecognized the carrying value of assets and liabilities transferred to the Buyer or otherwise derecognized in connection with in the AHP Sale, and recorded a gain on sale for the excess of consideration received over carrying value of assets derecognized and liabilities recognized.

The Company elected to record the contingent portion of consideration receivable at fair value on the sale date pursuant to the guidance in FASB Emerging Issues Task Force Issue 09-4, “Seller Accounting for Contingent Consideration,” (“EITF 09-4”). The fair value of consideration received and receivable is shown in the following table:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Upfront Cash Consideration paid at signing |  | $ | 750,000 |  |
|  |  |  |  |  |
| Incremental Cash Consideration |  |  | 1,311,567 |  |
| IPO Share Consideration |  |  | 1,463,517 |  |
| 2022 MSSP Consideration |  |  | 312,987 |  |
| Physician Advance Consideration |  |  | 199,645 |  |
| Stub Period Reimbursement |  |  | 31,381 |  |
| Total fair value of contingent consideration receivable |  |  | 3,319,097 |  |
|  |  |  |  |  |
| Total fair value of consideration received and receivable |  | $ | 4,069,097 |  |

F-18

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 4 – DISCONTINUED OPERATIONS (CONTINUED)**

The fair value of contingent consideration receivable was determined using an expected present value approach, which applies a discount rate to a probability-weighted stream of net cash flows based on multiple scenarios, as estimated by management. As such, the fair values of contingent consideration receivable rely on significant unobservable inputs and assumptions and there is uncertainty in the expected future cash flows used in the fair valuation. Significant assumptions related to the valuation of contingent consideration receivable include the likelihood of a Buyer IPO, the valuation of the Buyer’s common stock in a potential IPO, the likelihood that AHP would meet its performance benchmarks to the extent that it will receive shared savings for plan year 2022, the likelihood that AHP under the management of the Buyer would receive sufficient shared savings in plan years 2023 and/or 2024 to pay the Physician Advance Consideration, and the likelihood that the Company would be able to transfer or add new participating physicians to AHP before July 31, 2023 in order to collect the Incremental Cash Consideration.

The book value of the assets and liabilities derecognized on January 17, 2023 in connection with the sale were as follows:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Prepaid expenses |  | $ | 1,500 |  |
| Intangible asset - ACO physician contract |  |  | 1,073,000 |  |
| Goodwill |  |  | 381,856 |  |
| Contract liability |  |  | (20,278 | ) |
| Contingent acquisition consideration |  |  | (185,024 | ) |
| Net Book Value of Assets and Liabilities Sold |  | $ | 1,251,054 |  |

Prepaid expenses reflect prepaid services from which the Buyer benefited following the AHP Sale. Intangible assets and goodwill represented the carrying value of assets recorded at the time the Company acquired CHM and AHP in 2020 (the “Original Acquisition”). Contract liability represented remaining unearned revenue for which the Buyer was required to provide the performance obligations after January 17, 2023. In connection with the AHP Sale, the remaining value of contingent acquisition consideration (“CAC”) related to the Original Acquisition was written off.

After recording the fair value of consideration and derecognition of assets and liabilities, and an estimated liability related to the Indemnification Clause, the Company recorded a gain from disposal of discontinued operations in the amount of $2,674,069 in the year ended December 31, 2023 as follows:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Total fair value of consideration received and receivable |  | $ | 4,069,097 |  |
| Less: net book value of assets and liabilities sold |  |  | (1,251,054 | ) |
| Less: fair value of Indemnification Clause |  |  | (143,974 | ) |
|  |  |  |  |  |
| Gain from disposal of discontinued operations |  | $ | 2,674,069 |  |

After January 17, 2023, and as prescribed under EITF 09-4, the Company has elected to subsequently treat the contingent consideration receivable using gain contingency guidance and only record a gain or loss when the contingency is resolved. Accordingly, the Company does not prospectively remeasure the fair value of contingent consideration receivable each reporting period.

Receipt and Extension of Contingent Sale Consideration Receivable

The Company has received the following consideration from the AHP Merger Agreement through December 31, 2024: (i) $750,000 upon signing of the AHP Merger Agreement in January 2023, (ii) the $31,381 Stub Period Reimbursement in March 2023, (iii) $1,750,000 ($1,540,000 net after commissions) Incremental Cash Consideration during June, July and August 2023 for meeting 100% of the participating physician transfer milestones outlined in the AHP Merger Agreement, (iv) $1,873,993 ($1,186,231 net after commissions and other expenses) in October 2023 related to AHP’s Plan Year 2022 MSSP shared savings, and (v) $500,000 gross ($325,000 net) from the receipt of Physician Advance Consideration in November 2024.

The Company recognizes gains and losses from realization of contingent sale consideration receivable for the difference between the realized (or realizable) value of resolved contingent consideration components and the initial fair value recorded at the sale date. Gain from realization of contingent sale consideration receivable was $125,355 and $1,090,857 during the years ended December 31, 2024 and 2023, respectively. Gains in 2023 relate to excess value realized over the carrying value of the Incremental Cash Consideration and the 2022 MSSP Consideration. Gains in 2024 relate to excess value realized over the carrying value of the Physician Advance Consideration.

F-19

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 4 – DISCONTINUED OPERATIONS (CONTINUED)**

The carrying value of the remaining unresolved components of contingent consideration receivable as of December 31, 2024 and 2023 was as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Physician Advance Consideration |  | $ | --- |  |  | $ | 199,645 |  |
| IPO Share Consideration |  |  | 1,463,518 |  |  |  | 1,463,518 |  |
| Total contingent consideration receivable |  |  | 1,463,518 |  |  |  | 1,663,163 |  |

**NOTE 5 – PREPAID EXPENSES AND OTHER**

Prepaid and other expenses as of December 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Insurance prepayments |  | $ | 5,916 |  |  | $ | 11,209 |  |
| Other expense prepayments |  |  | 19,838 |  |  |  | 38,391 |  |
| Lease deposits |  |  | 55,047 |  |  |  | 50,547 |  |
| Contract assets |  |  | 20,058 |  |  |  | 5,110 |  |
| Total prepaid expenses and other |  |  | 100,859 |  |  |  | 105,257 |  |
| Less: long term portion |  |  | (44,140 | ) |  |  | (50,047 | ) |
| Prepaid expenses and other, current portion |  | $ | 56,719 |  |  | $ | 55,210 |  |

Contract assets relate to amounts incurred to obtain a customer contract that would not have been incurred if the contract had not been obtained, such as commissions, associated with NCFM annual access contracts.

**NOTE 6 – PROPERTY AND EQUIPMENT**

Property and equipment as of December 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Medical equipment |  | $ | 496,452 |  |  | $ | 493,854 |  |
| Furniture, office equipment and leasehold improvements |  |  | 314,963 |  |  |  | 317,963 |  |
|  |  |  |  |  |  |  |  |  |
| Total property and equipment |  |  | 811,415 |  |  |  | 811,817 |  |
| Less: accumulated depreciation |  |  | (634,839 | ) |  |  | (521,062 | ) |
|  |  |  |  |  |  |  |  |  |
| Property and equipment, net |  | $ | 176,576 |  |  | $ | 290,755 |  |

Depreciation expense was $115,102 and $123,868 during the years ended December 31, 2024 and 2023, respectively. The Company recognized a loss on disposal of equipment of $1,675 and $-0- during the years ended December 31, 2024 and 2023, respectively, related to office equipment no longer in use.

F-20

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 7 – INTANGIBLE ASSETS**

Identifiable intangible assets as of December 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| NCFM: Medical database |  | $ | --- |  |  | $ | 1,101,538 |  |
| NCFM: Website |  |  | --- |  |  |  | 41,000 |  |
|  |  |  |  |  |  |  |  |  |
| Total intangible assets |  |  | --- |  |  |  | 1,142,538 |  |
| Less: accumulated amortization |  |  | --- |  |  |  | (258,690 | ) |
|  |  |  |  |  |  |  |  |  |
| Intangible assets, net |  | $ | --- |  |  | $ | 883,848 |  |

Intangible assets arose from the acquisition of NCFM in April 2019. The NCFM Medical Database was being prospectively amortized starting January 1, 2023 over an estimated five-year useful life. The NCFM website began being amortized over a five-year life from the acquisition date. Amortization expense related to intangible assets in the years ended December 31, 2024 and 2023 was $167,848 and $228,159, respectively.

As a result of the full impairment of the NCFM medical database during the year ended December 31, 2024 as described below, there is no expected future amortization expense of intangible assets.

Impairment of NCFM Medical Database – 2024

During the third quarter of 2024, the Company determined that triggering events had occurred that required an impairment assessment of the NCFM Medical Database. The triggering events included (i) a material decline in revenue during third quarter 2024, including a 65% decline compared to the third quarter of 2023 and a 35% decline compared to the preceding second quarter of 2024, (ii) substantial operating losses and negative cash flows generated from the practice during the third quarter of 2024 for the first time since its acquisition, and (iii) substantial downsizing of the practice personnel and overhead. The Company does not believe that the levels of revenue and profitability achieved since acquisition of NCFM in 2019 are reasonably likely to return to the extent that projected cash flows from the practice can substantiate the carrying value of the NCFM Medical Database.

An impairment loss is recognized if the carrying amount of a reporting unit exceeds its fair value. The amount of impairment loss is measured as the excess of the reporting unit’s carrying value over its fair value. The Company determined that the carrying amount of the reporting unit, which consists of the NCFM practice, exceeded its estimated fair value. Accordingly, the Company recorded an impairment charge in the amount of $716,000 to adjust carrying value of the NCFM Medical Database to its estimated fair value of $-0- in the year ended December 31, 2024.

Impairment of AEU Goodwill – 2023

In connection with the acquisition of AEU in May 2022, the Company recorded goodwill of $319,958, representing the excess fair value of consideration transferred over the fair value of the net identifiable assets acquired.

During the third quarter of 2023, the Company determined that triggering events had occurred that required an impairment assessment of the AEU goodwill. The triggering events included (i) a material decline in revenue during third quarter 2023, and (ii) an inability of the business to achieve profitability since its acquisition. An impairment loss is recognized if the carrying amount of a reporting unit exceeds its fair value. The amount of impairment loss is measured as the excess of the reporting unit’s carrying value over its fair value. The Company determined that the carrying amount of the reporting unit, which consists of the AEU practice, exceeded its estimated fair value. Accordingly, the Company recorded an impairment charge in the amount of $319,958 to adjust carrying value of AEU goodwill to its estimated fair value of $-0- in the year ended December 31, 2023.

F-21

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 8 – LEASES**

The Company has separate operating leases, and related amendments thereto, for office space related to its CCN (formerly used for NWC through October 2024), NCFM, and BTG practices, its corporate headquarters, and a copier lease that expire in July 2026, May 2025, March 2025, November 2026, and January 2027, respectively. As of December 31, 2024, the Company’s weighted-average remaining lease term relating to its operating leases was 1.6 years, with a weighted-average discount rate of 34.54%.

Effective in April 2024, the Company renewed its lease for its BTG facility for a period of one year, until March 31, 2025. In connection with the lease extension, the Company recognized an ROU lease asset and lease liability each in the amount of $28,044. The discount rate used to estimate the fair value of the ROU lease asset and lease liability was 51.87%.

In July 2024, the Company terminated without penalty its lease for its AEU facility, which was set to expire in March 2026, and relocated its AEU practice to the NWC facility. In connection with the lease termination, the Company wrote off the ROU lease asset in the amount of $36,319 and lease liability in the amount of $37,469, and recognized a gain on termination of lease in the amount of $1,148.

Effective in October 2024, the rentable space at the Company’s corporate headquarters was reduced from 7,650 to 4,133 square feet with a corresponding reduction in rent. In connection with the lease modification, the Company remeasured the ROU lease asset and lease liability, resulting in a reduction of $257,227 of each of the ROU lease asset and lease liability in the year ended December 31, 2024. The discount rate used to estimate the fair value of the ROU lease asset and lease liability was 52.05%.

The table below summarizes the Company’s lease-related assets and liabilities as of December 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| Lease assets |  | $ | 361,109 |  |  | $ | 935,812 |  |
|  |  |  |  |  |  |  |  |  |
| **Lease liabilities** |  |  |  |  |  |  |  |  |
| Lease liabilities (short term) |  | $ | 208,549 |  |  | $ | 326,033 |  |
| Lease liabilities (long term) |  |  | 153,592 |  |  |  | 613,386 |  |
| Total lease liabilities |  | $ | 362,141 |  |  | $ | 939,419 |  |

Lease expense was $477,063 and $468,901 during the years ended December 31, 2024 and 2023, respectively.

Maturities of operating lease liabilities were as follows as of December 31, 2024:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 2025 |  | $ | 312,605 |  |
| 2026 |  |  | 200,969 |  |
| 2027 |  |  | 990 |  |
| Total lease payments |  |  | 514,564 |  |
| Less interest |  |  | (152,423 | ) |
| Present value of lease liabilities |  | $ | 362,141 |  |

F-22

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 9 – ACCOUNTS PAYABLE, ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES**

Amounts related to accounts payable, accrued expenses and other current liabilities as of December 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Trade accounts payable |  | $ | 468,803 |  |  | $ | 251,479 |  |
| Accrued payroll liabilities |  |  | 17,827 |  |  |  | 110,103 |  |
| Accrued operating expenses |  |  | 90,462 |  |  |  | 91,238 |  |
| Accrued interest |  |  | 161,171 |  |  |  | 57,074 |  |
| Accrued commissions payable from 2022 MSSP Consideration |  |  | 25,000 |  |  |  | 100,000 |  |
| Contingent acquisition consideration payable |  |  | --- |  |  |  | 2,189 |  |
| Product return allowance |  |  | 2,049 |  |  |  | 2,095 |  |
|  |  | $ | 765,312 |  |  | $ | 614,178 |  |

**NOTE 10 – CONTRACT LIABILITIES**

Amounts related to contract liabilities as of December 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Patient services paid but not provided - NCFM |  | $ | 86,201 |  |  | $ | 95,334 |  |
| Patient services paid but not provided - BTG |  |  | 111,877 |  |  |  | 100,857 |  |
| Patient services paid but not provided - NWC |  |  | --- |  |  |  | 75,438 |  |
| Patient services paid but not provided - CCN |  |  | 32,743 |  |  |  | --- |  |
| Unshipped products - MOD |  |  | 1,724 |  |  |  | 145 |  |
|  |  | $ | 232,545 |  |  | $ | 271,774 |  |

Contract liabilities relate to (i) NCFM annual access contracts, including Medical Membership, Concierge Service and Optimal Health 365 Access Plan contracts pursuant to which patients prepay for access to services to be provided at the patient’s request over a period of time, (ii) BTG contracts pursuant to which patients prepay for access to a fixed number of visits used at the patients’ discretion, (iii) CCN annual and semi-annual concierge fees, (iv) NWC annual administration fees, and (v) MOD sold but unshipped products.

F-23

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS**

Amounts due to related parties as of December 31, 2024 and 2023 were comprised of the following:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Note Payable to Dr. Michael Dent, March 2023 |  | $ | --- |  |  | $ | 12,601 |  |
| Note Payable to Dr. Michael Dent, June 2023 |  |  | --- |  |  |  | 26,875 |  |
| Note Payable to Dr. Michael Dent, December 2023 |  |  | --- |  |  |  | 166,500 |  |
| Convertible Note Payable I to Dr. Michael Dent, March 2024 \*\* |  |  | 393,317 |  |  |  | --- |  |
| Convertible Note Payable II to Dr. Michael Dent, March 2024 \*\* |  |  | 131,615 |  |  |  | --- |  |
| Convertible Note Payable III to Dr. Michael Dent, March 2024 \*\* |  |  | 146,093 |  |  |  | --- |  |
| Convertible Note Payable IV to Dr. Michael Dent, April 2024 |  |  | 150,000 |  |  |  | --- |  |
| Convertible Note Payable V to Dr. Michael Dent, April 2024 |  |  | 50,000 |  |  |  | --- |  |
| Convertible Note Payable VI to Dr. Michael Dent, June 2024 |  |  | 1,000,000 |  |  |  | --- |  |
| Convertible Note Payable VII to Dr. Michael Dent, September 2024 |  |  | 36,842 |  |  |  | --- |  |
| Convertible Note Payable VIII to Dr. Michael Dent, April 2025 |  |  | 10,526 |  |  |  | --- |  |
| Convertible Note Payable IX to Dr. Michael Dent, September 2024 |  |  | 73,684 |  |  |  | --- |  |
| Convertible Note Payable X to Dr. Michael Dent, September 2024 |  |  | 21,053 |  |  |  | --- |  |
| Convertible Note Payable X to Dr. Michael Dent, September 2024 |  |  | 105,263 |  |  |  | --- |  |
| Convertible Note Payable XI to Dr. Michael Dent, September 2024 |  |  | 126,316 |  |  |  | --- |  |
| Convertible Note Payable XII to Dr. Michael Dent, September 2024 |  |  | 105,263 |  |  |  | --- |  |
| Convertible Note Payable XIII to Dr. Michael Dent, September 2024 |  |  | 52,632 |  |  |  | --- |  |
| Convertible Note Payable XIV to Dr. Michael Dent, September 2024 |  |  | 157,895 |  |  |  | --- |  |
| Convertible Note Payable XV to Dr. Michael Dent, September 2024 |  |  | 210,526 |  |  |  | --- |  |
| Advances payable to Dr. Michael Dent, September 2024 |  |  | 40,000 |  |  |  | --- |  |
| Advances payable to Dr. Michael Dent, October 2024 |  |  | 270,000 |  |  |  | --- |  |
| Advances payable to Dr. Michael Dent, November 2024 |  |  | 110,000 |  |  |  | --- |  |
| Convertible Note Payable XVI to Dr. Michael Dent, December 2024 |  |  | 25,000 |  |  |  | --- |  |
| Convertible Note Payable XVII to Dr. Michael Dent, December 2024 |  |  | 70,000 |  |  |  | --- |  |
| Convertible Note Payable XVIII to Dr. Michael Dent, December 2024 |  |  | 120,000 |  |  |  | --- |  |
| Face value of notes payable to related party |  |  | 3,406,025 |  |  |  | 205,976 |  |
| Less: unamortized discounts |  |  | (494,104 | ) |  |  | (34,834 | ) |
| Notes payable to related party, total |  |  | 2,911,921 |  |  |  | 171,142 |  |
| Plus deferred compensation payable to Dr. Michael Dent |  |  | 300,600 |  |  |  | 300,600 |  |
| Total due to related party |  | $ | 3,212,521 |  |  | $ | 471,742 |  |

|  |  |  |
| --- | --- | --- |
|  | \*\* | - denotes note payable carried at fair value |

Notes Payable to Related Parties

On November 8, 2022, the Company entered into a Merchant Cash Advance Factoring Agreement with a trust controlled by Dr. Dent, pursuant to which the Company received an advance of $150,000 (the “November MCA”). The Company was required to repay the November MCA at the rate of $3,750 per week until the balance of $195,000 was repaid, which was scheduled for November 2023. At inception, the Company recognized a note payable in the amount of $195,000 and a discount against the note payable of $45,000. The discount was being amortized over the life of the November MCA. The Company made payments totaling $-0- and $172,500 in the years ended December 31, 2024 and 2023, respectively. Amortization of debt discount was $-0- and $38,836 in the years ended December 31, 2024 and 2023, respectively. The November MCA was repaid in full during the fourth quarter of 2023. As of December 31, 2024 and 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

F-24

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS (CONTINUED)**

On December 13, 2022, the Company entered into a Merchant Cash Advance Factoring Agreement with a trust controlled by Dr. Dent, pursuant to which the Company received an advance of $110,000 (the “December MCA”). The Company was required to repay the December MCA at the rate of $2,750 per week until the balance of $143,000 was repaid, which was scheduled for December 2023. In connection with the December MCA, the Company issued 3,142,857 three-year warrants to the holder with an exercise price of $0.035. The fair value of the warrants was $63,420. At inception, the Company recognized a note payable in the amount of $143,000 and a discount against the note payable of $68,281 for the allocated fair value of the original issue discounts and warrants. The discount was being amortized over the life of the December MCA. The Company made payments totaling $-0- and $137,500 in the years ended December 31, 2024 and 2023, respectively. Amortization of debt discount was $-0- and $65,655 in the years ended December 31, 2024 and 2023, respectively. The December MCA was repaid in full during the fourth quarter of 2023. As of December 31, 2024 and 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On January 5, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $10,000 (the “$10k Dent Note”). The $10k Dent Note bore interest at a rate of 15% per annum and was scheduled to mature six months from issuance. In connection with the $10k Dent Note, the Company issued 96,154 five-year warrants to the holder with an exercise price of $0.104. The fair value of the warrants was $6,843. At inception, the Company recognized a note payable in the amount of $10,000 and a discount against the note payable of $3,851 for the allocated fair value of the warrants. The discount was to be amortized over the life of the $10k Dent Note. The $10k Dent Note was repaid in full during January 2023. Amortization of debt discount and interest expense prior to repayment were $269 and $53, respectively, in the year ended December 31, 2023. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $3,582 in the year ended December 31, 2023.

On January 13, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $161,000 (the “January 2023 Dent Note”). Net proceeds were $160,000, taking into account the original issue discount of $1,000. The January 2023 Dent Note bore interest at a rate of 15% per annum and was scheduled to mature six months from issuance. In connection with the January 2023 Dent Note, the Company issued 860,215 three-year warrants to Dr. Dent with an exercise price of $0.093. The fair value of the warrants was $56,123. At inception, the Company recognized a note payable in the amount of $161,000 and a discount against the note payable of $42,553 for the allocated fair value of the original issue discount and warrants. The discount was to be amortized over the life of the January 2023 Dent Note. The January 2023 Dent Note was repaid in full during January 2023. Amortization of debt discount and interest expense prior to repayment were $1,373 and $397, respectively, in the year ended December 31, 2023. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $41,181 in the year ended December 31, 2023. As of December 31, 2024 and 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On February 14, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $186,000 (the “February 2023 Dent Note”). Net proceeds were $185,000 after an original issue discount of $1,000. The February 2023 Dent Note bore interest at a rate of 15% per annum and matured six months from issuance. In connection with the February 2023 Dent Note, the Company issued 685,185 three-year warrants to Dr. Dent with an exercise price of $0.135. The fair value of the warrants was $66,136. At inception, the Company recognized a note payable in the amount of $186,000 and a discount against the note payable of $50,989 for the allocated fair value of the original issue discounts and warrants. The discount was amortized over the life of the February 2023 Dent Note. The February 2023 Dent Note was repaid in full during August 2023. Amortization of debt discount and interest expense prior to repayment were $50,989 and $13,875, respectively, in the year ended December 31, 2023. No loss on extinguishment of debt was recognized because the discount was fully amortized at the time of repayment.

F-25

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS (CONTINUED)**

On March 14, 2023, the Company issued a promissory note payable to a trust controlled by Dr. Dent with a stated principal amount of $112,510 and prepaid interest of $13,501 for total scheduled repayments of $126,011 (the “March 2023 Dent Note”). The March 2023 Dent Note had an original issue discount of $12,510, resulting in net proceeds to the Company of $100,000. At inception, the Company recognized a note payable in the amount of $126,011 and a discount against the note payable of $26,011. The March 2023 Dent Note did not bear interest in excess of the prepaid interest and original issue discount and matures on March 14, 2024. The Company is required to make 10 monthly payments of $12,601 starting April 30, 2023. At inception, the Company recorded a discount against the note of $26,011, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. The March 2023 Dent Note gave the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. The Company made payments totaling $12,601 and $113,410 in the years ended December 31, 2024 and 2023, respectively. Amortization of debt discount was $2,504 and $23,507 in the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, remaining payments were $0-0- and $12,601, respectively, and the net carrying value was $-0- and $10,097, respectively. The March 2023 Dent Note was repaid in January 2024.

On April 13, 2023, the Company issued an unsecured promissory note to Dr. Michael Dent with a face value of $100,000 (the “April 2023 Dent Note”). Net proceeds were $100,000. The April 2023 Dent Note bore a fixed interest charge of $15,000 (15% per annum) and had an original maturity date of May 12, 2023. At inception, the Company recorded a note payable in the amount of $115,000 and a discount against the note of $15,000, representing the difference between the total required repayments and the net proceeds received. On May 12, 2023, the Company issued 654,450 five-year warrants with an exercise price of $0.0764 to Dr. Michael Dent in exchange for extending the maturity date of the April 2023 Dent Note until September 30, 2023. The April 2023 Dent Note was repaid in full on June 29, 2023. Amortization of debt discount prior to repayment was $15,000 in the year ended December 31, 2023. In connection with the extension and repayment, the Company recognized a loss on extinguishment of debt of $31,621 in the year ended December 31, 2023. As of December 31, 2024 and 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On April 27, 2023, the Company issued an unsecured promissory note to George O’Leary, its Chief Financial Officer, with a face value of $35,000 (the “April 2023 O’Leary Note”). Net proceeds were $35,000. The April 2023 O’Leary Note bore a fixed interest charge of $5,250 (15% per annum) and was scheduled to mature May 25, 2023. At inception, the Company recorded a note payable in the amount of $40,250 and a discount against the note of $5,250, representing the difference between the total required repayments and the net proceeds received. On June 2, 2023, the Company issued 261,194 five-year warrants with an exercise price of $0.067 to Mr. O’Leary in exchange for extending the maturity date of the April 2023 O’Leary Note until July 13, 2023. The April 2023 O’Leary Note was repaid in full on June 15, 2023. Amortization of debt discount prior to repayment was $5,250 in the year ended December 31, 2023. In connection with the extension and repayment, the Company recognized a loss on extinguishment of debt of $12,549 in the year ended December 31, 2023. As of December 31, 2024 and 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On June 8, 2023, the Company issued an unsecured promissory note to Dr. Michael Dent with a face value of $30,000 (the “June 2023 Dent Note”). Net proceeds were $30,000. The June 2023 Dent Note bore a fixed interest charge of $4,500 (15% per annum) and had a maturity date of June 30, 2023. At inception, the Company recorded a note payable in the amount of $34,500 and a discount against the note of $4,500, representing the difference between the total required repayments and the net proceeds received. Amortization of the debt discount was $4,500 in the year ended December 31, 2023. The June 2023 Dent Note was repaid in full in June 2023. No loss on extinguishment of debt was recognized because the discount was fully amortized at the time of repayment. As of December 31, 2024 and 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On June 26, 2023, the Company issued an unsecured promissory note to Dr. Michael Dent with a face value of $25,000 (the “June 2023 Dent Note II”). The June 2023 Dent Note II bore a fixed interest charge of $1,875 (15% per annum) and matured on December 26, 2023. At inception, the Company recorded a note payable in the amount of $26,875 and a discount against the note of $1,875. Amortization of the debt discount was $-0- and $1,875 in the years ended December 31, 2024 and 2023. The Company made payments totaling $26,875 and $-0- in the years ended December 31, 2024 and 2023, respectively. The June 2023 Dent Note II was repaid in full in January 2024. As of December 31, 2024 and 2023, the remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $26,875.

F-26

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS (CONTINUED)**

On August 17, 2023, the Company issued to a trust controlled by Dr. Dent a promissory note (the “August 2023 Dent Note”) with an initial stated principal amount equal to $330,000 at a purchase price equal to the principal amount less any original issue discounts and fees. The August 2023 Dent Note included a 5% original issue discount, accrues interest at a rate of 0%, and was scheduled to be repaid in four equal semi-monthly installments beginning on October 15, 2023, with each payment including a 2% payment premium, totaling $343,200 in cash repayments. The Company received net proceeds of $308,500 after discounts and fees. In connection with the note, the Company issued 500,000 five-year warrants to the holder with an exercise price of $0.15. The fair value of the warrants was $25,311. At inception, the Company recorded a note payable in the amount of $343,200 and a discount against the note payable of $56,739 for the allocated fair value of the original issue discount and warrants. Amortization of debt discount was $-0- and $30,261 in the years ended December 31, 2024 and 2023, respectively. The Company made payments totaling $-0- and $343,200 in the years ended December 31, 2024 and 2023, respectively. The August 2023 Dent Note was repaid in full in October 2023. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $26,478 in the year ended December 31, 2023. As of December 31, 2024 and 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On August 30, 2023, the Company issued an unsecured promissory note to Dr. Michael Dent with a face value of $10,000 (the “August 2023 Dent Note II”). The August 2023 Dent Note II had no original issue discount and did not bear interest. Net proceeds to the Company were $10,000. The August 2023 Dent Note II was scheduled to mature on September 5, 2023. The Company repaid the August 2023 Dent Note II in full on August 31, 2023. As of December 31, 2024 and 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On September 13, 2023, the Company issued to Dr. Michael Dent a promissory note with a face value of $93,500 (the “September 2023 Dent Note”). Net proceeds were $85,000. The September 2023 Dent Note bore a fixed interest charge of $8,500 (10% per annum) and had a maturity date of October 12, 2023. In connection with the note, the Company issued 850,000 five-year warrants to the holder with an exercise price of $0.06. The fair value of the warrants was $31,714. At inception, the Company recorded a note payable in the amount of $93,500 and a discount against the note payable of $30,672 for the allocated fair value of the original issue discount and warrants. Amortization of debt discount was $29,615 in the year ended December 31, 2023. The Company made payments totaling $-0- and $93,500 in the years ended December 31, 2024 and 2023, respectively. The September 2023 Dent Note was repaid in full in October 2023. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $1,058 in the year ended December 31, 2023. As of December 31, 2024 and 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On December 1, 2023, the Company issued an unsecured promissory note to a trust controlled by Dr. Dent a promissory note with a face value of $150,000 (the “December 2023 Dent Note”). The December 2023 Dent Note bears a fixed interest charge of $15,000 (10% per annum) and $1,500 in fixed fees and matures on February 28, 2024. The Company received net proceeds of $150,000 after discounts and fees. In connection with the note, the Company issued 1,500,000 five-year warrants to the holder with an exercise price of $0.06. The fair value of the warrants was $32,269. At inception, the Company recorded a note payable in the amount of $166,500 and a discount against the note payable of $48,769 for the allocated fair value of the original issue discount and warrants. The Company made no payments in the years ended December 31, 2024 or 2023. Amortization of the debt discount was $32,330 and $16,439 in the years ended December 31, 2024 and 2023, respectively. On March 27, 2024, the December 2023 Dent Note was refinanced and replaced with the March 2024 Dent Note III as described below. No loss on extinguishment of debt was recognized in the nine months ended September 30, 2024 because the discount was fully amortized at the time of the refinancing. As of December 31, 2024 and 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On March 27, 2024, the Company issued to a trust controlled by Dr. Michael Dent three separate notes payable as follows: (1) a note payable with a principal of $350,000, an interest rate of 12% per annum, and a maturity date of June 27, 2024 (the “March 2024 Dent Note I”), (2) a note payable with a principal of $150,000, an interest rate of 12% per annum, and an original maturity date of August 24, 2024 (the “March 2024 Dent Note II”), and (3) a note payable with a principal of $166,500, an interest rate of 12% per annum, and a maturity date of August 28, 2024 (the “March 2024 Dent Note III”, and collectively, the “March 2024 Dent Notes”). The full amount of principal and accrued interest on each of the March 2024 Dent Notes is due at the respective maturity date of each note. Each of the March 2024 Dent Notes is convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.0573 per share. In connection with the issuance of the March 2024 Dent Notes, the Company also issued to the holder a ten-year warrant to purchase 6,660,000 shares of the Company’s common stock at an exercise price of $0.06 per share (the “March 2024 Warrant”). The fair value of the March 2024 Warrant was $254,345.

F-27

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS (CONTINUED)**

Net proceeds from the March 2024 Dent Note I were $350,000. At inception, the Company recorded a discount of $203,588, representing the allocated fair value of the beneficial conversion feature (“BCF”) and the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note I. The discount was being amortized over the original life of the note. Amortization of debt discount was $203,588 and $-0- in the years ended December 31, 2024 and 2023, respectively. The Company made no payments against the March 2024 Dent Note I in the years ended December 31, 2024 or 2023. On June 27, 2024, the maturity date on the March 2024 Dent Note I was extended until December 27, 2024 in exchange for a ten-year warrant to purchase 393,750 shares of the Company’s common stock at an exercise price of $0.081 per share. Because the discounted cash flows from the note before and after the extension were determined to be substantially different, the extension was treated as an extinguishment and reissuance. In connection with the extension, the Company recognized a loss on extinguishment of debt of $65,936 and $-0- in the years ended December 31, 2024 and 2023, respectively. The March 2024 Dent Note I was recorded at its fair value of $405,006 following the extension. On December 31, 2024, in exchange for a ten-year warrant to purchase 618,750 shares of the Company’s common stock at an exercise price of $0.0226 per share, the maturity date on the March 2024 Dent Note I was extended until June 27, 2025, the maturity date on the April 2024 Dent Note I (as defined below) was extended until April 10, 2025, the maturity date on the April 2024 Dent Note II (as defined below) was extended until April 18, 2025, and the interest rate on each of the extended notes was increased from 12% to 15% (the “December Extension”). The fair value of the warrant was $8,653. Because the discounted cash flows from the March 2024 Dent Note I before and after the December Extension were determined to be substantially different, the extension was treated as an extinguishment and reissuance. In connection with the December Extension, the Company recognized a loss on extinguishment of debt of $11,339 and $-0- in the years ended December 31, 2024 and 2023, respectively, related to the extension of the March 2024 Dent Note I. The March 2024 Dent Note I continues to be recorded at its fair value following the December Extension. The Company recognized a gain on change in fair value of debt in the amount of $17,522 and $-0- in the years ended December 31, 2024 and 2023, respectively, to revalue the note at its fair value at period end. As of December 31, 2024 and 2023, the fair value (which equals the carrying value) of the March 2024 Dent Note I was $393,317 and $-0-, respectively, and remaining principal payments were $350,000 and $-0-, respectively. The March 2024 Dent Note I will continue to be revalued at future period ends.

Net proceeds from the March 2024 Dent Note II were $150,000. At inception, the Company recorded a discount of $89,222, representing the allocated fair value of the BCF and the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note II. The discount is being amortized over the life of the note. Amortization of debt discount was $89,222 and $-0- in the years ended December 31, 2024 and 2023, respectively. The Company made no payments against the March 2024 Dent Note II in the years ended December 31, 2024 or 2023. On September 17, 2024, the maturity date on the March 2024 Dent Note II (as well as March 2024 Dent Note III) was extended until February 28, 2025 in exchange for a ten-year warrant to purchase 356,063 shares of the Company’s common stock at an exercise price of $0.0465 per share. Because the discounted cash flows from the note before and after the extension were determined to be substantially different, the extension was treated as an extinguishment and reissuance. In connection with the extension, the Company recognized a gain on extinguishment of debt of $8,089 and $-0- in years ended December 31, 2024 and 2023. The March 2024 Dent Note II was recorded at its fair value of $150,788 following the extension. The Company recognized a gain on change in fair value of debt in the amount of $13,059 and $-0- in the years ended December 31, 2024 and 2023, respectively, to revalue the note at its fair value at period end. As of December 31, 2024 and 2023, the fair value (which equals the carrying value) of the March 2024 Dent Note II was $131,615 and $-0-, respectively, and remaining principal payments were $150,000 and $-0-, respectively. The March 2024 Dent Note II will continue to be revalued at future period ends.

The March 2024 Dent Note III refinanced the previously issued December 2023 Dent Note in the same principal amount of $166,500. Because the two notes were determined to be substantially different, the issuance of the March 2024 Dent Note III and repayment of the December 2023 Dent Note was treated as an extinguishment and reissuance. Accordingly, the Company recognized a loss on debt extinguishment of $96,660 and $-0- in the years ended December 31, 2024 and 2023, respectively, related to the original issuance of the March 2024 Dent Note III. On September 17, 2024, the maturity date on the March 2024 Dent Note III (as well as March 2024 Dent Note II) was extended until February 28, 2025 in exchange for a ten-year warrant to purchase 356,063 shares of the Company’s common stock at an exercise price of $0.0465 per share. Because the discounted cash flows from the note before and after the extension were determined to be substantially different, the extension was treated as an extinguishment and reissuance. In connection with the extension, the Company recognized an additional loss on extinguishment of debt of $5,508 and $-0- in the years ended December 31, 2024 and 2023, respectively. The Company recognized gains on the change in fair value of debt in the amount of $53,528 and $-0- in the years ended December 31, 2024 and 2023, respectively, to revalue the note at its fair value at period end. As of December 31, 2024 and 2023, the fair value (which equals the carrying value) of the March 2024 Dent Note III was $146,093 and $-0-, respectively, and remaining principal payments were $166,500 and $-0-, respectively. The March 2024 Dent Note II will continue to be revalued at future period ends.

F-28

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS (CONTINUED)**

On April 10, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of October 10, 2024 (the “April 2024 Dent Note I”). The April 2024 Dent Note I is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.0577 per share. The Company received net proceeds of $150,000. At inception, the Company recorded a note payable in the amount of $150,000 with no related discounts. On December 31, 2024, in connection with the December Extension, the maturity date on the April 2024 Dent Note I was extended until April 10, 2025. Because the discounted cash flows from the note before and after the extension were determined to be not substantially different, the extension was treated as a modification. In connection with the modification, the Company recognized a discount of $7,279 against the April 2024 Dent Note I as of December 31, 2024. Amortization of debt discount was $-0- and $-0- in the years ended December 31, 2024 and 2023, respectively. The Company made no payments against the April 2024 Dent Note I in the years ended December 31, 2024 or 2023. As of December 31, 2024 and 2023, the net carrying value of the April 2024 Dent Note I was $142,721 and $-0-, respectively, and remaining principal payments were $150,000 and $-0-, respectively.

On April 18, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $50,000, an interest rate of 12% per annum, and a maturity date of October 18, 2024 (the “April 2024 Dent Note II”). The April 2024 Dent Note II is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.05 per share. The Company received net proceeds of $50,000. At inception, the Company recorded a note payable in the amount of $50,000 with no related discounts. On December 31, 2024, in connection with the December Extension, the maturity date on the April 2024 Dent Note II was extended until April 18, 2025. Because the discounted cash flows from the note before and after the extension were determined to be not substantially different, the extension was treated as a modification. In connection with the modification, the Company recognized a discount of $2,836 against the April 2024 Dent Note II as of December 31, 2024. Amortization of debt discount was $-0- and $-0- in the years ended December 31, 2024 and 2023, respectively. The Company made no payments against the April 2024 Dent Note II in the years ended December 31, 2024 or 2023. As of December 31, 2024 and 2023, the net carrying value of the April 2024 Dent Note II was $47,164 and $-0-, respectively, and remaining principal payments were $50,000 and $-0-, respectively.

On June 3, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $1,000,000, an interest rate of 12% per annum, and a maturity date of June 3, 2025 (the “June 2024 Dent Note”). The June 2024 Dent Note is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.0497 per share. The Company received net proceeds of $950,000 after original issue discount. In connection with the June 2024 Dent Note, the Company issued 10,000,000 ten-year warrants to the holder with an exercise price of $0.0497. The fair value of the warrants was $333,111. The fair value of the embedded conversion feature (“ECF”) was $392,905. At inception, the Company recorded a note payable in the amount of $1,000,000 and a discount against the note payable of $785,811 for the allocated fair value of the ECF, original issue discount and warrants. Amortization of debt discount was $454,263 and $-0- in the years ended December 31, 2024 and 2023, respectively. The Company made no payments in the years ended December 31, 2024 or 2023. As of December 31, 2024 and 2023, the net carrying value was $668,453 and $-0-, respectively, and remaining principal payments were $1,000,000 and $-0-, respectively.

F-29

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS (CONTINUED)**

On September 19, 2024, the Company issued to a trust controlled by Dr. Michael Dent ten separate senior secured convertible promissory note in the aggregate principal amount of $900,000, each with an interest rate of 12% per annum and maturity dates between January 1, 2025 and March 10, 2025 (the “September 2024 Notes”). Each of the September 2024 Dent Notes is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.0486 per share and is secured by all of the Company’s assets. The Company received net proceeds of $855,000 after original issue discount. The details of the September 2024 Notes are as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | |  |  | **Original** | |  |  |  | |  |
|  |  | **Maturity** |  | **Note** | |  |  | **Issue** | |  |  | **Net** | |  |
| **Note Date** |  | **Date** |  | **Principal** | |  |  | **Discount** | |  |  | **Proceeds** | |  |
| 09/18/24 |  | 01/10/25 |  | $ | 36,842 |  |  | $ | 1,842 |  |  | $ | 35,000 |  |
| 09/18/24 |  | 01/16/25 |  |  | 10,526 |  |  |  | 526 |  |  |  | 10,000 |  |
| 09/18/24 |  | 01/16/25 |  |  | 73,684 |  |  |  | 3,684 |  |  |  | 70,000 |  |
| 09/18/24 |  | 01/19/25 |  |  | 21,053 |  |  |  | 1,053 |  |  |  | 20,000 |  |
| 09/18/24 |  | 01/30/25 |  |  | 105,263 |  |  |  | 5,263 |  |  |  | 100,000 |  |
| 09/18/24 |  | 02/14/25 |  |  | 126,316 |  |  |  | 6,316 |  |  |  | 120,000 |  |
| 09/18/24 |  | 02/20/25 |  |  | 105,263 |  |  |  | 5,263 |  |  |  | 100,000 |  |
| 09/18/24 |  | 02/28/25 |  |  | 52,632 |  |  |  | 2,632 |  |  |  | 50,000 |  |
| 09/18/24 |  | 03/04/25 |  |  | 157,895 |  |  |  | 7,895 |  |  |  | 150,000 |  |
| 09/18/24 |  | 03/10/25 |  |  | 210,526 |  |  |  | 10,526 |  |  |  | 200,000 |  |
| Total |  |  |  | $ | 900,000 |  |  | $ | 45,000 |  |  | $ | 855,000 |  |

In connection with the September 2024 Notes, the Company issued to the holder a ten-year warrant to purchase 9,259,258 shares of common stock with an exercise price of $0.0486 (the “September 2024 Warrant”). The full amount of principal and accrued interest on each of the September 2024 Notes is due at the respective maturity date of each note. Each of the September 2024 Notes is convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.0486 per share. The fair value of the September 2024 Warrant was $271,256.

The combined fair value of the ECFs on the September 2024 Notes was $244,979. At inception, the Company recorded notes payable in the amount of $900,000 and a discount against the September 2024 Notes of $486,288 for the allocated fair value of the ECF, original issue discount and warrants. Amortization of debt discount was $333,847 and $-0- in the years ended December 31, 2024 and 2023, respectively. The Company made no payments against the September 2024 Note in the years ended December 31, 2024 or 2023. As of December 31, 2024 and 2023, the net carrying value of the September 2024 Notes was $747,558 and $-0-, respectively, and remaining principal payments were $900,000 and $-0-, respectively.

During September, October and November 2024, a trust controlled by Dr. Michael Dent advanced $550,000 to the Company in the form of interest-free undocumented advances (the “Undocumented Advances”). The Company repaid an aggregate of $130,000 of the Undocumented Advances during September and November 2024. As of December 31, 2024 and 2023, the net carrying value of the Undocumented Advances was $550,000 and $-0-, respectively, and remaining principal payments were $420,000 and $-0-, respectively.

On December 4, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $25,000, an interest rate of 12% per annum, and a maturity date of May 4, 2025 (the “December 2024 Dent Note I”). The December 2024 Dent Note I is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.033 per share. The Company received net proceeds of $25,000. At inception, the Company recorded a note payable in the amount of $25,000 with no related discounts. The Company made no payments in the years ended December 31, 2024 or 2023. As of December 31, 2024 and 2023, the net carrying value was $25,000 and $-0-, respectively, and remaining principal payments were $25,000 and $-0-, respectively.

F-30

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS (CONTINUED)**

On December 17, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $70,000, an interest rate of 12% per annum, and a maturity date of June 17, 2025 (the “December 2024 Dent Note II”). The December 2024 Dent Note II is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.026 per share. The Company received net proceeds of $70,000. At inception, the Company recorded a note payable in the amount of $70,000 with no related discounts. The Company made no payments in the years ended December 31, 2024 or 2023. As of December 31, 2024 and 2023, the net carrying value was $70,000 and $-0-, respectively, and remaining principal payments were $70,000 and $-0-, respectively.

On December 4, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $120,000, an interest rate of 12% per annum, and a maturity date of July 1, 2025 (the “December 2024 Dent Note III”). The December 2024 Dent Note III is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.023 per share. The Company received net proceeds of $120,000. At inception, the Company recorded a note payable in the amount of $120,000 with no related discounts. The Company made no payments in the years ended December 31, 2024 or 2023. As of December 31, 2024 and 2023, the net carrying value was $120,000 and $-0-, respectively, and remaining principal payments were $120,000 and $-0-, respectively.

Interest accrued on notes and convertible notes payable to related parties as of December 31, 2024 and 2023 was $121,456 and $7,456, respectively. Interest expense on notes and convertible notes payable to related parties was $140,468 and $21,331 in the years ended December 31, 2024 or 2023, respectively.

Deferred Compensation Payable to Dr. Michael Dent

There was no activity related to deferred compensation payable to Dr. Michael Dent and therefore, as of December 31, 2024 and 2023, the balance was $300,600 and $300,600, respectively.

Other Related Transactions

During the years ended December 31, 2024 and 2023, the Company paid Dr. Dent’s spouse $145,000 and $139,423, respectively, in consulting fees pursuant to a consulting agreement.

The Company’s outside directors each receive compensation equal to $20,000 in shares of restricted stock per annum. As of December 31, 2024 and 2023, we had 1,632,652 and 408,164 shares, respectively, issuable to our directors under such compensation arrangements.

**NOTE 12 – NOTES PAYABLE**

Notes payable as of December 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| SBA Disaster Relief Loans |  | $ | 450,000 |  |  | $ | 450,000 |  |
| 1800 Diagonal Note Payable III, August 2023 |  |  | --- |  |  |  | 97,279 |  |
| Yorkville Note Payable III, November 2023 |  |  | --- |  |  |  | 302,400 |  |
| 1800 Diagonal Note Payable III, December 2023 |  |  | --- |  |  |  | 162,131 |  |
| Yorkville Note Payable III, December 2023 |  |  | --- |  |  |  | 189,000 |  |
| 1800 Diagonal Note Payable IV, April 2024 |  |  | 36,064 |  |  |  | --- |  |
| Leaf Capital Note Payable, August 2024 |  |  | 177,055 |  |  |  | --- |  |
| Face value of notes payable |  |  | 663,119 |  |  |  | 1,200,810 |  |
| Less: unamortized discounts |  |  | (27,414 | ) |  |  | (166,487 | ) |
| Notes payable, total |  |  | 635,705 |  |  |  | 1,034,323 |  |
| Less: long term portion |  |  | (508,610 | ) |  |  | (450,000 | ) |
| Notes payable, current portion |  | $ | 127,095 |  |  | $ | 584,323 |  |

F-31

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 12 – NOTES PAYABLE (CONTINUED)**

Government Notes Payable

During June, July and August 2020, the Company and its subsidiaries received an aggregate of $450,000 in Disaster Relief Loans from the SBA. The loans bear interest at 3.75% per annum and mature 30 years from issuance. Mandatory principal and interest payments were originally scheduled to begin 12 months from the inception date of each loan and were subsequently extended by the SBA until 30 months from the inception date. Installment payments, which are first applied to accrued but unpaid interest and then to principal, began in 2023.

Interest accrued on SBA loans as of December 31, 2024 and 2023 was $17,725 and $27,628, respectively. Interest expense (income) recognized on the loans was $16,413 and $7,533 in the years ended December 31, 2024 and 2023, respectively. Payments against interest were $26,316 and $21,530 in the years ended December 31, 2024 or 2023, respectively. As of December 31, 2024 and 2023, remaining principal payments were $450,000 and $450,000, respectively, and the net carrying value was $450,000 and $450,000, respectively.

Other Notes Payable

On July 19, 2022, pursuant to a Note Purchase Agreement between the Company and Yorkville, dated July 5, 2022, the Company issued to Yorkville a promissory note (the “Promissory Note”) with an initial stated principal amount equal to $550,000 at a purchase price equal to the principal amount of the Promissory Note less any original issue discounts and fees. The Promissory Note included a 5% original issue discount, accrues interest at a rate of 0%, and was scheduled to mature on January 19, 2023. The Company received net proceeds of $522,500. Each payment included a 2% payment premium, totaling $561,000 in total cash repayments. At inception, the Company recorded a discount against the note of $38,500, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. On November 15, 2022, the Company and Yorkville entered into an Amended and Restated Note (the “Amended Note”) to, among other things, extend the original note’s maturity date of January 19, 2023 to March 15, 2023. Amortization expense related to the discount was $-0- and $4,748 in the years ended December 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $-0- and $168,300 in the years ended December 31, 2024 and 2023, respectively. Payments in the years ended December 31, 2023 included $18,765 applied from proceeds of sales of common stock under the SEPA. The Amended Note was repaid in March 2023. As of December 31, 2024 and 2023, the net carrying value was $-0- and $-0-, respectively, and remaining principal payments were $-0- and $-0-, respectively.

On October 21, 2022, the Company issued a promissory note payable to an investor in the principal amount of $144,760 (the “October 2022 Note”). The October 2022 Note had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The October 2022 Note did not bear interest in excess of the original issue discount and had a maturity date of October 31, 2023. The Company was required to make 10 monthly payments of $16,213 starting November 30, 2022 and ending August 31, 2023. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which was amortized over the repayment period. Amortization expense related to the note discount was $-0- and $29,012 in the years ended December 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $-0- and $129,705 in the years ended December 31, 2024 and 2023, respectively. The October 2022 Note was repaid in August 2023. As of December 31, 2024 and 2023, the net carrying value was $-0- and $-0-, respectively, and remaining principal payments were $-0- and $-0-, respectively.

On November 4, 2022, AEU borrowed a gross amount of $41,009 from a third-party lender, receiving net proceeds of $35,800 after fees and discounts (the “AEU Loan”). At inception of the note, the Company recognized a discount of $5,209. During the years ended December 31, 2024 and 2023, amortization expense related to the note discount was $-0- and $3,998, respectively, and the Company made payments of $-0- and $31,394, respectively, against the outstanding balance. The AEU Loan was repaid in June 2023. As of December 31, 2024 and 2023, the net carrying value was $-0- and $-0-, respectively, and remaining principal payments were $-0- and $-0-, respectively.

F-32

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 12 – NOTES PAYABLE (CONTINUED)**

On March 10, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $116,760 and prepaid interest of $14,011 for total repayments of $130,771 (the “March 2023 Note”). The March 2023 Note had an original issue discount of $12,510 and fees of $4,250, resulting in net proceeds to the Company of $100,000. The March 2023 Note did not bear interest in excess of the original issue discount and matured on March 10, 2024. The Company was required to make 10 monthly payments of $13,077 starting April 30, 2023. At inception, the Company recorded a discount against the note of $30,771, representing the difference between the total required repayments and the net proceeds received, which was being amortized over the repayment period. Amortization expense related to the note discount was $-0- and $25,993 in the years ended December 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $-0- and $130,771 in the years ended December 31, 2024 and 2023, respectively. The final installment payment was made in December 2023. In connection with the early repayment, the company recognized a loss on extinguishment of debt of $4,778 in the year ended December 31, 2023. As of December 31, 2024 and 2023, the net carrying value was $-0- and $-0-, respectively, and remaining principal payments were $-0- and $-0-, respectively.

On May 10, 2023, the Company issued to Yorkville a note payable (the “May 2023 Note”) with an initial principal amount equal to $330,000 at a purchase price equal to the principal amount of the May 2023 Note less any original issue discounts and fees. The Company received net proceeds of $308,500. The May 2023 Note was scheduled to mature on July 31, 2023. The May 2023 Note accrued interest at a rate of 0% but was issued with 5% original issue discount. The May 2023 Note was scheduled to be repaid in four equal semi-monthly installments beginning on June 15, 2023, with each payment including a 2% payment premium, totaling $343,200 in cash repayments. At inception, the Company recorded a discount against the note of $34,700, representing the difference between the total required repayments and the net proceeds received, which was being amortized over the repayment period. Amortization expense related to the note discount was $-0- and $34,700 in the years ended December 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $-0- and $343,200 in the years ended December 31, 2024 and 2023, respectively. The May 2023 Note was repaid in July 2023. As of December 31, 2024 and 2023, the net carrying value was $-0- and $-0-, respectively, and remaining principal payments were $-0- and $-0-, respectively.

On August 8, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $144,760 and prepaid interest of $17,371 for total repayments of $162,131 (the “August 2023 Note”). The August 2023 Note had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The August 2023 Note did not bear interest in excess of the original issue discount and was scheduled to mature on June 30, 2024. The Company was required to make 10 monthly payments of $16,213 starting September 30, 2023 and ending on June 30, 2024. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which was being amortized over the repayment period. Amortization expense related to the note discount was $13,098 and $16,401 in the years ended December 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $97,279 and $64,852 and $-0- in the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, remaining payments were $-0- and $97,279, respectively, and the net carrying value was $-0- and $76,549, respectively. The final installment payment was made in April 2024. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $7,631 in the year ended December 31, 2024. As of December 31, 2024 and 2023, the net carrying value was $-0- and $76,549 respectively, and remaining principal payments were $-0- and $97,279, respectively.

On November 3, 2023, the Company issued to Yorkville a note payable (the “November 2023 Note”) with an initial principal amount equal to $350,000 at a purchase price equal to the principal amount of the November 2023 Note less any original issue discounts and fees. The Company received net proceeds of $317,000. The November 2023 Note was scheduled to mature on September 3, 2024. The November 2023 Note accrued interest at a rate of 0% but was issued with an 8% original issue discount and was scheduled to be repaid in ten equal semi-monthly installments beginning on December 3, 2023, with each payment including an 8% payment premium, totaling $378,000 in cash repayments. At inception, the Company recorded a discount against the note of $61,000, representing the difference between the total required repayments and the net proceeds received, which was being amortized over the repayment period. Amortization expense related to the note discount was $49,400 and $11,600 in the years ended December 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $302,400 and $75,600 in the years ended December 31, 2024 and 2023, respectively. The final installment payment on the November 2023 Note was made in September 2024. As of December 31, 2024 and 2023, the net carrying value was $-0- and $253,000, respectively, and remaining principal payments were $-0- and $302,400, respectively.

F-33

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 12 – NOTES PAYABLE (CONTINUED)**

On December 12, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $144,760 and prepaid interest of $17,371 for total repayments of $162,131 (the “December 2023 Note I”). The December 2023 Note I had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The December 2023 Note I does not bear interest in excess of the original issue discount and matures on October 15, 2024. The Company is required to make 10 monthly payments of $16,213 starting January 15, 2024 and ending on October 15, 2024. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. The December 2023 Note I gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. Amortization expense related to the note discount was $34,840 and $2,291 in the years ended December 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $162,131 and $-0- in the years ended December 31, 2024 and 2023, respectively. The final installment on the December 2023 Note I was made in October 2024. As of December 31, 2024 and 2023, the net carrying value was $-0- and $127,291, respectively, and remaining principal payments were $-0- and $162,131, respectively.

On December 13, 2023, the Company issued to Yorkville a convertible note (the “December 2023 Note II”) with an initial principal amount equal to $175,000 at a purchase price equal to the principal amount of the December 2023 Note II less any original issue discounts and fees. The Company received net proceeds of $156,000. The December 2023 Note II was scheduled to mature on September 3, 2024. The December 2023 Note II accrued interest at a rate of 0% but was issued with an 8% original issue discount and is scheduled to be repaid in ten equal semi-monthly installments beginning on March 3, 2024, with each payment including an 8% payment premium, totaling $189,000 in cash repayments. The December 2023 Note II was convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.05 per share. At inception, the Company recorded a discount against the note of $66,000, representing the fair value of the conversion option and the difference between the total required repayments and the net proceeds received. The discount was being amortized over the repayment period. Amortization expense related to the note discount was $61,517 and $4,483 in the years ended December 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $189,000 and $-0- in the years ended December 31, 2024 and 2023, respectively. The final installment payment on the December 2023 Note II was made in September 2024. As of December 31, 2024 and 2023, the net carrying value was $-0- and $127,483, respectively, and remaining principal payments were $-0- and $189,000, respectively.

On April 22, 2024, the Company issued a promissory note payable (the “April 2024 Note”) to an investor with a stated principal amount of $161,000 and prepaid interest of $19,320 for total repayments of $180,320. The Company received net proceeds of $118,787 after original issue discount of $21,000, fees of $5,000, and withholding of the final payment due on the August 2023 Note to the same investor in the amount of $16,213. The April 2024 Note does not bear interest in excess of the original issue discount and prepaid interest and matures on February 28, 2025. The Company is required to make 10 monthly payments of $18,032 starting May 30, 2024 and ending on February 28, 2025. The April 2024 Note gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock only in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. Amortization expense related to the note discount was $36,548 and $-0- in the years ended December 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $144,256 and $-0- in the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, the net carrying value was $27,292 and $-0-, respectively, and remaining principal payments were $36,064 and $-0-, respectively.

On July 30, 2024, the Company’s wholly owned subsidiary, HLYK Florida LLC, which owns NCFM, issued a promissory note payable to an investor with total principal repayments of $223,649 (the “July 2024 Note”). The Company received net proceeds of $200,000 after original issue discount of $19,649 and fees of $4,000. The July 2024 Note does not bear interest in excess of the original issue discount. The Company is required to make 24 monthly payments of $9,319 starting August 20, 2024 and ending on July 20, 2026. The July 2024 Note is secured by all of NCFM’s assets and is personally guaranteed by the Company’s CEO, Dr. Michael Dent. At inception, the Company recorded a discount against the note of $23,649, representing the difference between the total required repayments and the net proceeds received. The discount is being amortized over the repayment period. Amortization expense related to the note discount was $5,007 and $-0- in the years ended December 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $46,594 and $-0- in the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, the net carrying value was $158,413 and $-0-, respectively, and remaining principal payments were $177,056 and $-0-, respectively.

F-34

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 12 – NOTES PAYABLE (CONTINUED)**

Interest accrued on notes and convertible notes payable to third parties as of December 31, 2024 and 2023 was $21,990 and $49,618, respectively. Interest expense on notes and convertible notes payable to third parties was $-0- and $-0- in the years ended December 31, 2024 and 2023, respectively.

**NOTE 13 – SHAREHOLDERS’ EQUITY (DEFICIT)**

SEPA Advances

On July 5, 2022, the Company entered into the SEPA with Yorkville, pursuant to which the Company shall have the right, but not the obligation, to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the commitment period commencing on July 5, 2022 and terminating on the earliest of (i) the first day of the month following the 36-month anniversary of the SEPA and (ii) the date on which Yorkville shall have made payment of any advances requested pursuant to the SEPA for shares of the Company’s common stock equal to the commitment amount of 30,000,000 shares of common stock. Each SEPA advance (an “Advance”) may be for a number of shares of common stock with an aggregate value of up to greater of: (i) an amount equal to thirty percent (30%) of the aggregate daily volume traded of the Company’s common stock for the three (3) trading days immediately preceding notice from the Company of an Advance, or (ii) 2,000,000 shares of common stock. The shares would be purchased at 96.0% of the average of the daily volume weighted average price of the Company’s common stock as reported by Bloomberg L.P. during regular trading hours during each of the three consecutive trading days commencing on the trading day following the Company’s submission of an Advance notice to Yorkville and would be subject to certain limitations, including that Yorkville could not purchase any shares that would result in it owning more than 4.99% of the Company’s outstanding common stock at the time of an Advance. On July 11, 2022, the Company filed a Form S-1 registration statement registering up to 30,000,000 shares of common stock underlying the SEPA. The registration statement was declared effective on July 19, 2022.

During the year ended December 31, 2023, the Company sold 225,000 shares of its common stock, receiving $18,765 in proceeds, all of which was applied to the balance of the July 2022 Note that was retired in first quarter 2023. No Advances were made during the year ended December 31, 2024.

Private Placements

During the year ended December 31, 2024, the Company sold 5,977,193 shares of common stock to four investors in separate private placement transactions. The Company received $405,000 in proceeds from the sales. In connection with the sales, the Company also issued 2,500,000 five-year warrants to purchase shares of common stock at an exercise price of $0.17 per share and 438,596 five-year warrants to purchase shares of common stock at an exercise price of $0.16 per share. The Company is also obligated to issue 547,828 shares with a value of $35,134 as a stock issuance fee related to the private placement sales.

During the year ended December 31, 2023, the Company sold 15,952,992 shares of common stock to six separate sophisticated investors in private placement transactions. The Company received $850,000 in proceeds from the sales. In connection with the stock sales, the Company also issued 7,330,662 five-year warrants to purchase shares of common stock at exercise prices between $0.08 and $0.20 per share and a 6-month warrant to purchase 5,000,000 shares of common stock at an exercise price of $0.05. Of the $850,000 proceeds, $546,183 was allocated to common stock and $303,817 to warrants.

Shares issued to Consultants

During the year ended December 31, 2024, the Company issued to a consultant a ten-year stock option to purchase 2,504,974 shares of common stock at an exercise price equal of $0.0569 in satisfaction of common stock issuable accrued to the consultant for services provided between 2021 and 2024.

During the year ended December 31, 2023, the Company issued 200,000 common shares to consultants for services rendered. In connection with the issuances, the Company recognized expenses totaling $15,400 in the year ended December 31, 2023.

F-35

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 13 – SHAREHOLDERS’ EQUITY (DEFICIT) (CONTINUED)**

Common Stock Issuable

As of December 31, 2024 and 2023, the Company was obligated to issue the following shares:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31, 2024** | | | | | |  |  | **December 31, 2023** | | | | | |  |
|  |  | **Amount** | |  |  | **Shares** | |  |  | **Amount** | |  |  | **Shares** | |  |
|  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Shares issuable to employees and consultants |  | $ | 81,632 |  |  |  | 1,430,536 |  |  | $ | 261,682 |  |  |  | 2,356,188 |  |
| Shares issuable to independent directors |  |  | 80,000 |  |  |  | 1,632,652 |  |  |  | 20,000 |  |  |  | 408,164 |  |
|  |  | $ | 161,632 |  |  |  | 3,063,188 |  |  | $ | 281,682 |  |  |  | 2,764,352 |  |

Stock Warrants

Transactions involving our stock warrants during the years ended December 31, 2024 and 2023 are summarized as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2024** | | | | | |  |  | **2023** | | | | | |  |
|  |  |  | |  |  | **Weighted** | |  |  |  | |  |  | **Weighted** | |  |
|  |  |  | |  |  | **Average** | |  |  |  | |  |  | **Average** | |  |
|  |  |  | |  |  | **Exercise** | |  |  |  | |  |  | **Exercise** | |  |
|  |  | **Number** | |  |  | **Price** | |  |  | **Number** | |  |  | **Price** | |  |
| Outstanding at beginning of the period |  |  | 77,414,648 |  |  | $ | 0.20 |  |  |  | 68,109,094 |  |  | $ | 0.22 |  |
| Granted during the period |  |  | 30,226,417 |  |  | $ | 0.06 |  |  |  | 18,487,860 |  |  | $ | 0.10 |  |
| Exercised during the period |  |  | --- |  |  | $ | --- |  |  |  | --- |  |  | $ | --- |  |
| Expired during the period |  |  | (6,152,244 | ) |  | $ | (0.21 | ) |  |  | (9,182,306 | ) |  | $ | (0.14 | ) |
| Outstanding at end of the period |  |  | 101,488,821 |  |  | $ | 0.16 |  |  |  | 77,414,648 |  |  | $ | 0.20 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Exercisable at end of the period |  |  | 101,488,821 |  |  | $ | 0.16 |  |  |  | 77,414,648 |  |  | $ | 0.20 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Weighted average remaining life |  |  | 3.6 years | | | | |  |  |  | 2.2 years | | | | |  |

The following table summarizes information about the Company’s stock warrants outstanding as of December 31, 2024:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Warrants Outstanding** | | | | | | | | | | | | | |  |  | **Warrants Exercisable** | | | | | |  |
|  | |  |  |  | |  |  | **Weighted-** | |  |  |  | |  |  |  | |  |  |  | |  |
|  | |  |  |  | |  |  | **Average** | |  |  | **Weighted-** | |  |  |  | |  |  | **Weighted-** | |  |
|  | |  |  |  | |  |  | **Remaining** | |  |  | **Average** | |  |  |  | |  |  | **Average** | |  |
| **Exercise** | |  |  | **Number** | |  |  | **Contractual** | |  |  | **Exercise** | |  |  | **Number** | |  |  | **Exercise** | |  |
| **Prices** | |  |  | **Outstanding** | |  |  | **Life (years)** | |  |  | **Price** | |  |  | **Exercisable** | |  |  | **Price** | |  |
| $ | 0.0001 to 0.09 |  |  |  | 50,596,110 |  |  |  | 5.6 |  |  | $ | 0.06 |  |  |  | 50,596,110 |  |  | $ | 0.06 |  |
| $ | 0.10 to 0.24 |  |  |  | 22,452,322 |  |  |  | 2.6 |  |  | $ | 0.16 |  |  |  | 22,452,322 |  |  | $ | 0.16 |  |
| $ | 0.25 to 0.49 |  |  |  | 25,480,465 |  |  |  | 0.8 |  |  | $ | 0.31 |  |  |  | 25,480,465 |  |  | $ | 0.31 |  |
| $ | 0.50 to 1.05 |  |  |  | 2,959,924 |  |  |  | 1.5 |  |  | $ | 0.68 |  |  |  | 2,959,924 |  |  | $ | 0.68 |  |
| $ | 0.05 to 1.00 |  |  |  | 101,488,821 |  |  |  | 3.6 |  |  | $ | 0.16 |  |  |  | 101,488,821 |  |  | $ | 0.16 |  |

F-36

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 13 – SHAREHOLDERS’ EQUITY (DEFICIT) (CONTINUED)**

During the years ended December 31, 2024 and 2023, the Company issued 30,226,417 and 18,487,860 warrants, respectively, the aggregate grant date fair value of which was $1,046,188 and $794,220, respectively. The fair value of the warrants was calculated using the following range of assumptions:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **2024** |  | **2023** |
| Pricing model utilized |  | Binomial Lattice |  | Binomial Lattice |
| Risk free rate range |  | 3.65% to 4.69% |  | 3.45% to 5.43% |
| Expected life range (in years) |  | 5.00 years to 10.00 years |  | 0.28 years to 5.00 years |
| Volatility range |  | 139.73% to 173.25% |  | 126.30% to 165.20% |
| Dividend yield |  | 0.00% |  | 0.00% |
| Expected forfeiture |  | 33.00% |  | 20.00% |

There were no warrants exercised during the years ended December 31, 2024 or 2023.

Equity Incentive Plans

On January 1, 2016, the Company adopted the 2016 Equity Incentive Plan (the “2016 EIP”) for the purpose of having equity awards available to allow for equity participation by its employees, consultants and non-employee directors. The 2016 EIP allowed for the issuance of up to 15,503,680 shares of the Company’s common stock, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2016 EIP is governed by the Board, or a committee that may be appointed by the Board in the future. The 2016 EIP expired during 2021 but allows for the prospective issuance of common shares upon vesting of stock awards or exercise of stock options granted prior to expiration of the 2016 EIP.

On September 9, 2021, the Company adopted the 2021 Equity Incentive Plan (the “2021 EIP” and, together with the 2016 EIP, the “EIPs”) for the purpose of having equity awards available to allow for equity participation by its employees, consultants and non-employee directors. The 2021 EIP allows for the issuance of up to 20,000,000 shares of the Company’s common stock, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2021 EIP is governed by the Board, or a committee that may be appointed by the Board in the future.

Amounts recognized in the financial statements with respect to the EIPs in the years ended December 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| Total cost of share-based payment plans during the period |  | $ | 153,186 |  |  | $ | 228,978 |  |
| Amounts capitalized in deferred equity compensation during period |  | $ | --- |  |  | $ | --- |  |
| Amounts written off from deferred equity compensation during period |  | $ | 57,147 |  |  | $ | 64,647 |  |
| Amounts charged against income for amounts previously capitalized |  | $ | --- |  |  | $ | 10,353 |  |
| Amounts charged against income, before income tax benefit |  | $ | 210,333 |  |  | $ | 303,979 |  |
| Amount of related income tax benefit recognized in income |  | $ | --- |  |  | $ | --- |  |

F-37

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 13 – SHAREHOLDERS’ EQUITY (DEFICIT) (CONTINUED)**

*Stock Options*

Stock options granted under the EIPs typically vest over a period of three to four years or based on achievement of Company and individual performance goals. The following table summarizes stock option activity as of and for the years ended December 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | |  |  |  | |  |  | **Weighted** | |  |  |  | |  |
|  |  |  | |  |  | **Weighted** | |  |  | **Average** | |  |  |  | |  |
|  |  |  | |  |  | **Average** | |  |  | **Remaining** | |  |  | **Aggregate** | |  |
|  |  |  | |  |  | **Exercise** | |  |  | **Contractual** | |  |  | **Intrinsic** | |  |
|  |  | **Number** | |  |  | **Price** | |  |  | **Term (Yrs.)** | |  |  | **Value** | |  |
| Outstanding at January 1, 2023 |  |  | 5,222,982 |  |  | $ | 0.17 |  |  |  | 7.2 |  |  | $ | 10,200 |  |
| Granted during the period |  |  | 493,756 |  |  | $ | 0.07 |  |  |  |  |  |  |  |  |  |
| Exercised during the period |  |  | --- |  |  | $ | --- |  |  |  |  |  |  |  |  |  |
| Forfeited during the period |  |  | (623,000 | ) |  | $ | (0.18 | ) |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Outstanding at December 31, 2023 |  |  | 5,093,738 |  |  | $ | 0.17 |  |  |  | 6.3 |  |  | $ | 2,400 |  |
| Granted during the period |  |  | 4,804,974 |  |  | $ | 0.06 |  |  |  |  |  |  |  |  |  |
| Exercised during the period |  |  | --- |  |  | $ | --- |  |  |  |  |  |  |  |  |  |
| Forfeited during the period |  |  | (3,741,290 | ) |  | $ | (0.17 | ) |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Outstanding at December 31, 2024 |  |  | 6,157,422 |  |  | $ | 0.07 |  |  |  | 3.2 |  |  | $ | --- |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Exercisable at December 31, 2024 |  |  | 4,807,422 |  |  | $ | 0.07 |  |  |  | 7.8 |  |  | $ | --- |  |

As of December 31, 2024, there was $34,294 of total unrecognized compensation cost related to options granted under the EIPs. That cost is expected to be recognized over a weighted-average period of 1.6 years.

The weighted-average grant-date fair value of options granted during the years ended December 31, 2024 and 2023 was $0.04 and $0.05 per share, respectively. The total fair value of options vested during the years ended December 31, 2024 and 2023 was $153,542 and $89,270, respectively. No options were exercised during the years ended December 31, 2024 or 2023. Stock based compensation expense related to stock options was $77,860 and $94,598 in the years ended December 31, 2024 and 2023, respectively.

The fair value of each stock option award is estimated on the date of grant using a binomial lattice option-pricing model based on the assumptions noted in the following table. The Company’s accounting policy is to estimate forfeitures in determining the amount of total compensation cost to record each period. The fair value of options granted for the years ended December 31, 2024 and 2023 was calculated using the following range of assumptions:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **2024** |  | **2023** |
| Pricing model utilized |  | Binomial Lattice |  | Binomial Lattice |
| Risk free rate range |  | 4.20% to 4.23% |  | 3.48%% to 3.89% |
| Expected life range (in years) |  | 10.00 years |  | 10.00 years |
| Volatility range |  | 173.09% to 173.25% |  | 145.03% to 168.24% |
| Dividend yield |  | 0.00% |  | 0.00% |
| Expected forfeiture |  | 30.00% |  | 20.00% to 30.00% |

F-38

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 13 – SHAREHOLDERS’ EQUITY (DEFICIT) (CONTINUED)**

The following table summarizes the status and activity of nonvested options issued pursuant to the EIPs as of and for the years ended December 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2024** | | | | | |  |  | **2023** | | | | | |  |
|  |  |  | |  |  | **Weighted** | |  |  |  | |  |  | **Weighted** | |  |
|  |  |  | |  |  | **Average** | |  |  |  | |  |  | **Average** | |  |
|  |  |  | |  |  | **Grant Date** | |  |  |  | |  |  | **Grant Date** | |  |
| ***Stock options*** |  | **Shares** | |  |  | **Fair Value** | |  |  | **Shares** | |  |  | **Fair Value** | |  |
| Nonvested options at beginning of period |  |  | 1,073,084 |  |  | $ | 0.06 |  |  |  | 2,260,417 |  |  | $ | 0.08 |  |
| Granted |  |  | 4,804,974 |  |  | $ | 0.04 |  |  |  | 493,756 |  |  | $ | 0.05 |  |
| Vested |  |  | (3,732,224 | ) |  | $ | (0.04 | ) |  |  | (1,264,589 | ) |  | $ | (0.07 | ) |
| Forfeited |  |  | (795,834 | ) |  | $ | (0.06 | ) |  |  | (416,500 | ) |  | $ | (0.11 | ) |
| Nonvested options at end of period |  |  | 1,350,000 |  |  | $ | 0.05 |  |  |  | 1,073,084 |  |  | $ | 0.06 |  |

*Stock Grants*

Stock grant awards made under the EIPs typically vest either immediately or over a period of up to four years. The following table summarizes stock grant activity as of and for the years ended December 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2024** | | | | | |  |  | **2023** | | | | | |  |
|  |  |  | |  |  | **Weighted** | |  |  |  | |  |  | **Weighted** | |  |
|  |  |  | |  |  | **Average** | |  |  |  | |  |  | **Average** | |  |
|  |  |  | |  |  | **Grant Date** | |  |  |  | |  |  | **Grant Date** | |  |
| ***Stock Grants*** |  | **Shares** | |  |  | **Fair Value** | |  |  | **Shares** | |  |  | **Fair Value** | |  |
| Nonvested grants at beginning of period |  |  | 1,484,488 |  |  | $ | 0.05 |  |  |  | 1,651,435 |  |  | $ | 0.05 |  |
| Granted |  |  | --- |  |  | $ | --- |  |  |  | 1,793,596 |  |  | $ | 0.05 |  |
| Vested |  |  | (1,229,488 | ) |  | $ | (0.05 | ) |  |  | (1,945,543 | ) |  | $ | (0.05 | ) |
| Forfeited |  |  | (255,000 | ) |  | $ | (0.06 | ) |  |  | (15,000 | ) |  | $ | (0.26 | ) |
| Nonvested grants at end of period |  |  | --- |  |  | $ | --- |  |  |  | 1,484,488 |  |  | $ | 0.05 |  |

As of December 31, 2024, there was $-0- of total unrecognized compensation cost related to stock grants made under the EIPs. The weighted-average grant-date fair value of share grants made during the years ended December 31, 2024 and 2023 was $0.00 and $0.05 per share, respectively. The aggregate fair value of share grants that vested during the years ended December 31, 2024 and 2023 was $60,588 and $97,556, respectively. Stock based compensation expense related to stock grants was $3,788 and $93,972 in the years ended December 31, 2024 and 2023, respectively.

The fair value of each stock grant is calculated using the closing sale price of the Company’s common stock on the date of grant. The Company’s accounting policy is to estimate forfeitures in determining the amount of total compensation cost to record each period.

*Liability-Classified Equity Instruments*

During 2021, the Company made certain stock grants from the 2021 EIP that vest over a four-year period and that are settleable for a fixed dollar amount rather than a fixed number of shares. During 2022, the Company made an additional grant of stock options from the 2021 EIP with a fixed fair value that may be earned based on achievement of performance targets on a quarterly basis through June 2025. The Company recognized an asset captioned “Deferred equity compensation” and an offsetting liability captioned as a “Liability-classified equity instrument” related to such instruments. Amortization of deferred stock compensation assets in the years ended December 31, 2024 and 2023 was $-0- and $10,353, respectively. The Company also de-recognized Deferred equity compensation and Liability-classified equity instrument in the amount of $-0- and $64,647 in the years ended December 31, 2024 and 2023, respectively, based on failure to achieve targets and termination of future rights under such grants. No further equity-related assets or liabilities remained as of December 31, 2024.

F-39

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 14 – COMMITMENTS AND CONTINGENCIES**

Supplier Concentration

The Company relied on a single supplier for the fulfillment of approximately 96% and 94% of its product sales made through MOD in the years ended December 31, 2024 and 2023, respectively.

Service Contracts

The Company carries various service contracts on its office buildings and certain copier equipment for repairs, maintenance and inspections. All contracts are short term and can be cancelled.

Leases

Maturities of operating lease liabilities were as follows as of December 31, 2024:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 2025 |  | $ | 312,605 |  |
| 2026 |  |  | 200,969 |  |
| 2027 |  |  | 990 |  |
| Total lease payments |  |  | 514,564 |  |
| Less interest |  |  | (152,423 | ) |
| Present value of lease liabilities |  | $ | 362,141 |  |

Employment/Consulting Agreements

The Company has employment agreements with certain of its physicians, nurse practitioners and physical therapists in the Health Services Division. The agreements generally call for a fixed salary plus performance-based pay.

On July 1, 2016, the Company entered into an employment agreement with Dr. Michael Dent, Chief Executive Officer and a member of the Board of Directors. Dr. Dent’s employment agreement continues until terminated by Dr. Dent or the Company. If Dr. Dent’s employment is terminated by the Company (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Dr. Dent will be entitled to severance in an amount equal to 12 months of his then-current annual base salary, as well as the pro-rata portion of any bonus that would be due and payable to him. In the event that Dr. Dent terminates the employment agreement, he shall be entitled to any accrued but unpaid salary and other benefits up to and including the date of termination, and the pro-rata portion of any unvested time-based options up until the date of termination.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. The Company is not aware of any such legal proceedings that will have, individually or in the aggregate, a material adverse effect on its business, financial condition or operating results.

**NOTE 15 – INCOME TAXES**

The tax reform bill that Congress voted to approve December 20, 2017, also known as the “Tax Cuts and Jobs Act”, made sweeping modifications to the Internal Revenue Code, including a much lower corporate tax rate, changes to credits and deductions, and a move to a territorial system for corporations that have overseas earnings. The act replaced the prior-law graduated corporate tax rate, which taxed income over $10 million at 35%, with a flat rate of 21%. Due to the continuing loss position of the Company, management believes changes from the “Tax Cuts and Jobs Act” should not be material in the periods presented.

F-40

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 15 – INCOME TAXES (CONTINUED)**

The components of earnings before income taxes for the years ended December 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| ***Loss before income taxes*** |  |  | |  |  |  | |  |
| Domestic |  | $ | (6,131,500 | ) |  | $ | (1,012,200 | ) |
| Foreign |  |  | --- |  |  |  | --- |  |
| Total loss before income taxes |  | $ | (6,131,500 | ) |  | $ | (1,012,200 | ) |

Income tax provision (benefit) consists of the following for the years ended December 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
| ***Income tax provision (benefit)*** |  | **2024** | |  |  | **2023** | |  |
| **Current** |  |  | |  |  |  | |  |
| Federal |  | $ | --- |  |  | $ | --- |  |
| State |  |  | --- |  |  |  | --- |  |
| Foreign |  |  | --- |  |  |  | --- |  |
| Total current |  |  | --- |  |  |  | --- |  |
| **Deferred** |  |  |  |  |  |  |  |  |
| Federal |  |  | --- |  |  |  | --- |  |
| State |  |  | --- |  |  |  | --- |  |
| Foreign |  |  | --- |  |  |  | --- |  |
| Total deferred |  |  | --- |  |  |  | --- |  |
|  |  |  |  |  |  |  |  |  |
| Total income tax provision (benefit) |  | $ | --- |  |  | $ | --- |  |

A reconciliation of the income tax provision (benefit) by applying the statutory United States federal income tax rate to income (loss) before income taxes is as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| ***Rate Reconciliation*** |  |  | |  |  |  | |  |
| Expected tax at statutory rate |  | $ | (1,287,600 | ) |  | $ | (212,600 | ) |
| Permanent differences |  |  | 187,900 |  |  |  | 97,700 |  |
| State income tax, net of federal benefit |  |  | (184,600 | ) |  |  | (19,500 | ) |
| Current year change in valuation allowance |  |  | 945,500 |  |  |  | 102,900 |  |
| Prior year true-ups |  |  | 338,800 |  |  |  | 31,500 |  |
| Income tax provision (benefit) |  | $ | --- |  |  | $ | --- |  |

F-41

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 15 – INCOME TAXES (CONTINUED)**

Deferred tax assets and liabilities are provided for significant income and expense items recognized in different years for tax and financial reporting purposes. Temporary differences, which give rise to a net deferred tax asset is as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| ***Deferred Tax Assets (Liabilities) Detail*** |  |  | |  |  |  | |  |
| Net operating loss deferred tax asset |  | $ | 10,185,600 |  |  | $ | 9,020,200 |  |
| Gain from disposal of discontinued operations |  |  | (474,200 | ) |  |  | (253,800 | ) |
| Gain from change in fair value of derivative financial instruments |  |  | (199,300 | ) |  |  | (199,300 | ) |
| Gain from change in fair value of contingent acquisition consideration |  |  | (151,700 | ) |  |  | (121,000 | ) |
| Loss from change in fair value of debt |  |  | 73,000 |  |  |  | 93,600 |  |
| Right of use lease asset |  |  | (326,500 | ) |  |  | (229,500 | ) |
| Lease liability |  |  | 327,600 |  |  |  | 230,400 |  |
| Stock compensation |  |  | 416,100 |  |  |  | 364,500 |  |
| Deferred tax assets (liabilities) |  |  | 9,850,600 |  |  |  | 8,905,100 |  |
| Valuation allowance |  |  | (9,850,600 | ) |  |  | (8,905,100 | ) |
| Net deferred tax assets (liabilities) |  | $ | --- |  |  | $ | --- |  |

As of December 31, 2024 and 2023, the Company had available for income tax purposes approximately $42.9 million and $36.8 million, respectively, in federal and state net operating loss carry forwards, which may be available to offset future taxable income, of which $3.2 million expire in 2035-37 and $39.7 million carry forward indefinitely. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable.

Prior to 2014, the Company was an S-Corporation, as defined in the Internal Revenue Code. During 2014, the Corporation defaulted to C-Corporation status. Pre C-Corporation losses were passed through to qualified S-Corporation shareholders. The net operating loss (“NOL”) carryovers presented in this note are C-Corporation losses. NOLs are subject to limitations imposed by IRC Section 382/383 resulting from changes in ownership. At the date of this filing, management has not reviewed the Company’s ownership changes and will perform the study in advance of any potential use of the NOLs. Based upon management’s assessment, a full valuation allowance has been placed upon the net deferred tax assets, since it is more likely than not that such assets will not be realized. Therefore, no financial statement benefit has been taken for the deferred tax assets, as of the filing date.

The Company has not taken any uncertain tax positions on any of its open income tax returns filed through the period ended December 31, 2024. The Company’s methods of accounting are based on established income tax principles in the Internal Revenue Code and are reflected within its filed income tax returns on an accrual basis. The Company re-assesses the validity of its conclusions regarding uncertain tax positions on a quarterly basis to determine if facts or circumstances have arisen that might cause the Company to change its judgment regarding the likelihood of a tax position’s sustainability under audit. The Company has determined that there were no uncertain tax positions for the years ended December 31, 2024 and 2023.

**NOTE 16 – SEGMENT REPORTING**

As of December 31, 2024, the Company had three reportable segments: Health Services, Digital Healthcare, and Medical Distribution. The Health Services division is comprised of the operations of (i) NCFM, a functional medical practice engaged in improving the health of its patients through individualized and integrative health care, (ii) BTG, a physical therapy practice in Bonita Springs, Florida that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery, (iii) CCN, a primary care providing a comprehensive range of medical services, and (iv) AEU, a minimally and non-invasive cosmetic services. During 2024, we replaced our NWC Obstetrics and Gynecology (OB/GYN) practice with CCN and relocated its AEU practice to the CCN office location. The Digital Healthcare segment develops and plans to operate an online personal medical information and record archive system, the “HealthLynked Network,” which facilitates efficient management of medical records and care, allowing seamless patient appointment scheduling, comprehensive telemedicine services, and a cloud-based system for medical information and records management. The Medical Distribution Division is comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States.

F-42

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 16 – SEGMENT REPORTING (CONTINUED)**

On January 17, 2023, the Company entered into the AHP Merger Agreement pursuant to which the Company sold AHP and discontinued the operations of CHM, comprising its ACO/MSO Division. The Company has classified the results of the ACO/MSO Division as discontinued operations in the accompanying consolidated statement of operations for all periods presented. See Note 4, “Discontinued Operations,” for additional information.

The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.

Segment information for the year ended December 31, 2024 was as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31, 2024** | | | | | | | | | | | | | |  |
|  |  | **Health Services** | |  |  | **Digital Healthcare** | |  |  | **Medical Distribution** | |  |  | **Total** | |  |
| **Revenue** |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Patient service revenue, net |  | $ | 2,872,177 |  |  | $ | --- |  |  | $ | --- |  |  | $ | 2,872,177 |  |
| Subscription revenue |  |  | --- |  |  |  | 32,425 |  |  |  | --- |  |  |  | 32,425 |  |
| Product and other revenue |  |  | --- |  |  |  | --- |  |  |  | 103,759 |  |  |  | 103,759 |  |
| Total revenue |  |  | 2,872,177 |  |  |  | 32,425 |  |  |  | 103,759 |  |  |  | 3,008,361 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Operating Expenses** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Practice salaries and benefits |  |  | 1,995,127 |  |  |  | --- |  |  |  | --- |  |  |  | 1,995,127 |  |
| Other practice operating expenses |  |  | 1,556,759 |  |  |  | --- |  |  |  | --- |  |  |  | 1,556,759 |  |
| Cost of product revenue |  |  | --- |  |  |  | --- |  |  |  | 96,237 |  |  |  | 96,237 |  |
| Selling, general and administrative expenses |  |  | --- |  |  |  | 2,974,130 |  |  |  | 64,806 |  |  |  | 3,038,936 |  |
| Depreciation and amortization |  |  | 277,866 |  |  |  | 5,084 |  |  |  | --- |  |  |  | 282,950 |  |
| Impairment loss |  |  | 716,000 |  |  |  | --- |  |  |  | --- |  |  |  | 716,000 |  |
| Total Operating Expenses |  |  | 4,545,752 |  |  |  | 2,979,214 |  |  |  | 161,043 |  |  |  | 7,686,009 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss from operations |  | $ | (1,673,575 | ) |  | $ | (2,946,789 | ) |  | $ | (57,284 | ) |  | $ | (4,677,648 | ) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Other Segment Information** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss on extinguishment of debt |  | $ | --- |  |  | $ | 178,986 |  |  | $ | --- |  |  | $ | 178,986 |  |
| Change in fair value of debt |  | $ | --- |  |  | $ | (84,109 | ) |  | $ | --- |  |  | $ | (84,109 | ) |
| Amortization of original issue discounts on notes payable |  | $ | 5,007 |  |  | $ | 1,311,158 |  |  | $ | --- |  |  | $ | 1,316,165 |  |
| Gain from realization of contingent sale consideration receivable |  | $ | --- |  |  | $ | (125,355 | ) |  | $ | --- |  |  | $ | (125,355 | ) |
| Interest expense |  | $ | 11,506 |  |  | $ | 156,638 |  |  | $ | --- |  |  | $ | 168,144 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Identifiable Assets** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Identifiable assets as of December 31, 2024 |  | $ | 496,391 |  |  | $ | 1,719,020 |  |  | $ | 7,578 |  |  | $ | 2,222,989 |  |

F-43

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 16 – SEGMENT REPORTING (CONTINUED)**

Segment information for the year ended December 31, 2023 was as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31, 2023** | | | | | | | | | | | | | |  |
|  |  | **Health Services** | |  |  | **Digital Healthcare** | |  |  | **Medical Distribution** | |  |  | **Total** | |  |
| **Revenue** |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Patient service revenue, net |  | $ | 5,484,278 |  |  | $ | --- |  |  | $ | --- |  |  | $ | 5,484,278 |  |
| Subscription revenue |  |  | --- |  |  |  | 58,901 |  |  |  | --- |  |  |  | 58,901 |  |
| Product and other revenue |  |  | --- |  |  |  | --- |  |  |  | 179,200 |  |  |  | 179,200 |  |
| Total revenue |  |  | 5,484,278 |  |  |  | 58,901 |  |  |  | 179,200 |  |  |  | 5,722,379 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Operating Expenses** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Practice salaries and benefits |  |  | 3,231,117 |  |  |  | --- |  |  |  | --- |  |  |  | 3,231,117 |  |
| Other practice operating expenses |  |  | 2,205,085 |  |  |  | --- |  |  |  | --- |  |  |  | 2,205,085 |  |
| Cost of product revenue |  |  | --- |  |  |  | --- |  |  |  | 142,501 |  |  |  | 142,501 |  |
| Selling, general and administrative expenses |  |  | --- |  |  |  | 3,520,811 |  |  |  | 102,591 |  |  |  | 3,623,402 |  |
| Depreciation and amortization |  |  | 346,375 |  |  |  | 5,652 |  |  |  | --- |  |  |  | 352,027 |  |
| Impairment loss |  |  | 319,958 |  |  |  | --- |  |  |  | --- |  |  |  | 319,958 |  |
| Total Operating Expenses |  |  | 6,102,535 |  |  |  | 3,526,463 |  |  |  | 245,092 |  |  |  | 9,874,090 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss from operations |  | $ | (618,257 | ) |  | $ | (3,467,562 | ) |  | $ | (65,892 | ) |  | $ | (4,151,711 | ) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Other Segment Information** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss on extinguishment of debt |  | $ | --- |  |  | $ | 145,212 |  |  | $ | --- |  |  | $ | 145,212 |  |
| Gain from expiration of liability classified equity instruments |  | $ | --- |  |  | $ | (92,641 | ) |  | $ | --- |  |  | $ | (92,641 | ) |
| Amortization of original issue discounts on notes payable |  | $ | 423,820 |  |  | $ | 3,988 |  |  | $ | --- |  |  | $ | 427,808 |  |
| Gain from realization of contingent sale consideration receivable |  | $ | (1,090,857 | ) |  | $ | --- |  |  | $ | --- |  |  | $ | (1,090,857 | ) |
| Interest expense and other |  | $ | 22,178 |  |  | $ | 50,540 |  |  | $ | --- |  |  | $ | 72,718 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Identifiable Assets** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Identifiable assets as of December 31, 2023 |  | $ | 1,812,609 |  |  | $ | 2,457,849 |  |  | $ | 9,682 |  |  | $ | 4,280,140 |  |

The Digital Healthcare made intercompany sales of $1,116 and $790 in the years ended December 31, 2024 and 2023, respectively, related to subscription revenue billed to and paid for by the Company’s physicians for access to the HealthLynked Network. The Medical Distribution segment made intercompany sales of $238 and $19,547 in the years ended December 31, 2024 and 2023, respectively, related to medical products sold to practices in the Company’s Health Services segment. Intercompany revenue and the related costs are eliminated on consolidation. The revenues, significant expense categories and amounts align with the segment-level information that is regularly provided to the Company’s chief operating decision maker (“CODM”), which is the Company’s CEO, Dr. Michael Dent.

**NOTE 17 – FAIR VALUE OF FINANCIAL INSTRUMENTS**

The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate their respective fair values due to the short-term nature of such instruments. The Company measures certain financial instruments at fair value on a recurring basis, including certain convertible notes payable and related party loans, which were extinguished and reissued and are therefore subject to fair value measurement, derivative financial instruments arising from conversion features embedded in convertible promissory notes for which the conversion rate was not fixed, and equity-class. All financial instruments carried at fair value fall within Level 3 of the fair value hierarchy as their value is based on unobservable inputs. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made.

F-44

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 17 – FAIR VALUE OF FINANCIAL INSTRUMENTS (CONTINUED)**

The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **As of December 31, 2024** | | | | | | | | | | | | | |  |  | **As of December 31, 2023** | | | | | | | | | | | | | |  |
|  |  | **Level 1** | |  |  | **Level 2** | |  |  | **Level 3** | |  |  | **Total** | |  |  | **Level 1** | |  |  | **Level 2** | |  |  | **Level 3** | |  |  | **Total** | |  |
| ***Assets:*** |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Contingent sale consideration receivable |  | $ | --- |  |  | $ | --- |  |  | $ | 1,463,518 |  |  | $ | 1,463,518 |  |  | $ | --- |  |  | $ | --- |  |  | $ | 1,663,163 |  |  | $ | 1,663,163 |  |
| ***Liabilities:*** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Contingent acquisition consideration payable |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 2,189 |  |  |  | 2,189 |  |
| Convertible notes payable to related party |  |  | --- |  |  |  | --- |  |  |  | 671,025 |  |  |  | 671,025 |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |
|  |  | $ | --- |  |  | $ | --- |  |  | $ | 671,025 |  |  | $ | 671,025 |  |  | $ | --- |  |  | $ | --- |  |  | $ | 2,189 |  |  | $ | 2,189 |  |

Certain notes payable to a related party carried at fair value and contingent acquisition consideration payable are each Level 3 financial instrument that are measured at fair value on a recurring basis. Gains (losses) from the change in fair value of Level 3 financial instruments during the years ended December 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Year Ended December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Change in fair value of debt |  | $ | 84,109 |  |  | $ | --- |  |
| Change in fair value of contingent acquisition consideration payable |  | $ | 2,189 |  |  | $ | --- |  |
| Total gains |  | $ | 86,298 |  |  | $ | --- |  |

**NOTE 18 – SUBSEQUENT EVENTS**

On January 16, 2025, the Company issued a promissory note payable (the “January 2025 Note I”) to an investor with a stated principal amount of $150,650 and prepaid interest of $18,078 for total repayments of $168,278. The Company received net proceeds of $125,000 after original issue discount of $19,650 and fees of $6,000. The January 2025 Note I does not bear interest in excess of the original issue discount and prepaid interest and matures on November 15, 2025. The Company is required to make 10 monthly payments of $16,873 starting February 15, 2025 and ending on November 15, 2025. The January 2025 Note I gives the holder a conversion right at a 39% discount to the market price of the Company’s common stock only in the event of default.

On January 24, 2025, the Company issued a promissory note payable (the “January 2025 Note II”) to an investor with a stated principal amount of $98,900 and prepaid interest of $13,846 for total repayments of $112,746. The Company received net proceeds of $80,000 after original issue discount of $12,900 and fees of $6,000. The January 2025 Note II does not bear interest in excess of the original issue discount and prepaid interest and matures on November 30, 2025. The Company is required to make a payment of $56,373 on July 30, 2025 and monthly installments of $14,093 thereafter ending on November 30, 2025. The January 2025 Note II gives the holder a conversion right at a 39% discount to the market price of the Company’s common stock only in the event of default.

On February 14, 2025, the Company issued a promissory note payable (the “February 2025 Note”) to an investor with a stated principal amount of $121,900 and prepaid interest of $13,846 for total repayments of $14,628. The Company received net proceeds of $100,000 after original issue discount of $15,900 and fees of $6,000. The February 2025 Note does not bear interest in excess of the original issue discount and prepaid interest and matures on December 15, 2025. The Company is required to make 10 monthly payments of $13,653 starting March 15, 2025 and ending on December 15, 2025. The February 2025 Note gives the holder a conversion right at a 25% discount to the market price of the Company’s common stock only in the event of default.

F-45

**HEALTHLYNKED CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 18 – SUBSEQUENT EVENTS (CONTINUED)**

On February 24, 2025, holders of the majority of the voting power of the Company’s common stock and our Board of Directors approved an amendment to the Company’s articles of incorporation to effect a reverse stock split of the Company’s common stock by a ratio of 100-for-1 not later than ninety (90) days after the amendment is filed with the Secretary of State of the State of Nevada, with the Company’s Board of Directors having the discretion as to the exact date of any reverse stock split to be set. The corporate actions will become effective no earlier than forty (40) days after the date notice of the internet availability of such Information Statement materials is first sent to stockholders, which was on or approximately March 19, 2025.

On March 4, 2025, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $50,000, an interest rate of 12% per annum, and a maturity date of September 4, 2025. The note is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.049 per share. The Company received net proceeds of $50,000.

On March 12, 2025, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $60,000, an interest rate of 12% per annum, and a maturity date of September 12, 2025. The note is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.03 per share. The Company received net proceeds of $60,000.

On March 20, 2025, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $420,000, an interest rate of 12% per annum, and a maturity date of September 20, 2025. The note is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.0375 per share. The note was issued in exchange for the Undocumented Advances totaling $420,000 made by the trust between September and November 2024.

On March 20, 2025, the maturity dates on twelve notes payable to a trust controlled by Dr. Michael Dent with aggregate principal totaling $1,216,500 were extended until September 20, 2025 in exchange for a ten-year warrant to purchase 1,353,356 shares of the Company’s common stock at an exercise price of $0.0375 per share. The interest rate on the extended notes was also increased from 12% to 15% after March 20, 2025.

On March 27, 2025, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $65,000, an interest rate of 12% per annum, and a maturity date of September 27, 2025. The note is convertible at any time at the holder’s option into shares of the Company’s common stock at a fixed conversion price of $0.031 per share. The Company received net proceeds of $65,000.

The Company has evaluated subsequent events through March 31, 2025, which is the date the financial statements were available to be issued. Except as disclosed above, no other events have occurred that would require adjustment to or disclosure in these financial statements.

F-46

**Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure**

None.

**Item 9A. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of December 31, 2024 based on the framework in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on that evaluation, and in light of the material weaknesses found in our internal controls over financial reporting, our management concluded that our disclosure controls and procedures were not effective as of December 31, 2024.

**Management’s Report on Internal Control over Financial Reporting**

Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined by the SEC, internal control over financial reporting is a process designed by, or under the supervision of our Principal Executive and Financial Officer and implemented by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements in accordance with U.S. generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework. Based on this assessment, management identified the following material weakness that has caused management to conclude that, as of December 31, 2024, our disclosure controls and procedures, and our internal control over financial reporting, were not effective at the reasonable assurance level:

|  |  |  |
| --- | --- | --- |
|  | 1. | We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness. |

**Remediation of Material Weaknesses**

To remediate the material weakness in our documentation of internal controls we intend to formally document the design of our internal control policies and procedures when resources allow.

**Changes in Internal Control over Financial Reporting**

Except for the matters discussed above, there was no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the fiscal quarter ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

**Item 9B. Other Information**

Not applicable.

**Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections**

Not applicable.

34

**PART III.**

**Item 10. Directors, Executive Officers and Corporate Governance**

The following table sets forth information regarding our executive officers and directors. All directors hold office for one-year terms until the election and qualification of their successors. Officers are elected by the Board and serve at the discretion of the Board.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name** |  | **Age** |  | **Positions with the Company** |
| Michael Dent, MD |  | 60 |  | Chief Executive Officer and Chairman of the Board of Directors |
| Jeremy Daniel |  | 48 |  | Chief Financial Officer |
| William Crupi |  | 36 |  | Chief Operating Officer |
| George O’Leary |  | 62 |  | Director |
| Robert Gasparini |  | 70 |  | Director |
| Heather Monahan |  | 50 |  | Director |
| Daniel Hall |  | 52 |  | Director |
| Dr. Paul Hobaica |  | 60 |  | Director |

***Michael T. Dent, MD, Founder, Chief Executive Officer and Chairman of the Board of Directors*.** Dr. Dent founded the Naples Women’s Center in 1996 where he served as its principal executive from formation through February 2016. He is also Co-Founder and Managing Director of InLight Capital Partners LLC since January 2014 and is responsible for its healthcare, information technology and life science investments. He has held key leadership positions in business development, operations, corporate development, and strategy in the healthcare and technology industries since the mid-90s. Prior to founding InLight Capital Partners, Dr. Dent was Founder, Chairman and Chief Executive Officer of NeoGenomics Laboratories (Nasdaq: NEO) where he was on the board of directors from 1998 until July 2015. As a retired physician, Dr. Dent is uniquely qualified to understand the challenges and opportunities in healthcare and emerging technologies. Dr. Dent received his bachelor’s degree from Davidson College, where he majored in both Biology and Pre-Med, and went on to earn his medical degree from The University of South Carolina in Charleston, South Carolina. Dr. Dent also attended Florida Gulf Coast University’s Business Executive Education program. Dr. Dent holds a board affiliation with MedOfficeDirect (Founder). Our Board of Directors believes Dr. Dent’s perspective as the founder of the Company, his industry knowledge and prior experience as a director of a public company and familiarity with public company governance, provide him with the qualifications and skills to serve as a director.

***Jeremy Daniel, Chief Financial Officer***. Mr. Daniel was appointed as our Chief Financial Officer effective January 15, 2025. Mr. Daniel has served as Chief Financial Officer for Innoveren Scientific, a publicly traded biotech firm, since 2019. Before his time at Innoveren, Mr. Daniel held the positions of Chief Financial Officer at Regenerative Medicine Solutions (2013-19) and at Sleep Apnea Treatment Centers of America, and Controller for Omnicare (2012-14). Mr. Daniel holds a Master of Business Administration in Business Administration from Xavier University and a Bachelor of Business Administration and Accounting from The University of Cincinnati. Mr. Daniel is also a Certified Public Accountant.

***William Crupi, Chief Operating Officer***. Mr. Crupi was appointed as our Chief Operating Officer effective June 25, 2024. Mr. Crupi had served as the Company’s Operations Manager since April 2023. Mr. Crupi previously served as Area Manager for Quigley Eye Specialists and Business Manager at Eye Site of Tampa Bay, both where he managed daily operations of multiple medical facilities, and as an Executive Recruiter at Morisey-Dart Group, where he partnered with clients in identifying qualified candidates for difficult executive roles in the medical device, manufacturing, and engineering fields

***George G. O’Leary, Director.*** Mr. O’Leary served as our Chief Financial Officer from August 6, 2014 until April 4, 2024. Mr. O’Leary is also Co-Founder and Managing Director of InLight Capital Partners LLC since January 2014. He is a financially trained senior executive specializing in innovative strategic problem solving across functional and industry boundaries. Mr. O’Leary is Vice Chairman of Referrizer, LLC, a private marketing automation company, since January 2016. Mr. O’Leary was the Vice-Chairman of the board of directors of Timios Holdings Corp. from March 2014 through January 2021 and on the board of directors of MedOfficeDirect since October 2013. From June 2009 to May 2013 Mr. O’Leary was Chairman of the Board and Chief Financial Officer of Protection Plus Securities Corporation until it was sold to Universal Protection Services. From February 2007 to June 2015, Mr. O’Leary was a member of the Board of Directors of NeoMedia Technologies. Mr. O’Leary is founder and President of SKS Consulting of South Florida Corp. (“SKS”) since June 2006 where he works with public and private companies in board representation and/or under consulting agreements providing executive level management expertise, as well as helping the implementation and execution of their companies’ strategic & operational plans. Mr. O’Leary started SKS with the mission to help companies focus on high growth initiatives and execution of their core business while shedding non-core business assets. From 1996 to 2000, Mr. O’Leary was Chief Executive Officer and President of Communication Resources Incorporated (“CRI”), where annual revenues grew from $5 million to $40 million during his tenure. Prior to CRI, Mr. O’Leary was Vice President of Operations of Cablevision Industries, where he ran $125 million of business until it was sold to Time Warner. Mr. O’Leary started his professional career as a senior accountant with Peat Marwick and Mitchell (KPMG). Mr. O’Leary holds a B.B.A. degree in Accounting with honors from Siena College. Our Board of Directors believes Mr. O’Leary’s extensive business experience provides him with the qualifications and skills to serve as a director.

35

***Robert Gasparini, Director***. Mr. Gasparini started his career in the genetics laboratories at the University of CT and became an assistant professor there from 1985-1990. From 1990-1993 he was Technical Director of Genetics at Tufts and from 1993-1997 he was Assistant Director for the Prenatal Diagnostic Center in Lexington MA (a Mass General affiliate). Mr. Gasparini also worked as a Manager of Worldwide and Strategic Marketing with Ventana Medical Systems from 1998-2000 and in 2001, he became Director of Genetics for US Labs in Irvine California. Mr. Gasparini was a key executive at NeoGenomics Laboratories serving in many capacities with the company including President and Chief Scientific Officer as well as being on the Board of Directors from 2004-2014. Mr. Gasparini has 28 years of combined service on national committees and boards of directors and has published 15 peer-reviewed articles and over 30 peer-reviewed abstracts. Our Board of Directors believes Mr. Gasparini’s extensive business experience provides him with the qualifications and skills to serve as a director.

***Heather Monahan, Director***. Ms. Monahan is a best-selling author, keynote speaker, Ted-X speaker, Executive Coach and founder of Boss In Heels. Ms. Monahan is a Glass Ceiling Award winner, was named one of the most Influential Women in Radio in 2017 and was selected as a Limit Breaking Female Founder by Thrive Global in 2018. Her book “Confidence Creator” was #1 on Amazon’s Business Biographies and Business Motivation lists the first week it debuted. Her podcast, Creating Confidence, which features noteworthy celebrities and entrepreneurs, debuted on the Top 200 Apple podcasts. Ms. Monahan was named one of the Top 40 Female Keynote Speakers for 2020 by Real Leaders. Her Ted-X talk was promoted to TED and translated into 6 languages. Harper Collins Leadership published her book, Overcome Your Villains: Mastering Your Beliefs, Actions, and Knowledge to Conquer Any Adversity, in 2021. Ms. Monahan has been featured in USA Today, CNN, Forbes, Fast Company and The Steve Harvey Show, and recently was named a Guest Professor at Harvard.

***Daniel Hall, Director***. Mr. Hall began his career performing a wide variety of accounting services for a wholly owned subsidiary of ConAgra. In 1995, Mr. Hall transitioned into the medical device industry when he began working for Arthrex, Inc., a world leader in orthopedic surgical device design, research, manufacturing and medical education. He has held various positions of increasing responsibility culminating in his current role as Vice-President of Shareholder Relations and Taxation, where he is responsible for the global enterprise’s treasury, investment, financial audit, tax strategy/compliance, and corporate structuring activities. In addition to his role with Arthrex, Mr. Hall is also Vice-President of Krisdan Management, Inc. a Single-Family Office. In this capacity, he is responsible for ultra-high net worth tax planning, strategy and compliance, as well as trust and estate planning, investment oversight, philanthropy and financial reporting. Mr. Hall earned a BS in Business Administration and Accounting from North Dakota State University. Mr. Hall is also Florida registered Certified Public Accountant and a member of both the American Institute of Certified Public Accountants (AICPA) and the Florida Institute of Certified Public Accountants (FICPA).

***Dr. Paul Hobaica, Director***. Dr. Hobaica is a highly accomplished board-certified physician with over 25 years of experience in the medical field. He is a graduate of Bridgewater State University with a degree in business administration. A Massachusetts native, Dr. Hobaica served on the staff at the University of Massachusetts Medical Center from 1996 through 1999 before relocating to Florida in 1999. In Florida, Dr. Hobaica initially joined the emergency department at Naples Community Hospital for a year before starting his own community practice. He also worked as a firefighter and emergency medical technician for several years and developed the only healthcare program specific for the needs of the first responders of Collier County, where he still serves as the District Physician for North Collier Fire Rescue and Immokalee Fire Rescue. Dr. Hobaica joined Arthrex, Inc., in the spring of 2011, where is currently the Corporate Medical Director, providing strategic leadership and direction to the company’s medical and wellness programs.

**Family Relationships**

No family relationships exist between any of our current or former directors or executive officers.

**Involvement is Certain Legal Proceedings**

No director, executive officer or control person of the Company has been involved in any legal proceeding listed in Item 401(f) of Regulation S-K in the past 10 years.

**Limitation of Liability of Directors**

Our Amended and Restated Articles of Incorporation states that directors and officers shall be indemnified and held harmless to the fullest extend legally permissible under the laws of the State of Nevada, from time to time, against all expenses, liability and loss (including attorney’s fees, judgments, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him/her in connection with acts performed in such capacity. Such right of indemnification shall be a contract right, which may be enforced in a nay manner desired by such person. The expenses of officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they are incurred and in advance of the final disposition of the action, suit or proceeding.

36

**Board Independence**

The Board determined that Mr. Gasparini, Ms. Monahan and Dr. Hobaica would be considered independent directors of the Company. Although we are not listed on the Nasdaq, we consider these directors independent as defined by NASDAQ Rule 5605(a)(2).

**Meetings**

During 2024, our Board held a total of four meetings. Each incumbent director attended at least 75% of the aggregate of (1) the total number of meetings of our Board during the period in which he or she was a director, and (2) 75% of the total number of meetings of all committees on which he or she served during the period in which he or she was a director.

**Board Committees**

Audit Committee

Our audit committee is comprised of independent directors Dan Hall (Chairperson) and Heather Monahan. Mr. Hall qualifies as an “audit committee financial expert” as defined in Item 407(d)(5) of Regulation S-K.

*Report of the Audit Committee*

The audit committee has reviewed and discussed the audited consolidated financial statements with management. The audit committee has discussed with RBSM the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the SEC. In addition, the audit committee has received the written disclosures and the letter from RBSM required by applicable requirements of the PCAOB regarding the independent accountant’s communications with the audit committee concerning independence and has discussed with RBSM its independence from the Company and management.

Based on the reviews and discussions referred to above, the audit committee recommended that the audited consolidated financial statements for the Company for the fiscal year ended December 31, 2024 be included in this Annual Report on Form 10-K for filing with the SEC.

THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

Dan Hall, Chairman

Heather Monahan

Compensation Committee

Our compensation committee is comprised of independent directors Robert Gasparini, and Heather Monahan.

Nominating and Governance Committee

Our nominating and governance committee is comprised of Dr. Michael Dent (Chairperson) and independent director Dr. Paul Hobaica.

**Director Nominees**

Except as may be provided in our bylaws, we do not currently have specified procedures in place pursuant to which security holders may recommend nominees to the Board of Directors.

37

**Compliance with Section 16(a) of Exchange Act**

Section 16(a) of the Securities Exchange Act of 1934 requires our officers and directors, and persons who own more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the SEC. These persons are required by regulation to furnish us with copies of all Section 16(a) reports that they file. Based solely on our review of copies of such reports and representations from the reporting persons, we believe that during the fiscal year ended December 31, 2024, we believe that six Forms 4 for Dr. Michael Dent (five related to shares underlying convertible notes and one related to a warrant issuance) and a Form 3 for David Rosal were not timely filed.

**Code of Ethics**

We have not adopted a code of ethics because our Board believes that our small size does not merit the expense of preparing, adopting and administering a code of ethics. Our Board intends to adopt a code of ethics when circumstances warrant.

**Insider Trading Policy**

We have adopted an Insider Trading Policy that governs the purchase, sale and/or other dispositions of our securities by directors, officers and employees. We believe that our Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations. A copy of our Insider Trading Policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K.

**Item 11. Executive Compensation**

The following table sets forth information regarding compensation paid to our principal executive officer, principal financial officer, and our highest paid executive officer, for the years ended December 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  | **All Other** | |  |  |  | |  |
|  |  |  |  |  | |  |  |  | |  |  | **Stock** | |  |  | **Option** | |  |  | **Compen-** | |  |  |  | |  |
|  |  |  |  | **Salary** | |  |  | **Bonus** | |  |  | **Awards (1)** | |  |  | **Awards (2)** | |  |  | **sation** | |  |  | **Total** | |  |
| **Name and Position** |  | **Year** |  | **($)** | |  |  | **($)** | |  |  | **($)** | |  |  | **($)** | |  |  | **($)** | |  |  | **($)** | |  |
|  |  |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Michael Dent |  | 2024 |  |  | 35,000 |  |  |  | --- |  |  |  | --- |  |  |  | 79,660 |  |  |  | --- |  |  |  | 114,660 |  |
| (Chief Executive Officer) |  | 2023 |  |  | 33,654 |  |  |  | --- |  |  |  | 1,800 |  |  |  | 1,390 |  |  |  | --- |  |  |  | 36,844 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| George O’Leary (3) |  | 2024 |  |  | 77,327 |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 77,327 |  |
| (Chief Financial Officer) |  | 2023 |  |  | 249,008 |  |  |  | 13,000 |  |  |  | 6,800 |  |  |  | 348 |  |  |  | --- |  |  |  | 269,156 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| David Rosal (4) |  | 2024 |  |  | 92,308 |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 92,308 |  |
| (Chief Financial Officer) |  | 2023 |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| William Crupi (5) |  | 2024 |  |  | 98,808 |  |  |  | --- |  |  |  | --- |  |  |  | 16,918 |  |  |  | --- |  |  |  | 115,726 |  |
| (Chief Operating Officer) |  | 2023 |  |  | 45,769 |  |  |  | --- |  |  |  | --- |  |  |  | 3,476 |  |  |  | --- |  |  |  | 49,245 |  |

|  |  |  |
| --- | --- | --- |
|  | (1) | Reflects fair value of unrestricted stock awards on the grant date. Stock awards for Dr. Dent include 50,000 shares granted in 2023 pursuant to a bonus grant. Stock awards for Mr. O’Leary in 2023 include 100,000 vested shares granted in connection with Mr. O’Leary’s 2022 employment agreement and 50,000 shares pursuant to a bonus grant. |

|  |  |  |
| --- | --- | --- |
|  | (2) | Reflects the grant date fair values of stock options. Option awards for Dr. Dent in 2024 include a 10-year option to purchase 2,000,000 shares of Company common stock at an exercise price of $0.0569 pursuant to a bonus grant that vested 900,000 shares upon grant, 700,000 between July 31, 2024 and March 29, 2026, and 400,000 that vest based on fiscal year 2024 and 2025 Company performance. Option awards for Dr. Dent in 2023 include a 10-year option to purchase 28,986 shares of Company common stock at an exercise price of $0.069 that vested 100% upon grant pursuant to a bonus grant. Option awards for Mr. O’Leary in 2023 include a 10-year option to purchase 7,246 shares of Company common stock at an exercise price of $0.069 that vested 100% upon grant pursuant to a bonus grant. Option awards for Mr. Crupi in 2024 include a 10-year option to purchase 300,000 shares of Company common stock at an exercise price of $0.081 that vest one-third each on June 25, 2025, 2026 and 2027. Option awards for Mr. Crupi in 2023 include a 10-year option to purchase 72,464 shares of Company common stock at an exercise price of $0.069 that vested 0.069 that vested 100% upon grant pursuant to a bonus grant. |

|  |  |  |
| --- | --- | --- |
|  | (3) | Mr. O’Leary resigned as Chief Financial Officer of the Company effective April 4, 2024. He remains a member of the Board of Directors. |

|  |  |  |
| --- | --- | --- |
|  | (4) | Mr. Rosal was appointed as Chief Financial Officer of the Company effective March 11, 2024. He resigned from the position effective January 15, 2025. Mr. Rosal was replaced by Jeremy Daniel. |

|  |  |  |
| --- | --- | --- |
|  | (5) | Mr. Crupi was appointed as Chief Operating Officer of the Company effective June 25, 2024. Prior to June 25, 2024, Mr. Crupi was employed by the Company in a non-executive role since April 23, 2023. |

38

**Employment Agreements**

On July 1, 2016, we entered into an employment agreement with Dr. Michael Dent, Chief Executive Officer and a member of the Board of Directors. Dr. Dent’s employment agreement continues until terminated by Dr. Dent or the Company. If Dr. Dent’s employment is terminated by us (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Dr. Dent will be entitled to severance in an amount equal to 12 months of his then-current annual base salary, as well as the pro-rata portion of any bonus that would be due and payable to him. In the event that Dr. Dent terminates the employment agreement, he shall be entitled to any accrued but unpaid salary and other benefits up to and including the date of termination, and the pro-rata portion of any unvested time-based options up until the date of termination.

**Outstanding Equity Awards at Year-End**

The following table contains information concerning unexercised options; shares of stock that have not vested; and equity incentive plan awards outstanding as of December 31, 2024 with respect to the executive officers named in the Summary Compensation Table:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | |  |  |  | |  |  | **Number of** | |  |  |  | |  |  |  | |  |
|  |  |  | |  |  |  | |  |  | **Securities** | |  |  |  | |  |  |  | |  |
|  |  | **Number of Securities** | | | | | |  |  | **Underlying** | |  |  |  | |  |  |  | |  |
|  |  | **Underlying** | | | | | |  |  | **Unexercised** | |  |  | **Option** | |  |  |  | |  |
|  |  | **Unexercised Options** | | | | | |  |  | **Unearned** | |  |  | **Exercise** | |  |  | **Option** | |  |
|  |  | **Exercisable** | |  |  | **Unexercisable** | |  |  | **Options** | |  |  | **Price** | |  |  | **Expiration** | |  |
|  |  | **(#)** | |  |  | **(#)** | |  |  | **(#)** | |  |  | **($)** | |  |  | **Date** | |  |
| Michael Dent |  |  | 750,000 |  |  |  | --- |  |  |  | --- |  |  | $ | 0.0800 |  |  |  | 7/1/2026 |  |
| (Chief Executive Officer) |  |  | 28,986 |  |  |  | --- |  |  |  | --- |  |  | $ | 0.0690 |  |  |  | 12/21/2033 |  |
|  |  |  | 1,050,000 |  |  |  | 950,000 |  |  |  | 950,000 |  |  | $ | 0.0569 |  |  |  | 3/28/2034 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| George O’Leary |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |
| (Chief Financial Officer) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| David Rosal |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |
| (Chief Financial Officer) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| William Crupi |  |  | 72,464 |  |  |  | --- |  |  |  | --- |  |  | $ | 0.0690 |  |  |  | 12/21/2033 |  |
| (Chief Operating Officer) |  |  | --- |  |  |  | 300,000 |  |  |  | 300,000 |  |  | $ | 0.0810 |  |  |  | 5/30/2032 |  |

On January 1, 2016, our Board adopted the 2016 Employee Equity Incentive Plan (the “2016 EIP”) for the purpose of having equity awards available to allow for equity participation by our employees. The 2016 EIP allowed for the issuance of up to 15,503,680 shares of our common stock to employees, which may have been issued in the form of stock options, stock appreciation rights, or common shares. The 2016 EIP was governed by our Board, or a committee appointed by the Board. The 2016 EIP expired during 2021 but allows for the prospective issuance of common shares upon vesting of stock awards or exercise of stock options granted prior to expiration of the 2016 EIP.

39

On September 9, 2021, our Board adopted the 2021 Employee Equity Incentive Plan (the “2021 EIP”) for the purpose of having equity awards available to allow for equity participation by its employees. The 2021 EIP was approved by a majority of our stockholders pursuant to a written resolution on September 13, 2021. The 2021 EIP allows for the issuance of up to 20,000,000 shares of our common stock to employees, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2021 EIP is governed by our Board, or a committee that may be appointed by our Board in the future.

**Director Compensation**

The following table sets forth information regarding compensation paid to our outside directors for the year ended December 31, 2024.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | |  |  |  | |  |  |  | |  |  | **Non-equity** | |  |  | **Nonqualified** | |  |  |  | |  |  |  | |  |
|  |  | **Fees** | |  |  |  | |  |  |  | |  |  | **Incentive** | |  |  | **Deferred** | |  |  | **All** | |  |  |  | |  |
|  |  | **Earned** | |  |  |  | |  |  |  | |  |  | **Plan** | |  |  | **Compen-** | |  |  | **Other** | |  |  |  | |  |
|  |  | **or Paid** | |  |  | **Stock** | |  |  | **Option** | |  |  | **Compen-** | |  |  | **sation** | |  |  | **Compen-** | |  |  |  | |  |
|  |  | **in Cash** | |  |  | **Awards** | |  |  | **Awards** | |  |  | **sation** | |  |  | **Earnings** | |  |  | **sation** | |  |  | **Total** | |  |
| **Name** |  | **($)** | |  |  | **($)** | |  |  | **($)** | |  |  | **($)** | |  |  | **($)** | |  |  | **($)** | |  |  | **($)** | |  |
| Robert Gasparini |  |  | --- |  |  | $ | 20,000 |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  | $ | 20,000 |  |
| Heather Monahan |  |  | --- |  |  | $ | 20,000 |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  | $ | 20,000 |  |
| Daniel Hall |  |  | --- |  |  | $ | 20,000 |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  | $ | 20,000 |  |
| Dr. Paul Hobaica |  |  | --- |  |  | $ | 35,000 |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  | $ | 35,000 |  |

**Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters**

**Equity Compensation Plan Information**

On January 1, 2016, our Board adopted the 2016 Employee Equity Incentive Plan (the “2016 EIP”) for the purpose of having equity awards available to allow for equity participation by our employees. The 2016 EIP allows for the issuance of up to 15,503,680 shares of our common stock to employees, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2016 EIP is governed by our Board, or a committee that may be appointed by the Board in the future. The 2016 EIP expired during 2021 but allows for the prospective issuance of common shares upon vesting of stock awards or exercise of stock options granted prior to expiration of the 2016 EIP.

On September 9, 2021, our Board adopted the 2021 Employee Equity Incentive Plan (the “2021 EIP”) for the purpose of having equity awards available to allow for equity participation by its employees. The 2021 EIP was approved by a majority of our stockholders pursuant to a written resolution on September 13, 2021. The 2021 EIP allows for the issuance of up to 20,000,000 shares of our common stock to employees, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2021 EIP is governed by our Board, or a committee that may be appointed by our Board in the future.

40

The following table summarizes the total number of outstanding options and share grants available for other future issuances under our equity compensation plans as of December 31, 2024:

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Number of Shares to be Issued Upon Exercise of Outstanding Options, Warrants and Rights** | |  |  | **Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights** | |  |  | **Number of Shares Remaining Available for Future Issuance Under the Equity Compensation Plan (Excluding Shares in First Column)** | |  |
| Equity compensation plans approved by stockholders |  |  | 5,313,672 |  |  | $ | 0.06 |  |  |  | 9,164,650 |  |
| Equity compensation plans not approved by stockholders |  |  | 843,750 |  |  | $ | 0.10 |  |  |  | --- |  |
|  |  |  | 6,157,422 |  |  | $ | 0.07 |  |  |  | 9,164,650 |  |

During the years ended December 31, 2024 and 2023, the Company made stock grants pursuant to the plans totaling -0- and 1,793,596 shares, respectively. During the years ended December 31, 2024 and 2023, the Company also made grants pursuant to the plans of options to purchase 4,804,974 and 493,756 shares of common stock. Certain of the stock options are subject to time-based vesting requirements and certain of the stock options are subject to performance-based vesting requirements based on future Company revenue and earnings metrics as well as individual performance goals.

We provide the following discussion of the timing of option awards in relation to the disclosure of material nonpublic information, as required by Item 402(x) of Regulation S-K. Our Company has certain practices relating to the timing of stock options grants and share grants. For option and share grants to our employees, including executive officers, grants of options are currently made by and at meetings of the Board. The Board does not currently take material non-public information into account when determining the timing and terms of stock option awards, except that if the Company determines that it is in possession of material non-public information on an anticipated grant date, the Board expects to defer the grant until a date on which the Company is not in possession of material non-public information. It is the Company’s practice not to time the disclosure of material non-public information for the purpose of affecting the value of executive compensation.

**Security Ownership of Certain Beneficial Owners and Management**

The following table sets forth information with respect to the beneficial ownership of our common stock as of March 31, 2025 by (i) each person known by us to beneficially own more than 5.0% of our common stock, (ii) each of our directors, (iii) each of the named executive officers, and (iv) all of our directors and executive officers as a group. The percentages of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the security. Except as indicated in the footnotes to this table, each beneficial owner named in the table below has sole voting and sole investment power with respect to all shares beneficially owned and each person’s address is c/o HealthLynked Corp., 1265 Creekside Parkway, Suite 302, Naples, Florida 34108. As of March 31, 2025, we had 281,947,151 common shares and 2,750,000 Series B Preferred shares issued and outstanding.

41

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Number of Common Shares (1)** | |  |  | **Percent of Class (Common Stock) (2)** | |  |  | **Number of Series B Preferred Shares** | |  |  | **Percent of Class (Series B Preferred Stock) (3)** | |  |  | **Total Percentage Held (Common and Series B Preferred) (4)** | |  |
| Dr. Michael Dent, Chief Executive Officer and Chairman (5) |  |  | 200,724,477 |  |  |  | 50.45 | % |  |  | 2,750,000 |  |  |  | 100.00 | % |  |  | 70.70 | % |
| Jeremy Daniel, Chief Financial Officer |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |
| William Crupi, Chief Operating Officer (6) |  |  | 72,464 |  |  |  | \* |  |  |  | --- |  |  |  | --- |  |  |  | \* |  |
| George O’Leary, Director (7) |  |  | 4,370,522 |  |  |  | 1.55 | % |  |  | --- |  |  |  | --- |  |  |  | \* |  |
| Robert Gasparini, Director (8) |  |  | 2,880,191 |  |  |  | 1.02 | % |  |  | --- |  |  |  | --- |  |  |  | \* |  |
| Paul Hobaica, Director (9) |  |  | 601,624 |  |  |  | \* |  |  |  | --- |  |  |  | --- |  |  |  | \* |  |
| Heather Monahan, Director (10) |  |  | 1,181,697 |  |  |  | \* |  |  |  | --- |  |  |  | --- |  |  |  | \* |  |
| Daniel Hall, Director (11) |  |  | 1,181,697 |  |  |  | \* |  |  |  | --- |  |  |  | --- |  |  |  | \* |  |
| All officers and directors as a group (8 persons) |  |  | 211,012,672 |  |  |  | 65.65 | % |  |  | 2,750,000 |  |  |  | 100.00 | % |  |  | 72.19 | % |

|  |  |  |
| --- | --- | --- |
|  | \* | less than 1% |

|  |  |  |
| --- | --- | --- |
|  | (1) | Under Rule 13d-3 of the Exchange Act of 1934, as amended (the “Exchange Act”), a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares: (i) voting power, which includes the power to vote or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the number of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. |

|  |  |  |
| --- | --- | --- |
|  | (2) | Based on 281,947,151 shares of common stock issued and outstanding as of March 31, 2025. |

|  |  |  |
| --- | --- | --- |
|  | (3) | Based on 2,750,000 shares of Series B Preferred stock issued and outstanding as of March 31, 2025. |

|  |  |  |
| --- | --- | --- |
|  | (4) | Reflects total percentage of combined voting power based on 100 votes per share of Series B Preferred stock outstanding. |

|  |  |  |
| --- | --- | --- |
|  | (5) | Beneficial ownership of common shares includes (i) 3,010,640 shares of common stock held by Dr. Dent directly, (ii) 81,996,472 shares of common stock held in the name of Mary S. Dent Gifting Trust, a trust of which Dr. Michael Dent is trustee (iii) 36,930,038 shares of common stock issuable upon exercise of warrants, (iv) 2,028,986 vested employee stock options, and (v) 76,758,341 shares issuable upon conversion at the option of the reporting person of convertible notes payable outstanding. Excludes 750,000 employee stock options which are subject to future vesting requirements and are not expected to vest within 60 days of March 31, 2025. Beneficial ownership of Series B preferred shares includes 2,750,000 shares of Series B Preferred Shares held in the name of the Michael Thomas Dent Declaration of Trust that are convertible into 13,750,000 shares of common stock and that have that number of votes equal to 100 shares of common stock for each share of Preferred B Preferred Stock held (which shall never be deemed less than 51% of the vote required to approve any action), or the equivalent of 275,000,000 votes. |

|  |  |  |
| --- | --- | --- |
|  | (6) | Includes 72,464 vested employee stock options. Excludes 300,000 employee stock options which are subject to future vesting requirements and are not expected to vest within 60 days of March 31, 2025. |

|  |  |  |
| --- | --- | --- |
|  | (7) | Includes (i) 3,188,781 shares of common stock held by SKS Consulting of South Florida Corp., a corporation directly controlled by George O’Leary, (ii) 729,115 shares of common stock held by George O’Leary directly, and (iii) 261,194 shares issuable upon exercise of warrants. |

|  |  |  |
| --- | --- | --- |
|  | (8) | Includes 2,472,028 shares of common stock held by Mr. Gasparini and his spouse and 408,163 vested stock grants subject to issuance. |

|  |  |  |
| --- | --- | --- |
|  | (9) | Includes 193,461 shares of common stock held by Mr. Hobaica and 408,163 vested stock grants subject to issuance. |

|  |  |  |
| --- | --- | --- |
|  | (10) | Includes 773,534 shares of common stock held by Ms. Monahan and 408,163 vested stock grants subject to issuance. |

|  |  |  |
| --- | --- | --- |
|  | (11) | Includes 773,534 shares of common stock held by Mr. Hall and 408,163 vested stock grants subject to issuance. |

42

**Item 13. Certain Relationships and Related Transactions, and Director Independence**

Amounts due to related parties as of December 31, 2024 and 2023 were comprised of the following:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **December 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Notes payable to Dr. Michael Dent and trust controlled by Dr. Dent, net of unamortized discount |  | $ | 2,911,921 |  |  | $ | 171,142 |  |
| Deferred compensation, Dr. Michael Dent |  |  | 300,600 |  |  |  | 300,600 |  |
|  |  |  |  |  |  |  |  |  |
|  |  | $ | 3,212,521 |  |  | $ | 471,742 |  |

*Notes Payable to Dr. Michael Dent and George O’Leary*

On January 5, 2023, we issued an unsecured promissory note to Dr. Dent with a face value of $10,000 (the “$10k Dent Note”). The $10k Dent Note bore interest at a rate of 15% per annum and was scheduled to mature six months from issuance. In connection with the $10k Dent Note, we issued 96,154 five-year warrants to the holder with an exercise price of $0.104. The fair value of the warrants was $6,843. The $10k Dent Note was repaid in full during January 2023.

On January 13, 2023, we issued an unsecured promissory note to Dr. Dent with a face value of $161,000 (the “January 2023 Dent Note”). Net proceeds were $160,000, taking into account the original issue discount of $1,000. The January 2023 Dent Note bore interest at a rate of 15% per annum and was scheduled to mature six months from issuance. In connection with the January 2023 Dent Note, we issued 860,215 three-year warrants to Dr. Dent with an exercise price of $0.093. The fair value of the warrants was $56,123. The January 2023 Dent Note was repaid in full during January 2023.

On February 14, 2023, we issued an unsecured promissory note to Dr. Dent with a face value of $186,000 (the “February 2023 Dent Note”). Net proceeds were $185,000 after an original issue discount of $1,000. The February 2023 Dent Note bore interest at a rate of 15% per annum and matured six months from issuance. In connection with the February 2023 Dent Note, we issued 685,185 three-year warrants to Dr. Dent with an exercise price of $0.135. The fair value of the warrants was $66,136. The February 2023 Dent Note was repaid in full during August 2023.

On March 14, 2023, we issued a promissory note payable to a trust controlled by Dr. Dent with a stated principal amount of $112,510 and prepaid interest of $13,501 for total scheduled repayments of $126,011 (the “March 2023 Dent Note”). The March 2023 Dent Note had an original issue discount of $12,510, resulting in net proceeds to us of $100,000. At inception, we recognized a note payable in the amount of $126,011 and a discount against the note payable of $26,011. The March 2023 Dent Note did not bear interest in excess of the prepaid interest and original issue discount and matures on March 14, 2024. We were required to make 10 monthly payments of $12,601 starting April 30, 2023. As of December 31, 2024 and 2023, remaining payments were $12,601 and $-0-, respectively, and the net carrying value was $10,097 and $-0-, respectively. The final payment on the March 2023 Dent Note was made in January 2024.

On April 13, 2023, we issued an unsecured promissory note to Dr. Michael Dent with a face value of $100,000 (the “April 2023 Dent Note”). Net proceeds were $100,000. The April 2023 Dent Note bore a fixed interest charge of $15,000 (15% per annum) and had an original maturity date of May 12, 2023. On May 12, 2023, we issued 654,450 five-year warrants with an exercise price of $0.0764 to Dr. Michael Dent in exchange for extending the maturity date of the April 2023 Dent Note until September 30, 2023. The April 2023 Dent Note was repaid in full in June 2023.

On April 27, 2023, we issued an unsecured promissory note to George O’Leary, its Chief Financial Officer, with a face value of $35,000 (the “April 2023 O’Leary Note”). Net proceeds were $35,000. The April 2023 O’Leary Note bore a fixed interest charge of $5,250 (15% per annum) and was scheduled to mature May 25, 2023. On June 2, 2023, we issued 261,194 five-year warrants with an exercise price of $0.067 to Mr. O’Leary in exchange for extending the maturity date of the April 2023 O’Leary Note until July 13, 2023. The April 2023 O’Leary Note was repaid in full in June 2023.

43

On June 8, 2023, we issued an unsecured promissory note to Dr. Michael Dent with a face value of $30,000 (the “June 2023 Dent Note”). Net proceeds were $30,000. The June 2023 Dent Note bore a fixed interest charge of $4,500 (15% per annum) and had a maturity date of June 30, 2023. The June 2023 Dent Note was repaid in full in June 2023.

On June 26, 2023, we issued an unsecured promissory note to Dr. Michael Dent with a face value of $25,000 (the “June 2023 Dent Note II”). The June 2023 Dent Note II bore a fixed interest charge of $1,875 (15% per annum) and matured on December 26, 2023. As of December 31, 2023, the remaining payments were $26,875 and $-0-, respectively, and the net carrying value was $26,875. As of December 31, 2023, the June 2023 Dent Note II was not in default and we were in compliance with the stated loan covenants. The June 2023 Dent Note II was subsequently repaid in full and retired in January 2024.

On August 17, 2023, we issued to a trust controlled by Dr. Dent a promissory note (the “August 2023 Dent Note”) with an initial stated principal amount equal to $330,000 at a purchase price equal to the principal amount less any original issue discounts and fees. The August 2023 Dent Note included a 5% original issue discount, accrues interest at a rate of 0%, and was scheduled to be repaid in four equal semi-monthly installments beginning on October 15, 2023, with each payment including a 2% payment premium, totaling $343,200 in cash repayments. We received net proceeds of $308,500 after discounts and fees. In connection with the note, we issued 500,000 five-year warrants to the holder with an exercise price of $0.15. The fair value of the warrants was $25,311. The August 2023 Dent Note was repaid in full in October 2023.

On August 30, 2023, we issued an unsecured promissory note to Dr. Michael Dent with a face value of $10,000 (the “August 2023 Dent Note II”). The August 2023 Dent Note II had no original issue discount and did not bear interest. Net proceeds to us were $10,000. The August 2023 Dent Note II was scheduled to mature on September 5, 2023. We repaid the August 2023 Dent Note II in full on August 31, 2023.

On September 13, 2023, we issued to Dr. Michael Dent a promissory note with a face value of $93,500 (the “September 2023 Dent Note”). Net proceeds were $85,000. The September 2023 Dent Note bore a fixed interest charge of $8,500 (10% per annum) and had a maturity date of October 12, 2023. In connection with the note, we issued 850,000 five-year warrants to the holder with an exercise price of $0.06. The fair value of the warrants was $31,714. The September 2023 Dent Note was repaid in full in October 2023.

On December 1, 2023, we issued an unsecured promissory note to a trust controlled by Dr. Dent a promissory note with a face value of $150,000 (the “December 2023 Dent Note”). The December 2023 Dent Note bears a fixed interest charge of $15,000 (10% per annum) and $1,500 in fixed fees and matures on February 28, 2024. We received net proceeds of $150,000 after discounts and fees. In connection with the note, we issued 1,500,000 five-year warrants to the holder with an exercise price of $0.06. The fair value of the warrants was $32,269. On March 27, 2024, the December 2023 Dent Note was refinanced and replaced with the March 2024 Dent Note III as described below.

On March 27, 2024, we issued to a trust controlled by Dr. Michael Dent three separate notes payable as follows: (1) a note payable with a principal of $350,000, an interest rate of 12% per annum, and a maturity date of June 27, 2024 (the “March 2024 Dent Note I”), (2) a note payable with a principal of $150,000, an interest rate of 12% per annum, and an original maturity date of August 24, 2024 (the “March 2024 Dent Note II”), and (3) a note payable with a principal of $166,500, an interest rate of 12% per annum, and a maturity date of August 28, 2024 (the “March 2024 Dent Note III”, and collectively, the “March 2024 Dent Notes”). The full amount of principal and accrued interest on each of the March 2024 Dent Notes is due at the respective maturity date of each note. Each of the March 2024 Dent Notes is convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.0573 per share. In connection with the issuance of the March 2024 Dent Notes, we also issued to the holder a ten-year warrant to purchase 6,660,000 shares of our common stock at an exercise price of $0.06 per share (the “March 2024 Warrant”). The fair value of the March 2024 Warrant was $254,345. On June 27, 2024, the maturity date on the March 2024 Dent Note I was extended until December 27, 2024 in exchange for a ten-year warrant to purchase 393,750 shares of our common stock at an exercise price of $0.081 per share. On September 17, 2024, the maturity date on the March 2024 Dent Note II (as well as March 2024 Dent Note III) was extended until February 28, 2025 in exchange for a ten-year warrant to purchase 356,063 shares of our common stock at an exercise price of $0.0465 per share. On December 31, 2024, in exchange for a ten-year warrant to purchase 618,750 shares of our common stock at an exercise price of $0.0226 per share, the maturity date on the March 2024 Dent Note I was extended until June 27, 2025, the maturity date on the April 2024 Dent Note I (as defined below) was extended until April 10, 2025, the maturity date on the April 2024 Dent Note II (as defined below) was extended until April 18, 2025, and the interest rate on each of the extended notes was increased from 12% to 15% (the “December Extension”).

On April 10, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of October 10, 2024 (the “April 2024 Dent Note I”). The April 2024 Dent Note I is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.0577 per share. We received net proceeds of $150,000. On December 31, 2024, in connection with the December Extension, the maturity date on the April 2024 Dent Note I was extended until April 10, 2025.

On April 18, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $50,000, an interest rate of 12% per annum, and a maturity date of October 18, 2024 (the “April 2024 Dent Note II”). The April 2024 Dent Note II is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.05 per share. We received net proceeds of $50,000.

44

On June 3, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $1,000,000, an interest rate of 12% per annum, and a maturity date of June 3, 2025 (the “June 2024 Dent Note”). The June 2024 Dent Note is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.0497 per share. We received net proceeds of $950,000 after original issue discount. In connection with the June 2024 Dent Note, we issued 10,000,000 ten-year warrants to the holder with an exercise price of $0.0497.

On September 19, 2024, we issued to a trust controlled by Dr. Michael Dent ten separate senior secured convertible promissory note in the aggregate principal amount of $900,000, each with an interest rate of 12% per annum and maturity dates between January 1, 2025 and March 10, 2025 (the “September 2024 Notes”). Each of the September 2024 Dent Notes is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.0486 per share and is secured by all of the Company’s assets. We received net proceeds of $855,000 after original issue discount. The details of the September 2024 Notes are as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | |  |  | **Original** | |  |  |  | |  |
| **Note** |  | **Maturity** |  | **Note** | |  |  | **Issue** | |  |  | **Net** | |  |
| **Date** |  | **Date** |  | **Principal** | |  |  | **Discount** | |  |  | **Proceeds** | |  |
| 09/18/24 |  | 01/10/25 |  | $ | 36,842 |  |  | $ | 1,842 |  |  | $ | 35,000 |  |
| 09/18/24 |  | 01/16/25 |  |  | 10,526 |  |  |  | 526 |  |  |  | 10,000 |  |
| 09/18/24 |  | 01/16/25 |  |  | 73,684 |  |  |  | 3,684 |  |  |  | 70,000 |  |
| 09/18/24 |  | 01/19/25 |  |  | 21,053 |  |  |  | 1,053 |  |  |  | 20,000 |  |
| 09/18/24 |  | 01/30/25 |  |  | 105,263 |  |  |  | 5,263 |  |  |  | 100,000 |  |
| 09/18/24 |  | 02/14/25 |  |  | 126,316 |  |  |  | 6,316 |  |  |  | 120,000 |  |
| 09/18/24 |  | 02/20/25 |  |  | 105,263 |  |  |  | 5,263 |  |  |  | 100,000 |  |
| 09/18/24 |  | 02/28/25 |  |  | 52,632 |  |  |  | 2,632 |  |  |  | 50,000 |  |
| 09/18/24 |  | 03/04/25 |  |  | 157,895 |  |  |  | 7,895 |  |  |  | 150,000 |  |
| 09/18/24 |  | 03/10/25 |  |  | 210,526 |  |  |  | 10,526 |  |  |  | 200,000 |  |
| Total |  |  |  | $ | 900,000 |  |  | $ | 45,000 |  |  | $ | 855,000 |  |

In connection with the September 2024 Notes, we issued to the holder a ten-year warrant to purchase 9,259,258 shares of common stock with an exercise price of $0.0486 (the “September 2024 Warrant”). The full amount of principal and accrued interest on each of the September 2024 Notes is due at the respective maturity date of each note. Each of the September 2024 Notes is convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.0486 per share.

During September, October and November 2024, a trust controlled by Dr. Michael Dent advanced $550,000 to us in the form of undocumented advances (the “Undocumented Advances”). We repaid an aggregate of $130,000 of the Undocumented Advances during September and November 2024.

On December 4, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $25,000, an interest rate of 12% per annum, and a maturity date of May 4, 2025 (the “December 2024 Dent Note I”). The December 2024 Dent Note I is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.033 per share. We received net proceeds of $25,000.

On December 17, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $70,000, an interest rate of 12% per annum, and a maturity date of June 17, 2025 (the “December 2024 Dent Note II”). The December 2024 Dent Note II is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.026 per share. We received net proceeds of $70,000.

On December 4, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $120,000, an interest rate of 12% per annum, and a maturity date of July 1, 2025 (the “December 2024 Dent Note III”). The December 2024 Dent Note III is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.023 per share. We received net proceeds of $120,000.

*Other Related Transactions*

During the years ended December 31, 2024 and 2023, we paid Dr. Dent’s spouse $145,000 and $139,423, respectively, in consulting fees pursuant to a consulting agreement.

*Director Compensation*

Our outside directors each receive compensation equal to $20,000 in shares of restricted stock per annum. As of December 31, 2024 and 2023, we had 1,632,652 and 408,164 shares, respectively, issuable to our directors under such compensation arrangements.

**Item 14. Principal Accounting Fees and Services**

During the years ended December 31, 2024 and 2023, our independent registered public accounting firm RBSM LLP billed us a total of $125,412 and $171,528, respectively, related to interim reviews and annual audits of our financial statements. There were no other fees billed for products offered or professional services rendered by RBSM LLP. All services provided by RBSM LLP were approved by our Board of Directors.

45

**PART IV.**

**Item 15. Exhibits, Financial Statement Schedules**

|  |  |  |
| --- | --- | --- |
| **Exhibit No.** |  | **Exhibit Description** |
| 2.1 |  | [Agreement and Plan of Merger, dated January 17, 2023, among ACO Health Partners, LLC, HealthLynked Corp., PBACO Holding, LLC and AHP Acquisition, LLC (Filed as Exhibit 10.1 to the Company’s Form 8-K filed with the Commission on January 23, 2023)](http://www.sec.gov/Archives/edgar/data/1680139/000121390023004434/ea171927ex10-1_health.htm) |
| 3.1 |  | [Amended and Restated Articles of Incorporation (Filed as Exhibit 3.1 to the Company’s Registration Statement on Form S-3 filed with the Commission on April 20, 2021)](http://www.sec.gov/Archives/edgar/data/1680139/000121390021022277/ea139566ex3-1_healthlynk.htm) |
| 3.2 |  | [By-Laws (Filed as Exhibit 3.3 to the Company’s Draft Registration Statement on Form S-1 filed with the Commission on January 9, 2017)](http://www.sec.gov/Archives/edgar/data/1680139/000121390017000173/filename5.htm) |
| 4.1 |  | [Form of Investor Warrant (Filed as Exhibit 4.1 to the Company’s Form 8-K filed with the Commission on August 30, 2021)](http://www.sec.gov/Archives/edgar/data/1680139/000121390021045668/ea146634ex4-1_healthlynked.htm) |
| 4.2 |  | [Form of Placement Agent Warrant (Filed as Exhibit 4.2 to the Company’s Form 8-K filed with the Commission on August 30, 2021)](http://www.sec.gov/Archives/edgar/data/1680139/000121390021045668/ea146634ex4-2_healthlynked.htm) |
| 4.3 |  | [Description of our Common Stock (Filed as Exhibit 4.3 to the Company’s Form 10-K filed with the Commission on March 31, 2022)](http://www.sec.gov/Archives/edgar/data/1680139/000121390022016741/f10k2021ex4-3_healthlynked.htm) |
| 4.4 |  | [Common Stock Purchase Warrant dated September 19, 2024 (Filed as Exhibit 4.1 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex4-1_health.htm) |
| 4.5 |  | [Common Stock Purchase Warrant dated June 3, 2024 (Filed as Exhibit 4.1 to the Company’s Form 8-K filed with the Commission on June 5, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024050045/ea020736801ex4-1_health.htm) |
| 10.1 |  | [Standby Equity Purchase Agreement, dated July 5, 2022, by and between HealthLynked Corp. and YA II PN, Ltd. (Filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on July 8, 2022)](http://www.sec.gov/Archives/edgar/data/1680139/000121390022038237/ea162603ex10-1_healthly.htm) |
| 10.2 |  | [Management Services Agreement, dated January 17, 2023 (Filed as Exhibit 10.2 to the Company’s Form 8-K filed with the Commission on January 23, 2023)](http://www.sec.gov/Archives/edgar/data/1680139/000121390023004434/ea171927ex10-2_health.htm) |
| 10.3 |  | [Note and Warrant Purchase Agreement, by and among the Company and the the Mary S. Dent Gifting Trust, dated June 3, 2024 (Filed as Exhibit 10.1 to the Company’s Form 8-K filed with the Commission on June 5, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024050045/ea020736801ex10-1_health.htm) |
| 10.4 |  | [Senior Secured Convertible Promissory Note dated June 3, 2024 (Filed as Exhibit 10.2 to the Company’s Form 8-K filed with the Commission on June 5, 2024)](https://www.sec.gov/Archives/edgar/data/1680139/000121390024050045/ea020736801ex10-2_health.htm) |
| 10.5 |  | [Security Agreement, by and among the Company and the Mary S. Dent Gifting Trust, dated June 3, 2024 (Filed as Exhibit 10.3 to the Company’s Form 8-K filed with the Commission on June 5, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024050045/ea020736801ex10-3_health.htm) |
| 10.6 |  | [Notes and Warrant Purchase Agreement, by and among the Company and the Purchaser, dated September 19, 2024 (Filed as Exhibit 10.1 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-1_health.htm) |
| 10.7 |  | [Security Agreement, by and among the Company and the Mary S. Dent Gifting Trust, dated September 19, 2024 (Filed as Exhibit 10.2 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-2_health.htm) |
| 10.8 |  | [Senior Secured Convertible Promissory Note 1 dated September 19, 2024 (Filed as Exhibit 10.3 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-3_health.htm) |
| 10.9 |  | [Senior Secured Convertible Promissory Note 2 dated September 19, 2024 (Filed as Exhibit 10.4 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-4_health.htm) |
| 10.10 |  | [Senior Secured Convertible Promissory Note 3 dated September 19, 2024 (Filed as Exhibit 10.5 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-5_health.htm) |
| 10.11 |  | [Senior Secured Convertible Promissory Note 4 dated September 19, 2024 (Filed as Exhibit 10.6 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-6_health.htm) |
| 10.12 |  | [Senior Secured Convertible Promissory Note 5 dated September 19, 2024 (Filed as Exhibit 10.7 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-7_health.htm) |
| 10.13 |  | [Senior Secured Convertible Promissory Note 6 dated September 19, 2024 (Filed as Exhibit 10.8 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-8_health.htm) |
| 10.14 |  | [Senior Secured Convertible Promissory Note 7 dated September 19, 2024 (Filed as Exhibit 10.9 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-9_health.htm) |
| 10.15 |  | [Senior Secured Convertible Promissory Note 8 dated September 19, 2024 (Filed as Exhibit 10.10 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-10_health.htm) |
| 10.16 |  | [Senior Secured Convertible Promissory Note 9 dated September 19, 2024 (Filed as Exhibit 10.11 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-11_health.htm) |
| 10.17 |  | [Senior Secured Convertible Promissory Note 10 dated September 19, 2024 (Filed as Exhibit 10.12 to the Company’s Form 8-K filed with the Commission on September 24, 2024)](http://www.sec.gov/Archives/edgar/data/1680139/000121390024081421/ea021515201ex10-12_health.htm) |
| 19.1\* |  | [Insider Trading Policy](file:////var/opt/apache-tomcat/temp/ea023517201ex19-1_health.htm) |
| 21.1\* |  | [Subsidiaries](file:////var/opt/apache-tomcat/temp/ea023517201ex21-1_health.htm) |
| 23.1\* |  | [Consent of RBSM LLP](file:////var/opt/apache-tomcat/temp/ea023517201ex23-1_health.htm) |
| 31.1\* |  | [Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer](file:////var/opt/apache-tomcat/temp/ea023517201ex31-1_health.htm) |
| 31.2\* |  | [Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer](file:////var/opt/apache-tomcat/temp/ea023517201ex31-2_health.htm) |
| 32.1\* |  | [Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer](file:////var/opt/apache-tomcat/temp/ea023517201ex32-1_health.htm) |
| 32.2\* |  | [Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer](file:////var/opt/apache-tomcat/temp/ea023517201ex32-2_health.htm) |
| 101\* |  | XBRL Instance Document |
|  |  | XBRL Taxonomy Extension Schema Document |
|  |  | XBRL Taxonomy Extension Calculation Linkbase Document |
|  |  | XBRL Taxonomy Extension Definition Linkbase Document |
|  |  | XBRL Taxonomy Extension Label Linkbase Document |
|  |  | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104\* |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

|  |  |  |
| --- | --- | --- |
|  | \* | - Provided herewith |

**Item 16. Form 10–K Summary**

None.

46

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 31, 2025

|  |  |
| --- | --- |
|  | **HEALTHLYNKED CORP.** |

|  |  |  |  |
| --- | --- | --- | --- |
|  | By: | /s/ Michael Dent | |
|  |  | Name: | Michael Dent |
|  |  | Title: | Chief Executive Officer  (Principal Executive Officer) |

|  |  |  |  |
| --- | --- | --- | --- |
|  | By: | /s/ Jeremy Daniel | |
|  |  | Name: | Jeremy Daniel |
|  |  | Title: | Chief Financial Officer  (Principal Financial and Accounting Officer) |

Pursuant to the requirements of the Securities Act of 1934, this annual report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Signature** |  | **Title** |  | **Date** |
|  |  |  |  |  |
| /s/ Michael Dent |  | Chief Executive Officer and Chairman of the Board of Directors |  | March 31, 2025 |
| Michael Dent |  | (*Principal Executive Officer*) |  |  |
|  |  |  |  |  |
| /s/ Jeremy Daniel |  | Chief Financial Officer |  | March 31, 2025 |
| Jeremy Daniel |  | (*Principal Financial and Accounting Officer*) |  |  |
|  |  |  |  |  |
| /s/ George O’Leary |  | Director |  | March 31, 2025 |
| George O’Leary |  |  |  |  |
|  |  |  |  |  |
| /s/ Dr. Paul Hobaica |  | Director |  | March 31, 2025 |
| Dr. Paul Hobaica |  |  |  |  |
|  |  |  |  |  |
| /s/ Robert Gasparini |  | Director |  | March 31, 2025 |
| Robert Gasparini |  |  |  |  |
|  |  |  |  |  |
| /s/ Heather Monahan |  | Director |  | March 31, 2025 |
| Heather Monahan |  |  |  |  |
|  |  |  |  |  |
| /s/ Daniel Hall |  | Director |  | March 31, 2025 |
| Daniel Hall |  |  |  |  |

47

**Supplemental Information to be Furnished With Reports Filed Pursuant to Section 15(d) of the Act by Registrants Which Have Not Registered Securities Pursuant to Section 12 of the Act**

The Company did not provide any annual report to its security holders covering the fiscal year ended December 31, 2024.

As of the date of this report, the Company has not sent a proxy statement, form of proxy or other proxy soliciting material to more than ten of its security holders with respect to any annual or other meeting of security holders during 2024.

48